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ABSTRACT 
 
The work presented in this thesis examines firstly, the effects of the sphingosine like 
immunomodulatory drug FTY720 on B-lineage acute lymphoblastic leukaemia (ALL) 
cells. This compound has recently come of interest in the setting of malignancies with 
promising pre-clinical data in a number of haematological tumours. Secondly, the 
research focuses on a related area, namely, the intra-cellular enzymes called 
sphingosine kinases (SphKs). In summary, FTY720 resulted in cytotoxic effects and 
the induction of autophagy, in vitro in ALL cells, however unexpectedly, the 
compound had variable therapeutic effects in mice engrafted with human ALL. 
Specifically, disparate in vivo effects were seen in Ph+ and Ph- ALL with a reduction 
in disease burden seen only in the former. This work resulted in the publication of two 
sequential papers, one in vitro and one in vivo, presented here as individual chapters. 
This work is novel in that FTY720 has not been examined in the ALL setting and 
furthermore, highlights the importance of and discrepancies between pharmacological 
testing in both in vitro and in vivo settings. 
 
Subsequent as yet unpublished chapters examine the importance of the sphingosine 
kinases in ALL. Briefly, sphingosine kinase 1 (SphK1) and sphingosine kinase 2 
(SphK2) are over-expressed in ALL and active. Inhibition of SphK1 and SphK2 
produced cytotoxic effects, autophagy and predominantly caspase-independent cell 
death. SphK1 and SphK2 gene deletion resulted in reduced leukaemia penetrance in a 
murine Ph+ disease model and SphK2 inhibition reduced the growth of human ALL 
xenografts. Furthermore, SphK2 inhibition resulted in lower MYC gene and protein 
expression through reduced association of acetylated histone H3 with the MYC 
promoter. This establishes a completely novel insight into the interactions of SphK2 
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in ALL cells and has significant translational potential. Thus sphingolipid signalling 
generally, and more specifically the sphingosine kinases, play important roles in ALL.  
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CHAPTER 1: INTRODUCTION 
 
 
This thesis contains eight Chapters of which three contain peer-reviewed published 
manuscripts. Each publication is clearly indicated in the text immediately before its 
inclusion. Chapter 2, the literature review, consists largely of a recently published 
review of the sphingosine kinases in haematological malignancies, expedited due to a 
notable absence of such dissertations in the field: 
 
Wallington-Beddoe CT, Bradstock KF, Bendall LJ. Oncogenic Properties 
of Sphingosine Kinases in Haematological Malignancies. Br J Haematol 
2013;161:623-638. 
 
Four of the Chapters present novel experimental data (Chapters 4 to 7), the first two 
of which are accepted peer-reviewed manuscripts whilst Chapter 6 has been submitted 
to the journal Blood and returned with review comments, requesting additional 
experimental work to be performed. The majority of these experiments have been 
undertaken at the time of writing, with the most recent version of the manuscript 
reproduced in this thesis.  Each of these Chapters is identical to the respective 
published or submitted manuscript except that the Materials and Methods section has 
been placed in Chapter 3 and the layout re-formatted to provide greater clarity. 
Chapter 7 contains material not yet submitted for publication. Due to the inclusion of 
published works in the thesis and in order to present a cohesive body of work, the 
following section outlines the course the research took during the PhD candidature 
and the reasoning behind this investigative path. 
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Initially, the PhD planned to investigate the effects of the compound FTY720 and the 
potential therapeutic efficacy thereof on B-lineage acute lymphoblastic leukaemia 
cells in both in vitro and in vivo settings. Remarkably good in vitro efficacy was 
found, resulting in the first publication, presented as Chapter 4: 
 
Wallington-Beddoe CT, Hewson J, Bradstock KF, Bendall LJ. FTY720 
Produces Caspase-Independent Cell Death in Acute Lymphoblastic 
Leukaemia Cells. Autophagy 2011;7:707-715. 
 
Unfortunately, FTY720 produced variable results in the in vivo setting, resulting in 
disparate effects between Philadelphia-positive and -negative (Ph+ and Ph-) xenografts 
in mice. Fortunately, however, this in itself was of interest, and this series of in vivo 
experiments was also published in a follow-up paper, presented as Chapter 5: 
 
Wallington-Beddoe CT, Don AS, Hewson J, Qiao E, Papa RA, Lock RB, 
Kenneth Bradstock KF, Bendall LJ. Disparate In Vivo Efficacy of 
FTY720 in Xenograft Models of Philadelphia Positive and Negative B-
lineage Acute Lymphoblastic Leukaemia. PloS ONE 2012;7:e36429. 
 
These two Chapters, based on FTY720, represent experimental work undertaken 
during the first year of candidature.  However, due to the inconsistent results observed 
with FTY720 and risk of persistent ‘negative’ experimental data, a major re-working 
of the PhD research proposal was necessary. Since FTY720 is a sphingosine analog, 
which is phosphorylated by sphingosine kinases (SphKs) and binds to sphingosine 1-
phosphate (S1P) receptors, the remainder of the PhD shifted focus to investigate the 
roles the SphKs themselves play in ALL cells. Thus, although FTY720 was no longer 
evaluated, the research remained firmly planted in the sphingolipid signalling field. 
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Chapter 6 contains very novel, exciting experimental data on the roles sphingosine 
kinase 2 (SphK2) plays in ALL, detailing in vitro and in vivo therapeutic effects upon 
enzyme inhibition and a possible mechanism behind the observed effects. This 
manuscript has undergone first round peer-review and the version presented here 
contains most requested experiments and is expected to be re-submitted in the near 
future: 
 
Craig T Wallington-Beddoe, Stuart M Pitson, Kenneth F Bradstock, 
Linda J Bendall. Sphingosine Kinase 2 Promotes Acute Lymphoblastic 
Leukaemia by Enhancing MYC Expression. 
 
Chapter 7 is as yet unpublished, examining sphingosine kinase 1 (SphK1) in ALL 
cells both in vitro and in vivo. Little is known about the roles these enzymes play in 
ALL cells, particularly relating to SphK2, and this body of work therefore provides 
valuable novel insights into the complexity of these enzymes in a hitherto unexamined 
disease. The specific hypotheses and aims of this PhD are outlined below. 
 
Hypotheses and Aims 
 
All work in this thesis focuses on B-lineage ALL, hereafter usually referred to as ALL 
 
Hypotheses 
1. FTY720 inhibits proliferation and induces death in ALL cells. 
 
2. Sphingosine kinases, through the production of sphingosine 1-phosphate are 
important in maintaining viable ALL cells and inhibition results in cell death. 
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Aims 
1. To examine the effects of FTY720 on ALL cells in both in vitro and in vivo 
settings and investigate mechanisms of cell death. 
 
2. To determine the dependency of ALL cells on SphK1- and SphK2-generated 
sphingosine 1-phosphate in both in vitro and in vivo settings. 
 
3. To elucidate the mechanism(s) through which SphK1/SphK2 contribute to 
ALL cellular function. 
	  
Author’s Contribution 
 
The work described in this thesis was carried out by the author under the supervision 
of Associate Professor Linda Bendall and Professor Kenneth Bradstock at the 
Westmead Institute for Cancer Research, Westmead Millennium Institute, Sydney 
Medical School, The University of Sydney. The author in conjunction with 
Supervisors, planned the overall project and research direction, designed experiments, 
analysed data and wrote the manuscripts presented in this thesis. The author 
performed all experiments except where otherwise indicated and was the primary 
contributor for all the manuscripts presented in this thesis. The specific contributions 
of the author and co-authors to each manuscript contributing to this thesis with signed 
declarations are provided in Appendix 1. 
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CHAPTER 2: LITERATURE REVIEW 
 
 
Normal Haematopoiesis 
 
Haematopoiesis is the process whereby multipotent long-term haematopoietic stem 
cells (LT-HSCs), located in the bone marrow, produce all of the blood cellular 
components [1]. LT-HSCs divide to produce short-term HSCs, which subsequently 
produce haematopoietic progenitor cells (HPCs) of myeloid and lymphoid lineages 
and ultimately mature blood cells (Figure 2.1) [2, 3]. Due to HSC self-renewal 
capacity, some daughter cells remain as HSCs, thereby maintaining the HSC bone 
marrow pool.  In the foetus, haematopoiesis occurs mainly in the liver while the bone 
marrow is the major haematopoietic organ in adults [4, 5]. 
 
A common property of stem cells is quiescence in terms of the cell cycle. Adult HSCs 
are predominantly quiescent, and it is likely that limiting HSC cycling could be 
critically involved in sustaining a self-renewing HSC compartment for life [6]. 
Indeed, sub-populations of LT-HSCs remain in a quiescent state and have robust 
haematopoietic reconstitution activity upon appropriate stimulation [6-8], a property 
required for sustaining the stem cell compartment long-term [9]. 
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Figure 2.1. Haematopoietic cell development. 
Reproduced from http://en.wikipedia.org by A. Rad. 
 
 
The Bone Marrow Microenvironment 
 
HSCs reside in specialised microenvionmental regions known as niches [10]. It is 
well established that the niche plays a vital role in the regulation of stem cell activity. 
In the bone marrow, the HSCs have been found in close proximity to the endosteum 
(termed the osteoblastic niche) and sinusoidal vascular endothelium (termed the 
vascular niche) [7, 11-14], however it is not clear whether these are truly distinct 
locations [15]. One interpretation is that the osteoblastic niche, which is relatively 
hypoxic, maintains HSCs in a quiescent state, while the vascular niche, an oxygenic 
niche, supports stem and progenitor cells that are actively proliferating [16, 17]. 
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However arguments have been presented whereby no such partitioning of the bone 
marrow microenvironment exists and HSCs reside throughout the bone marrow most 
likely in close proximity to their immature and mature progeny [15]. 
 
B-cell Lymphopoiesis 
 
The bone marrow is the exclusive site of B lymphopoiesis from mid-gestation. HSCs 
give rise to common lymphoid progenitors (CLPs), which differentiate into B, T, and 
NK cells. The earliest committed B-cell precursors are pre-pro-B-cells, which express 
low levels of the lymphocyte specific recombination activating genes, RAG-1 and 
RAG-2  (Figure 2.2) [18-20]. 
	  
Figure 2.2. Normal B-cell development. 
RAG expression and re-arrangements on both heavy (IgH) and light (IgL) chain loci are 
shown, reproduced from Mefre et al. [21]. GL, locus is in germline configuration. Cell 
surface expression of pro-B (calnexin and Igα-Igβ), pre-B (Igµ, ΨL and Igα-Igβ) or B (Igµ, 
Igκ or Igλ and Igα-Igβ) cell receptors is shown. 
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At the pro-B stage, cells express CD10, CD34, CD19, terminal deoxynucleotidyl 
transferase (TdT), re-arrange the diversity (D) and joining (J) segments of the Ig 
heavy chain (IgH) locus (V-to-DJH) [22, 23] and express a precursor form of the B-cell 
receptor (BCR) composed of Igα, Igβ and calnexin [24-26]. Pro-B cells differentiate 
into pre-B-cells with characteristic loss of CD34 and TdT and the acquisition of 
cytoplasmic Igµ (immunoglobulin heavy chain) [22, 27]. The Igµ then associates with 
the surrogate light chain, ΨL (VpreB and λ5) and the Igα/Igβ signal transducing 
heterodimer to form the pre-BCR complex (Figures 2.2 and 2.3).  
	  
Figure 2.3. Structure of the pre-BCR. 
Reproduced from www.fccc.edu by R. Hardy. 
 
 
Formation of the pre-BCR heralds a sequence of events, including (1) suppression of 
RAG-1/RAG-2 expression to ensure allelic exclusion at the Igµ locus, (2) a rapid 
burst of proliferation, and (3) re-expression of RAG-1/RAG-2 and initiation of light 
chain re-arrangement [28-30]. The expression of the surrogate light chain and 
consequently that of the pre-BCR is then down regulated, leading to the arrest of 
proliferation at the pre-B stage. RAG and Igκ germline transcripts are expressed and 
pre-B-cells undergo light chain (IgL) gene re-arrangements [31-33]. Failure to produce 
a functional κ light chain re-arrangement usually leads to re-arrangement of the λ 
light chain locus, and immature B-cells are therefore characterised by the expression 
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of cell surface CD19 and IgHµ heavy chain associated with κ or λ light chain. 
Immature B-cells expressing a complete BCR, composed of IgHµ and IgL chains 
associated with the Igα/Igβ heterodimer, are selected against self-reactivity before 
leaving the bone marrow and entering the peripheral B-cell pool [21]. Mature B-cells 
then migrate through the blood to lymph nodes where they are exposed to antigen, 
undergo somatic hypermutation and immunoglobulin class switching (IgM, IgG, IgA, 
IgE) and become antibody-secreting plasma cells or long-lived memory B-cells, 
reviewed in LeBien et al [34].  
 
Transcriptional Regulation of Early B-lymphopoiesis 
 
Studies in mice have found the transcription factors PU.1, Ikaros, E2A 
(immunoglobulin enhancer-binding factor E12/E47), EBF (early B-cell factor) and 
Pax-5 (paired box 5) to be significant in regulating early B-lymphopoiesis (Figure 
2.4) [35]. Ikaros [36, 37] and PU.1 [38] control the development of multiple 
haematopoietic lineages while differentiation of the common lymphoid progenitor 
(CLP) to committed pro-B-cells depends on the expression of the B-cell specific 
transcription factors, E2A [39], EBF [40] and Pax-5 [41, 42]. 
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Figure 2.4. Transcription factor expression during B lymphopoiesis. 
Shaded bars represent the levels of gene expression of transcription factors that are important 
in B-cell development during the course of differentiation (reproduced from Ramirez et al. 
[43]). HSCs (haematopoietic stem cells), MPPs (multipotent progenitors), LMPPs (lymphoid-
primed MPPs), ELPs (early lymphoid progenitors), CLPs (common lymphoid progenitors), 
ETPs (early T lineage progenitors). Darker shading indicates increased gene expression. 
 
 
Ikaros promotes lymphoid fate by repressing key myeloid genes and loss of function 
is associated with the development of Ph+ ALL and a poor prognosis in ALL patients 
[44, 45]. The B-cell developmental pathway is favoured by low levels of PU.1, while 
a high level of PU.1 suppresses B-cell fate [38]. Pax-5-deficient mice have an arrest in 
B-cell development at the transition from DJ to VDJ re-arrangement and their pro-B-
cells harbour the capacity to adopt non-B-lineage fates [41]. Pax-5 expression is EBF-
dependent but Pax-5 increases EBF expression forming a positive feed forward loop 
[46]. E2A [39] and EBF [40] regulate chromatin accessibility and the expression of 
key B-lineage genes, such as Igα, Igβ and λ5 with E2A and EBF gene-deficient mice 
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exhibiting arrested early B-cell development, lacking D-H re-arrangements in the Ig 
heavy chain locus. 
 
Growth Factor Regulation 
 
The bone marrow derived soluble factors required for B-lymphopoiesis identified so 
far include CXCL12, FMS-like tyrosine kinase 3 ligand (Flt3-L), interleukin-7 (IL-7), 
stem cells factor (SCF), and receptor activator for nuclear factor κB ligand (RANKL) 
[47, 48]. The primary cellular sources of CXCL12 and IL-7 are the CXCL12 reticular 
cells and IL-7 expressing cells respectively, whilst Flt3-L is expressed by numerous 
cell types [49]. These cells co-express vascular cell adhesion molecule 1 (VCAM-1), 
occur uniformly throughout the bone marrow, and are thought to create distinct 
microenvironments for B-lymphopoiesis [50]. Osteoblasts also express CXCL12 and 
support early B-lymphopoiesis in vitro. Furthermore, mouse primary osteoblasts also 
express RANKL, suggesting that osteoblasts may be the source of RANKL in the 
marrow. The VCAM-1 expressing cells in the bone marrow co-express SCF, 
however, the exact interaction of B-cell progenitors with these cells, and with Flt3-L 
producing cells, remains to be determined [50].  
 
Haematological Malignancies 
 
Haematological malignancies are clonal disorders arising from blood-forming cells of 
various maturation stages, from pluripotent stem cells to mature effector cells. These 
disorders may develop in the bone marrow or in secondary haematopoietic organs 
such as the spleen, thymus and lymph nodes and, by their very nature, are widely 
disseminated diseases. Such tumours are extremely varied, ranging from relatively 
Chapter 2 Literature Review 
	  
	  
12	  
indolent chronic clonal proliferations of myeloid cells, to the highly aggressive acute 
leukaemias, which are rapidly progressive and fatal if left untreated. In keeping with 
this variation in disease natural history, treatment may involve simple observation, 
management of incidental complications, complex cycles of multi-drug 
chemotherapy, or palliation. In many instances the prospects for long-term cure are 
only realised with the addition of autologous or allogeneic haematopoietic stem cell 
transplantation with all of its attendant complications. Traditional chemotherapeutic 
agents are often highly effective in reducing the burden of malignant cells, however, 
they suffer from lack of specificity and result in significant toxicity to normal tissues. 
Furthermore, relapse rates remain high for most disorders. 
 
Acute Lymphoblastic Leukaemia  
 
Definition 
 
B- or T-cell acute lymphoblastic leukaemia is a neoplasm of precursor lymphoid cells 
(lymphoblasts) in the bone marrow committed to the B- or T-cell lineage. The 
diagnosis is generally made when lymphoblasts comprise at least 20% of the 
nucleated bone marrow cells. By definition, the bone marrow is involved in all cases 
and the peripheral blood is usually involved. Extramedullary involvement is frequent, 
particularly the central nervous system, lymph nodes, liver, spleen and testes in males. 
Most patients present with symptoms of bone marrow failure such as lethargy, 
bleeding or infections due to anaemia, thrombocytopenia and leukopenia, 
respectively. The immunophenotypes usually found in precursor B-lineage ALL are 
(c: cytoplasmic): 
• Pro-B-ALL: HLA-DR, CD19, cCD79a, cCD22, TdT 
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• Intermediate stage (common ALL): As above plus CD10 
• Pre-B-ALL: As above plus cIgHµ  
Variable expression of CD34 and CD20 is found. 
 
Epidemiology 
 
Acute lymphoblastic leukaemia is the most common childhood cancer with a peak 
incidence between the ages of 6 and 10 years. ALL is much less common in adult 
populations, however, it usually carries a poorer prognosis due to the combination of 
the accumulation of unfavourable genetic changes with increasing age-related co-
morbidites. Of 3200 cases diagnosed in the United States in the year 2000, 75% of 
cases occurred in children less than 6 years of age whilst 80% to 85% of cases are of 
B-lineage with the remainder T-lineage. The proportion of T-ALL is approximately 
15% in children increasing to 25% in adults [51]. 
 
Aetiology 
 
Genetic abnormalities in transcription factors, tumour suppressor genes and proto-
oncogenes have been described as contributory to ALL development either through 
gene mutation or chromosomal translocation. Furthermore, distinct disease entities 
based on recurrent structural and other chromosomal abnormalities have been defined, 
harbouring unique clinical, phenotypic or prognostic attributes. Approximately 75% 
of childhood ALL cases harbour a recurring alteration detectable by karyotyping, 
fluorescence in situ hybridisation (FISH) or molecular techniques (Table 2.1) [51, 
52]. Although important in the pathogenesis of ALL, these re-arrangements are 
insufficient to fully explain leukaemogenesis [53]. 
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Table 2.1 Important cytogenetic alterations in childhood B-ALL. 
Subtype Frequency (%) Comment 
Hyperdiploidy (>50 
chromosomes) 20-30 Good prognosis. 
Hypodiploidy (<44 
chromosomes) 1-2 
Poor prognosis. High frequency 
of RAS pathway and IKAROS 
gene family members. 
t(12;21)(p13;q22) ETV6-
RUNX1 15-25 Good prognosis. 
t(1;19)(q23;p13) TCF3-PBX1 2-6 Generally good prognosis. Associated with CNS relapse. 
t(9;22)(q34;q11.2) BCR/ABL 2-4 
Historically poor prognosis. 
Improved outcomes with the 
addition of bcr/abl inhibitors. 
PAX5 re-arrangement ~2 Multiple partners. Outcome unknown. 
ABL1, PDGFRB, JAK2 re-
arrangements 2-5 
Identified in BCR/ABL-like 
ALL. Multiple re-arrangements 
possible. Associated with 
IKZF1 alteration and very high 
leukocyte count. Potential role 
for tyrosine kinase inhibitor 
therapy. 
t(4;11)(q21;q23) MLL-AF4 1-2 
Poor prognosis. Common in 
infant ALL (especially <6 
months). 
MYC re-arrangements 
t(8;14)(q24;q32), 
t(2;8)(q12;q24) 
2 Favourable prognosis. 
CRLF2 re-arrangements IGH@-
CRLF2, PAR1 deletion, and 
P2RY8-CRLF2 
5-7 
Very common in Down 
Syndrome (DS) ALL (55%). 
Associated with IKZF1 
deletion/mutation and JAK1/2 
mutation. Poor prognosis in 
patients without Down 
Syndrome. 
ERG deletion 7 Favourable prognosis. 
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It is now known that most ALL cases are characterised by not only structural re-
arrangements but also microscopic genetic alterations (Table 2.2) [54]. Many of the 
genes involved encode proteins with roles in lymphoid development (e.g. PAX5, 
IZKF1, EBF1 and LMO2), cell cycle regulation and tumour suppression 
(CDKN2A/CDKN2B, PTEN and RB1), lymphoid signalling (BTLA, CD200, TOX and 
NR3C1) and transcriptional regulation and co-activation (TBL1XR1, ETV6 and ERG). 
More recently, up to 15% of childhood B-ALL patients lack a previously identified 
chromosomal re-arrangement but exhibit a gene expression profile similar to that of 
BCR/ABL+ ALL. Termed ‘BCR/ABL-like’, these cases often have a deletion or 
mutation in the transcription factor IKZF1 and have a poor prognosis [52, 53]. 
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Table 2.2. Important gene alterations in B-ALL. 
Gene Alteration Frequency Consequences 
PAX5 
Deletions, 
translocations, 
sequence mutations 
One-third of B-ALL 
cases. 
B-lymphoid 
transcriptions factor. 
No association with 
outcome. 
IKZF1 Focal deletions or sequence mutations 
15% of all paediatric 
B-ALL, > 70% of 
BCR/ABL+ lymphoid 
leukaemia and one-
third of BCR/ABL- B-
ALL. 
Transcription factor 
required for lymphoid 
development. Co-
operates in 
pathogenesis of 
BCR/ABL+ ALL. 
Associated with poor 
prognosis in 
BCR/ABL+ and 
BCR/ABL- B-ALL. 
JAK1/2 
Inherited variants. 
Pseudokinase and 
kinase domain 
mutations. 
18%-35% DS-ALL and 
10% high-risk 
BCR/ABL- ALL. JAK1 
mutations also 
identified in T-ALL. 
JAK-STAT activation 
in model cell lines and 
primary leukaemia 
cells. 
CRLF2 
Re-arrangement of 
IGH@-CRLF2 or 
P2RY8-CRLF2 
resulting in over-
expression. F232C 
mutations. 
5%-16% of paediatric 
and adult B-ALL and > 
50% DS-ALL. 
Associated with JAK in 
up to 50% of cases. 
Associated with IKZF1 
alteration and poor 
outcome, particularly 
in non-DS-ALL. 
IL7R 
Complex in-frame 
mutations in the 
transmembrane 
domain. 
Up to 7% of B- and T-
ALL. 
Receptor dimerisation 
and constitutive IL7R 
signalling and JAK-
STAT activation. 
CREBBP Focal deletions and sequence mutations. 
19% of relapsed ALL. 
Commonly acquired at 
relapse. 
Mutations result in 
impaired histone 
acetylation and 
transcriptional 
regulation and 
glucocorticoid 
resistance. 
TP53 Deletions and sequence mutations. 
Up to 12% of B-ALL. 
Commonly acquired at 
relapse. 
Loss of function or 
dominant negative. 
Associated with poor 
outcome. 
Kinase re-
arrangements and 
mutations 
Re-arrangements of 
ABL1, PDGFRB, 
EPOR, JAK2, deletions 
of SH2B3. 
Present in half of 
BCR/ABL-like ALL 
cases. 
Results in kinase 
signalling activation 
that is attenuated with 
tyrosine kinase 
inhibitors. 
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Additionally, these genes are often involved in many different types of genetic 
alterations, such as copy number changes, translocation and sequence mutation with 
several of these alterations co-operating in leukaemogenesis (Figure 2.5) [52]. 
 
Figure 2.5. Postulated model for the role of genetic alterations in the pathogenesis of B-
ALL. 
 
 
Some chromosomal translocations associated with B-ALL have been detected in 
neonatal specimens long before the onset of leukaemia and monozygotic twins with 
concordant leukaemia frequently share genetic abnormalities, suggesting a possible 
inherited component to at least some cases [55, 56]. Finally, environmental factors 
also play an important role with chemicals (benzene, pesticides), ionising radiation, 
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bacteria (Helicobacter pylori) and viruses (human T-cell leukaemia virus type-1, 
Epstein-Barr virus) implicated [57]. 
	  
Current Therapy 
 
Approximately 80% of children achieve a long-term remission [58]. Substantially 
fewer adult patients perform so well and about 25% of children and 65% of adults 
develop disease relapse [59]. The 20-40% of adult and 2-5% of childhood patients 
whose disease is caused by the BCR/ABL proto-oncogene (Ph+ ALL) have a 
particularly poor prognosis although the introduction of an integrated approach 
combining chemotherapy, tyrosine kinase inhibitors and stem cell transplantation has 
significantly improved survival [60]. In addition, current chemotherapeutic protocols 
are long and arduous, involving the administration of numerous cycles of cytotoxic 
agents delivered in various combinations, resulting in significant toxicities [60, 61]. 
 
Despite the need for improved treatments with higher cure rates and reduced toxicity, 
ALL represents one of the success stories in the management of malignant 
haematological diseases. Although most children with ALL can expect a favourable 
overall long-term remission, only 30% to 50% of adults achieve this, usually with the 
use of allogeneic stem cell transplantation and possible complications such as acute 
and chronic graft-versus-host disease and opportunistic infections. The higher 
prevalence of Ph+ ALL in adult populations only partially explains the poorer 
prognosis experienced by adults with ALL. Adolescents and young adults (16 – 20 
years of age) are emerging as a group of interest due to the fact that traditionally they 
are treated on adult protocols. However, clinical trial data suggests that improved 
response rates are achieved when this group is treated on paediatric protocols [62]. 
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Whether this is due to factors such as the higher administered doses of non-
myelosuppressive agents, increased patient and doctor compliance in the paediatric 
setting or the innate biology of the disease, is unclear. 
 
More recently, Bcr/Abl tyrosine kinase inhibitors such as imatinib, dasatinib and 
nilotinib have improved response rates for patients with Ph+ ALL. The combination of 
conventional chemotherapy plus a tyrosine kinase inhibitor followed by allogeneic 
stem cell transplantation has improved complete remission and overall survival rates 
to such an extent that they are now comparable to adult ALL patients without the 
Philadelphia chromosome [59]. In spite of these advances, overall survival rates in 
adults are low compared to those obtained in children and relapse rates remain high. 
Furthermore, the majority of adult patients will require allogeneic stem cell 
transplantation to have a hope of long-term cure and this in itself is a tortuous therapy 
with many potential serious complications [59, 60, 63]. 
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The remainder of this literature review has been recently published as a review article 
in the British Journal of Haematology:  
 
Wallington-Beddoe C.T., Bradstock KF, Bendall LJ. Oncogenic Properties of 
Sphingosine Kinases in Haematological Malignancies. Br J Haematol 
2013;161:623-638. 
 
Therapeutic Challenges 
 
Lack of specificity with conventional agents has subsequently resulted in the 
development of targeted therapies which aim to inhibit tumour-specific processes, in 
most instances by interacting with a single cellular target, thereby inhibiting tumour 
growth or inducing cell death, whilst minimising treatment-related side effects and 
toxicity to normal tissue. A spectacular success has been the introduction of the 
tyrosine kinase competitive ATP inhibitor, imatinib, which blocks the kinase activity 
of the proto-oncogene protein Bcr/Abl, the product of the sole genetic aberration 
responsible for chronic myeloid leukaemia (CML) [64]. Although imatinib is not 
entirely specific for Bcr/Abl, inhibiting, most notably, the function of the receptor 
tyrosine kinases KIT and PDGFR (platelet-derived growth factor receptor), it has 
relatively few side effects and produces a major cytogenetic response in the vast 
majority of newly-diagnosed chronic phase CML patients [65, 66]. Furthermore, 
imatinib has largely obviated the need for haematopoietic stem cell transplantation, 
which prior to its introduction, was the only therapy resulting in long-term survival 
[65]. The field of B-cell lymphomas has also been revolutionised by the introduction 
of the humanised chimeric CD20 monoclonal antibody, rituximab. When combined 
with traditional chemotherapy, rituximab has resulted in significant improvements in 
cure and survival rates [67]. 
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Unfortunately, CML is unique in that BCR/ABL is sufficient for disease initiation and 
progression. Most haematological malignancies are much more complex, consisting 
of multiple genetic or epigenetic aberrations affecting numerous cellular processes 
such as those responsible for differentiation, cell cycle progression, proliferation and 
apoptosis. Constitutive tumour associated activation of pro-survival pathways such as 
the nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB), mitogen-
activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/mammalian 
target of rapamycin (mTOR) pathways, as well as over-expression of anti-apoptotic 
proteins such as Bcl-2 family members, are frequently present [68]. Although it seems 
unlikely that single agent therapy will be sufficient for these more complex disorders, 
the goal remains to target aberrant cellular processes within tumour cells. 
 
Overview of Sphingosine 1-Phosphate Metabolism 
 
The sphingolipids, ceramide and sphingosine 1-phosphate (S1P) belong to a family of 
membrane lipids recently shown to modulate a range of cellular processes including 
proliferation and apoptosis [69]. These bioactive lipids are part of a pathway where 
ceramide is hydrolysed by ceramidases to form sphingosine, which in turn is 
phosphorylated by sphingosine kinase 1 (SphK1) or sphingosine kinase 2 (SphK2) to 
generate S1P. S1P can be dephosphorylated and inactivated by S1P phosphatases or 
lipid phosphate phosphatases or irreversibly destroyed by S1P lyase [70, 71]. 
 
S1P is generally produced intra-cellularly and exported by a growing range of ATP-
dependent and independent mechanisms [72]. The ATP-binding cassette (ABC) super 
family of transporters, are important in platelets [72] and erythrocytes [73] with 
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ABCC1 being specifically identified in mast and breast cancer cells [74], ABCA1 in 
astrocytes [75] and ABCG2 in breast cancer cells [76]. The spinster homolog 2 
(Spns2), a recently identified S1P transporter [77, 78], plays a major role exporting 
S1P from endothelial cells [79]. However, SphK1 is also secreted from vascular 
endothelial cells where it can directly contribute to the extra-cellular pool of S1P [79, 
80]. Extra-cellular S1P binds to five heterotrimeric G protein-coupled receptors, S1P1 
to S1P5 (Figure 2.6), inducing diverse actions including vascular maturation and 
angiogenesis, lymphocyte trafficking through blood and lymphoid organs, 
inflammation and cell transformation [81]. S1P can also act intra-cellularly which, 
depending on the location of intra-cellular production, may result in pro- or anti-
proliferative effects. It modulates histone deacetylases, thereby inducing expression of 
c-fos and the cell cycle regulator p21 [82], and the ubiquitin ligase activity of tumour 
necrosis factor receptor-associated factor 2 (TRAF2) [83]. The latter results in a 
skewing of the response to tumour necrosis factor α (TNFα) towards pro-
survival/pro-proliferative effects via NF-κB activation. 
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Figure 2.6. S1P receptors and downstream signalling pathways. 
S1P receptors activate the G proteins Gi, Gq and G12/13, which interact with numerous intra-
cellular signalling pathways. Gi activates the MAPK and PI3K pathways, phospholipase C 
(PLC) and the small GTPase Rac whilst inhibiting adenylyl cyclase (not shown). Gq activates 
PLC and G12/13 activates small Rho GTPases while inhibiting ERK1/2. Stimulation of S1P1 
and S1P3 is generally viewed as having the opposite effects to S1P2, the former receptors 
resulting in cell survival, proliferation and migration whilst the latter inhibits cell movement. 
Although S1P2 and S1P3 interact with all G proteins, G12/13-mediated effects predominate 
upon S1P2 stimulation while Gq dominates S1P3 signalling. S1P4 and S1P5 couple to both Gi 
and G12/13 but not Gq. Not all interactions between S1P receptors, G proteins and signalling 
pathways are shown. The known roles of these receptors in normal haematopoietic processes 
are shown above the receptors and outcomes of receptor activation in the bottom line of the 
figure. A more detailed discussion can be found in [84] and references therein. 
 
 
A role for S1P in malignancy is inferred from elevated S1P concentrations in the 
plasma of cancer patients, suggesting that S1P contributes to cancer progression by 
promoting tumour growth via direct signalling through S1P receptors [85, 86]. 
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Furthermore, S1P receptors can crosstalk with receptor tyrosine kinases by 
transactivation [87], formation of complexes [88], and amplification of regulatory 
loops [89], to promote tumour genesis. In keeping with its mitogenic role, S1P 
induces autophagy, which in some circumstances can protect cells from cytotoxic 
insults [90, 91]. Taken together these data support a role for S1P metabolism in 
tumour genesis. It has also been suggested that shifting the sphingosine “rheostat” 
towards S1P plays a role in drug resistance [69, 92]. 
 
The Sphingosine Kinases 
 
SphK1 and SphK2 are encoded by different genes (SPHK1 and SPHK2) and belong to 
a family of proteins highly conserved throughout eukaryotic organisms ranging from 
yeast to human [93]. Both SphKs share regions of high sequence similarity including 
the catalytic domain and residues important for ATP and sphingosine binding (80% 
similarity and 45% identity) [69]. Almost all of the SphK1 polypeptide sequence 
aligns with regions of SphK2, however, SphK2 contains additional polypeptide 
regions at its N-terminus which appear to play a role in regulating membrane 
localisation, and a proline-rich insert in the middle of its sequence [94, 95]. Both 
SphKs catalyse the same reaction to generate S1P and dihydrosphingosine 1-
phosphate, however SphK2 can use a greater variety of substrates including some 
artificial substrates such as the ‘sphingosine-like’ immunomodulatory pro-drug 
FTY720 [96].  
 
SphKs have differential developmental expression [94] and somewhat different sub-
cellular localisation [97, 98], suggesting that they may have some distinct biological 
roles. Mice with genetic deletion of either SphK1 or SphK2 develop normally 
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suggesting there is considerable physiological redundancy, however, deletion of both 
enzymes results in lethality in utero due to defects in angiogenesis and neurogenesis 
[99].  
 
Sphingosine Kinase 1 
 
There are three isoforms of SphK1 resulting from alternative splicing that differ only 
in their N-termini (Figure 2.7) [69], however, little is known about their function in 
cancer. SphK1a is selectively secreted by human umbilical-vein endothelial cells and 
is thought to be the contributor to plasma S1P [80] whilst SphK1b exhibits cell 
membrane localisation in mice and increased resistance to proteosomal degradation 
compared to SphK1a in human prostate cancer cells [100, 101]. SphK1c is expressed 
at much lower levels than the other isoforms and appears to be localised to 
membranes, possibly golgi [80]. All isoforms have intrinsic catalytic activity [102], 
but can be further activated by a range of growth factors, cytokines and hormones and 
in turn modulate a number of signalling pathways [103, 104]. The expression and 
activation of SphK1 are induced by a range of agents, including growth factors such 
as TNFα [105] and epidermal growth factor (EGF) [106], and adhesion molecules 
such as PECAM1 [107]  interacting with receptor tyrosine kinases. Activation of 
SphK1 is mediated by protein kinase C (PKC), classical MAPK/extra-cellular-signal-
regulated kinases (ERKs) and PI3K/mTOR [108-110] and involves phosphorylation 
at Ser225 by ERK1/2 [109], however, oncogenic K-Ras activates SphK1 independently 
of Ser225 phosphorylation [111]. Generally, phosphorylation is transient, being 
countered by protein phosphatase 2A (PP2A) [112]. The localisation of SphK1 
appears critical for its functions [113] with phosphorylation inducing translocation to 
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the plasma membrane [109], which is critical for agonist-induced S1P generation and 
the proliferative, pro-survival and oncogenic effects of SphK1 [114].  
 
Activating mutations in SphK1 have not been identified, however, it has been 
suggested that malignancies become dependent on SphK1 through a non-oncogene 
addiction, that is, SphK1 over-expression and/or increased activity [115]. Research 
over the last two decades has led to a widely accepted model whereby SphK1 resides 
at the center of a cell survival rheostat that balances the cellular levels of pro-
apoptotic ceramide with anti-apoptotic, pro-proliferative S1P [116]. Thus, alterations 
in cellular SphK1 activity appear to play an important role in determining cell fate, 
with high SphK1 and S1P levels conferring enhanced cell survival and proliferation, 
while inhibition of SphK1 promotes apoptosis [105, 117]. As a result the so-called 
ceramide/S1P rheostat has received considerable interest as a potential target for 
cancer therapies [103, 118, 119]. Key early observations showing that over-
expression of SphK1 induced neoplastic transformation of NIH3T3 fibroblasts [105] 
provoked numerous studies supporting a role for SphK1 in cancer development and 
progression. For example, SphK1 is upregulated in astrocytoma, glioblastoma, non-
Hodgkin lymphoma, colon, lung and leukaemias [120-125]. High SphK1 levels have 
been associated with poor survival in gastric, breast, brain and lung tumour patients 
[121, 126-128], and targeting SphK1 by chemical or genetic means reduced tumour 
growth in mice [123, 129-132] and alleviated chemotherapeutic resistance in prostate 
[132, 133], CML [134, 135], acute myeloid leukaemia (AML) [136], pancreatic [137] 
and breast [92] tumours. 
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Figure 2.7. Sphingosine kinase isoforms and splice variants. 
The structure of the SPHK1 and SPHK2 genes are illustrated with alternatively spliced forms 
and respective NCBI reference sequence numbers provided. Two sphingosine kinase genes 
are found in humans resulting in SphK1 and SphK2 proteins. Five highly conserved regions 
are denoted by red, blue and black segments pertaining to ATP, lipid binding and the catalytic 
domains, respectively. Note that the second conserved ATP binding domain is split across an 
intron in both SPHK1 and SPHK2. 
 
 
Sphingosine Kinase 2 
 
Two SphK2 isoforms have been reported that appear to arise from alternative start 
codon usage (Figure 2.7) [69]. Compared to SphK2-S, SphK2-L possesses an 
additional 36 amino acids, and is more abundant in a range of human tissues and 
cultured cells [80, 95]. Furthermore, SphK2-L can be nuclear or cytoplasmic but 
accumulates in the nucleus under conditions of stress [95]. Like SphK1, SphK2 also 
has intrinsic activity that can be further enhanced by phosphorylation events. These 
are less well understood but it appears that ERK1/2 play a role and are thought to 
phosphorylate SphK2 on either or both Ser351 and Thr578 [138]. SphK2 can be located 
in the nucleus where it interacts with the histone deacetylases (HDAC)1/2. The 
locally produced S1P binds to and inhibits HDAC1/2, resulting in increased 
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acetylation of histones H3, H4 and H2B and the subsequent expression of the cyclin-
dependent kinase inhibitor p21, an inhibitor of cell cycle progression, and the 
transcriptional regulator c-fos [82]. Phosphorylation by protein kinase D on serine 
residues increases the activity of a putative nuclear export signal (NES) resulting in 
the export of SphK2 from the nucleus into the cytoplasm [139].  
 
In the cytoplasm SphK2 can play a pro-apoptotic role when associated with the 
endoplasmic reticulum. Here the locally generated S1P appears to be channeled into 
biosynthesis of pro-apoptotic ceramide [98]. Furthermore, SphK2 possesses BH3-
binding domain activity and can inhibit the anti-apoptotic protein Bcl-xL [95, 140]. 
These data provide a potential explanation for numerous reports that suggest SphK2 
has an opposing role to SphK1 by promoting apoptosis [95, 97, 98, 140, 141] and 
acting as a tumour suppressor [97]. SphK1 and SphK2 also have divergent roles in 
human mast cell functions [142], inflammatory arthritis [143], kidney ischemia-
reperfusion injury [144], and lipopolysaccharide-induced lung injury [145]. 
 
In contrast to the above findings, a number of other studies have suggested a pro-
survival role for SphK2, similar to SphK1, since its knockdown enhanced apoptosis 
and increased the sensitivity of glioblastoma, colon, breast and lung tumour cells to 
chemotherapy [121, 146-148]. Recent studies have also demonstrated a role for 
SphK2 in tumour development in mice, with knockdown of SphK2 in MCF7 human 
breast cancer cells inhibiting growth of xenografted tumours [149]. Chemical 
inhibition of SphK2 decreased proliferation in a number of solid tumour types in vitro 
and induced autophagic cell death in kidney, prostate and breast tumour cell lines 
[150, 151]. Additionally, in vivo inhibition of breast adenocarcinoma, hepatocellular 
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carcinoma and renal tumour xenografts has also been observed following SphK2 
inhibition [150-153]. It should also be noted that the selective SphK2 inhibitor 
ABC294640 has anti-eostrogen effects that contribute to cytotoxic effects in breast 
cancer cells [154, 155]. Thus, it appears SphK2 can have markedly different functions 
under different conditions, and the involvement of this enzyme in conditions such as 
cancer awaits further examination. 
 
Sphingosine 1-Phosphate in Normal Haematopoiesis 
 
S1P is present at high nanomolar to low micromolar concentrations in the circulation 
and micromolar concentrations in lymph but is maintained at low levels in tissues by 
high levels of S1P lyase, which irreversibly degrades S1P [156, 157]. This gradient of 
S1P plays a major role in directing haematopoietic cell trafficking. The high 
concentration of S1P in the plasma is derived from red blood cells [157] and vascular 
endothelium [79]. S1P in lymph is most likely derived from endothelium, as S1P 
concentrations were not affected by exposure to radiation [157]. Red blood cells do 
not generate S1P but protect it from degradation and gradually release it into plasma 
[158]. However recently, a critical role for endothelium in the production of plasma 
S1P was demonstrated with deletion of the S1P transporter, Spns2, in the endothelial 
compartment resulting in a similar reduction in plasma S1P concentrations to deletion 
of SphK1 [79]. While platelets generate and release S1P after activation, they do not 
significantly contribute to plasma S1P [158], however, localised production at 
thrombi may promote leukocyte infiltration [159].  
 
The first role for S1P and its receptors in haematopoietic systems emerged from the 
discovery that FTY720, a sphingosine analogue, induced a profound, rapid but 
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reversible lymphopenia, with lymphocytes accumulating in secondary lymphoid 
organs [160]. Once phosphorylated in vivo, FTY720 binds to 4 of the 5 S1P receptors 
(S1P1,3,4,5) [96, 161] where it acts as a super agonist, resulting in receptor 
internalisation and degradation, and subsequent loss of responsiveness to extra-
cellular S1P [162]. This functional antagonism of S1P receptors by FTY720 formed 
the basis for its approval for the treatment of multiple sclerosis [163]. These data 
place S1P as a major determinant of the movement of lymphocytes between blood 
and secondary lymphoid tissues, particularly lymph nodes, and this has been the 
subject of a number of recent reviews [81, 160]. Briefly, mature lymphocytes in the 
circulation have low surface S1P1 expression as a result of exposure to high plasma 
S1P concentrations [164] but are attracted into lymph nodes via the chemokine 
CCL21 [165]. Once in secondary lymphoid organs they re-express surface S1P1 over 
a number of hours, permitting egress into the efferent lymph in response to the S1P 
gradient between the tissues and the lymph [164]. Under inflammatory conditions 
interferons prevent re-expression of S1P1 by increasing CD69 expression, extending 
the time spent in the lymph node [166]. However, after antigen engagement and 
several divisions, S1P1 is upregulated enabling rapid egress into the circulation and 
transit to sites of inflammation [165].  
	  
Similar to the effect on normal mature lymphoid cells, S1P is responsible for the 
recirculation of haematopoietic stem (HSC), progenitor (HPC) and plasma cells back 
to the bone marrow following transit through peripheral tissues and secondary 
lymphoid organs [167, 168]. However, the direct homing of mobilised HSC/HPCs to 
the bone marrow is inhibited by over-expression of S1P1 suggesting the main activity 
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of S1P in HSC/HPCs recirculation is in the return of these cells to the circulation 
rather than bone marrow homing [169].  
 
S1P regulates the size and intravascular placement of platelets from megakaryocytes 
within the bone marrow in a S1P1-dependent manner [170] whilst S1P4 also 
contributes to megakaryocyte development and platelet production [171]. S1P3 directs 
the positioning of immature B-cells within bone marrow sinusoids for tolerance 
induction and maturation [172]. S1P has also been reported to facilitate the entry of 
mature cell types including T-cells [173] and natural killer cells [174] into the 
circulation from the bone marrow, the latter through S1P5 expression. Similar bone 
marrow exit roles have also been shown for immature B-cells [175], and most 
recently HSCs [176]. In the case of HSCs, the major bone marrow retentive factor, 
stromal derived factor 1 (SDF-1)/CXC chemokine ligand 12 (CXCL12) opposes S1P-
induced egress from the bone marrow [176] and may also counter the effects of S1P 
in other tissues where CXCL12 is highly expressed such as the liver, lung and skin 
[177]. For more information on the role of S1P in HSC/HPC trafficking readers are 
referred to the following references [176, 178-180].  
 
In peripheral tissues, S1P3 mediates the chemotaxis of macrophages [181], whilst 
within the spleen, S1P and its receptors orchestrate the movement of B-cells between 
the marginal zone where they are exposed to antigen, and the follicle, where antigen 
presentation occurs with these B-cells shuttling back and forth every few hours. 
Migration to the follicle requires the chemokine receptor CXCR5 whereas return to 
the marginal zone was prompted by S1P1 and S1P3 expression [182]. Taken together, 
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these data signify the importance of S1P in the trafficking of haematopoietic cells 
within and between distinct anatomical compartments.  
 
S1P Receptors in Haematologic Malignancies 
 
It now appears that extra-cellular S1P, signalling through S1P receptors, not only 
contributes to haematopoietic cell trafficking, but also to malignant cell biology. S1P1 
is strongly expressed in mantle cell, T-lymphoblastic lymphoma and diffuse large B-
cell lymphoma cells [183, 184] and its down-regulation inhibits STAT3 activity with 
anti-proliferative effects in the latter both in vitro and in vivo [184]. In contrast, S1P2 
suppresses the development of germinal center (GC)-derived diffuse large B-cell 
lymphoma, with mice lacking this receptor developing this neoplasm and a quarter of 
human patients with this malignancy harbouring mutations in the S1P2 gene [185]. 
Despite the well-known role of S1P in lymphocyte trafficking, its function in the 
dissemination of T-cell lymphoma is unclear. Stam et al showed that S1P was 
required for motility and invasion of	   fibroblast monolayers by T lymphoma cells in 
vitro [186], suggesting enhanced capacity for dissemination, a finding consistent with 
the broader literature concerning the role of S1P in cell motility. However, Feng and 
colleagues found S1P1 expression retarded the haematological dissemination of this 
disease [187].  
 
Sphingosine Metabolism and the Malignant Haematopoietic Cell 
 
A summary of the available literature is presented in Table 2.3 and Figure 2.8. S1P 
has well-known mitogenic activity, and factors that promote proliferation in 
haematological malignancies have been shown to activate SphK1. The clearest 
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example is activation of SphK1 by IL-6 in multiple myeloma cells [188], with PDGF 
also being predicted to similarly activate SphK1 in T-cell large granular lymphocytic 
leukaemia (T-LGL) [189]. S1P can also elicit mitogenic signalling by activating the 
transcription factor NF-κB in the AML cell line, U937 [190]. Furthermore, enzymes 
involved in the activation of SphK1 including protein kinase C (PKC), classical 
MAPK/ERKs and PI3K/mTOR are downstream of signalling pathways that play 
significant roles in leukaemogensis [108-110]. 
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Table 2.3. The role of S1P in haematological malignancies. 
Disease Component Significance 
CML 
S1P 
 
 
 
SphK1 
• Upregulates anti-apoptotic Mcl-1 [191]  
• Binding to S1P2 inhibits PP2A-dependent Bcr/Abl 
dephosphorylation [192]  
 
• Enhanced expression by Bcr/Abl and vice versa [191]  
• Inhibition results in cytotoxicity and enhances imatinib 
sensitivity [134] 
AML 
S1P 
 
 
 
 
SphK1 
• Elicits mitogenic signalling through NF-κB activation 
in U937 cells [190]  
• Inhibits classical apoptosis in U937 and HL-60 cells 
[193] 
 
• PU.1-induced over-expression contributes to 
development of erythroleukaemia in vivo [194]  
• Inhibition results in cytotoxicity in U937 xenografts 
[195]  
• Inhibition induces HL-60 cytotoxicity and sensitises 
chemoresistant HL-60 cells [135]  
ALL 
S1P 
 
 
 
SphK1 
 
 
 
 
SphK2 
• Inhibits classical apoptosis in T-ALL cells [193]  
• FTY720, acting through S1P receptors, induces 
autophagy [196]  
 
• Over-expressed in B-ALL [197]  
• Contributes to development of murine BCR/ABL-
driven ALL [197]  
• Inhibition results in cytotoxicity [197, 198]  
 
• Over-expressed in B-ALL [197]  
• Contributes to development of BCR/ABL-driven ALL 
[197, 198]  
• Inhibition results in cytotoxicity [197, 198]  
Plasma cell 
myeloma 
S1P 
 
 
 
SphK1 
• Protective against dexamethasone-induced cytotoxicity 
by upregulating Mcl-1 via ERK and AKT signalling 
[199]  
 
• Activated by IL-6 resulting in cell proliferation [188] 
Mantle cell 
lymphoma (MCL) 
S1P 
 
S1P1 
• Upregulates anti-apoptotic Mcl-1 
 
• Strongly expressed [183] 
Diffuse large B-cell 
lymphoma 
S1P1 
 
 
S1P2 
• Down regulation inhibits STAT3 with anti-
proliferative effects in vitro and in vivo [184]  
 
• Absence promotes development of GC-derived diffuse 
large B-cell lymphoma in vivo [185] 
• Commonly mutated in human patients [185]  
T-cell 
lymphoblastic 
lymphoma 
S1P1 
 
• Elevated levels result in inhibition of intravasation 
[187] 
T-cell large 
granulocytic 
leukaemia 
SphK1 • Activated by PDGF [189]  
• Inhibition results in cytotoxicity [189] 
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Further to this, oncogenic events contributing to the development of haematological 
malignancies, including PU.1 in erythroleukaemia, BCR/ABL in CML and the 
lymphoma associated RUNX genes have been linked to increased S1P production 
and/or SphK activity. The lymphoma associated RUNX genes increased the 
expression of genes involved in S1P production, Ugcg and St3gal5/Siat9, while 
suppressing Sgpp1, a S1P phosphatase. This would be expected to increase S1P 
concentrations, although direct measurements showed only modest effects. However, 
exogenous S1P partially replicated the Runx phenotype with reduced phosphorylation 
of p38MAPK and subsequent apoptosis [200]. PU.1-induced over-expression of 
SPHK1 was required for the development and progression of erythroleukaemia in vivo 
[194] and Bcr/Abl increased SphK1 expression in CML cells [191]. Activation of 
kinase pathways including the MAPK/ERK, PI3K/AKT/mTOR and JAK2 pathways, 
have often been reported to be involved in SphK1 activation [191]. 
 
Exogenous S1P provides direct pro-survival signals to malignant haematopoietic cells 
by preventing cytochrome c and Smac/DIABLO release from mitochondria in acute 
leukaemia cell lines [193] and upregulating the anti-apoptotic protein Mcl-1 in 
multiple myeloma and CML cells [191, 199]. 
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Figure 2.8. Involvement of S1P in the haematological malignancies. 
In CML, SphK1 stabilises Bcr/Abl and vice versa whilst S1P binding to S1P2 inhibits PP2A 
phosphatase activity thereby maintaining Bcr/Abl tyrosine kinase activity. In AML, S1P 
stimulates NFκB activity leading to cell proliferation whilst S1P induces autophagy in ALL 
cells leading to drug resistance and cell survival effects. In myeloma, S1P stimulates MAPK 
and AKT/mTOR signalling leading to anti-apoptotic protein expression and IL-6 stimulates 
SphK1 with proliferative and survival effects. See Table 2.3 for further details. Blue arrows: 
activating. Red arrows: inhibitory. AML, acute myeloid leukaemia; CML, chronic myeloid 
leukaemia; ALL, acute lymphoblastic leukaemia; Sph, sphingosine; S1P, sphingosine 1-
phosphate; SphK1, sphingosine kinase 1. 
 
 
Furthermore, S1P induces autophagy in a variety of cell types, in response to stressors 
such as nutrient starvation [90, 91, 201]. Autophagy permits cells to conserve and 
recycle their organelles when nutrient-deprived or stressed and as such it can be 
thought of as a ‘self preservation’ mechanism [202]. However, perhaps the most 
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convincing evidence of the pro-survival role of SphK1-generated S1P has been 
obtained using chemical inhibition or gene silencing of SphK1. Loss of SphK1 
activity induced cell death in cells from numerous haematological malignancies 
including U937 cells [195], CML cells [110, 134, 203] and T-cell large granular 
lymphocytic leukaemia [189].  
 
Extending beyond SphK1, interesting data has been obtained using FTY720, which 
although inhibiting SphK1 [96, 161], also binds and internalises S1P receptors, 
decreasing sensitivity to extra-cellular S1P [162]. FTY720 has documented in vitro 
activity against T-cell acute lymphoblastic leukaemia (T-ALL), multiple myeloma, 
chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), AML with c-
kit mutations, mouse models of CML and Ph+ (Philadelphia chromosome positive) 
ALL, Ph- ALL and NK cell leukaemia [196, 204-210]. The precise anti-tumour 
mechanism of FTY720, however, is unclear with re-activation of PP2A a postulated 
mechanism and PP2A-dependent dephosphorylation of SphK1, amongst others [192, 
210]. Most recently, a role for SphK2 in the development and maintenance of ALL 
has been suggested using a combination of in vitro and in vivo models but this work 
has yet to be published in full [197, 198]. 
 
Sphingosine Kinases and Drug Resistance 
 
There are numerous reports of SphKs contributing to the resistance of cancer cells to 
cytotoxic chemotherapy and radiation, with inhibition overcoming resistance or 
enhancing drug sensitivity. Early data suggesting a role for the ceramide/S1P balance 
in sensitivity to apoptotic stimuli came from studies on Jurkat T-cells where shifting 
the ceramide/S1P balance towards ceramide increased the sensitivity of these cells to 
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the cytotoxic effects of ionising radiation [211]. Inhibition of SphK1 sensitises HL-60 
acute myeloid leukaemia cells over-expressing the multi-drug resistant transporters 
MRP1 and MDR1 to chemotherapy [136]. In CML, a bi-directional relationship 
between SphK1 and Bcr/Abl, results in increased expression and activation of both 
kinases. Bcr/Abl increases the expression and activity of SphK1 through AKT2 
signalling in imatinib resistant K562 cells [110]. In these same cells, S1P binding to 
S1P2 inhibited PP2A-dependent dephosphorylation, and subsequent proteosomal 
degradation of Bcr/Abl [192]. Partial knockdown of SphK1 by siRNA rendered these 
cells sensitive to imatinib whereas forced expression resulted in resistance to 
apoptosis with a six-fold increase in the ratio of S1P to C18-ceramide [134]. It 
appears that the ability of SphK1 to promote drug resistance in CML extends beyond 
inhibitors of Bcr/Abl, with SphK1 inhibition increasing sensitivity to the proteosome 
inhibitor bortezomib in imatinib sensitive and resistant CML cells [212]. Thus it 
appears, SphK1 plays a significant interactive role in signalling pathways responsible 
for directing cell fate in response to drug therapy in CML. 
 
S1P-induced autophagy provides a survival advantage that can contribute to cytotoxic 
drug resistance. FTY720, acting as S1P receptor agonist, induces autophagy in a 
number of malignant haematopoietic cell types protecting against the actions of 
chemotherapeutic agents such as vincristine in ALL [196] and the monoclonal 
antibody milatuzumab in mantle cell lymphoma cells. Interestingly, the latter involved 
autophagy-lysosome dependent degradation of the therapeutic target CD74 with 
inhibition of autophagy increasing cell death [213]. 
 
Components of the sphingolipid pathway upstream of the SphKs have recently been 
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associated with drug resistance in haematological tumours. In CLL, sensitivity to 
mitochondria-targeting agents such as ABT-737 is significantly increased by 
inhibition of B-cell receptor signalling which has the effect of inhibiting UDP-glucose 
ceramide glucosyltransferase (UGCG), an enzyme responsible for the conversion of 
pro-apoptotic ceramide to pro-proliferative glucosylceramide [214]. Furthermore, 
inhibition of anti-apoptotic Bcl-2 like proteins and direct inhibition of UGCG resulted 
in synergistic cell death and increased ceramide and sphingosine in a range of non-
lymphoid haematopoietic malignancies [215]. These studies highlight the emerging 
significance of sphingolipid signalling, at multiple levels of the metabolic pathway, in 
contributing to drug resistance in haematopoietic malignancies. 
  
Pre-clinical In Vivo Studies Involving Sphingosine Kinases 
 
There are a number of pre-clinical studies examining the effect of FTY720 on 
haematological malignancies including cell line based xenograft models of 
disseminated lymphoma and mantle cell lymphoma [207, 213], murine cell line 
models of AML with c-kit mutations, CML and Ph+ ALL [208, 210], and a rat model 
of NK leukaemia [209]. Interestingly, positive in vitro data using Ph- ALL cells did 
not translate into improved outcomes in vivo [196, 216]. There is a single study 
examining the effects of specific SphK1 inhibition in a haematological malignancy. 
When the selective SphK1 inhibitor, SK1-I was administered to mice engrafted 
subcutaneously with human AML U937 cells, significantly reduced tumour growth 
was observed [195]. To date there is no published data examining SphK2 inhibitors in 
haematological malignancies except for a published abstract reporting in vitro and in 
vivo efficacy of ABC294640 in ALL [197]. 
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Therapeutic Effects of Sphingosine Kinase Inhibitors 
 
Broadly speaking, there are three strategies to inhibit the availability of S1P in 
biological systems, namely, (1) sequestration of S1P with S1P depleting antibodies, 
(2) inhibition of SphK enzyme activity, and (3) S1P receptor modulators. The 
following discussion outlines only those agents that have had a significant impact as 
potential anti-cancer therapy by altering SphK or S1P receptor activity or expression. 
The clinical trial of S1P sequestering antibody for solid tumours was completed in 
2011 but results have not been made available and this agent will not be discussed 
further here. Other putative agents are summarised in Table 2.4. SKI-II is an inhibitor 
of SphK1 and SphK2 with in vitro activity against a number of solid tumour cell lines 
and in vivo inhibition of breast adenocarcinoma cells [130, 217, 218]. Additionally, 
SKI-II was effective in vitro against CML cells [203]. SK1-I is a selective SphK1 
inhibitor with in vivo activity in acute myeloid leukaemia, glioblastoma and lung 
tumours [128, 195, 219]. ABC294640 is the first selective inhibitor of SphK2, that 
inhibits the proliferation of a number of solid tumour types in vitro and induces 
autophagic cell death in kidney, prostate and breast tumour cell lines [150, 152] and 
has recently been reported to have activity in ALL although full publications are not 
yet available [197, 198]. Inhibition of breast adenocarcinoma, hepatocellular 
carcinoma and renal tumour xenografts with good oral bioavailability has also been 
observed [150-153]. ABC294640 is currently being evaluated in phase 1/2 clinical 
trials for the treatment of solid organ malignancies. The most widely investigated 
agent is the immunomodulatory drug FTY720. Although FTY720 has shown pre-
clinical in vivo efficacy in a number of haematological malignancies, as with most 
SphK inhibitors, it has not progressed to clinical trial, possibly due to inconsistent 
outcomes and intolerable side effects [216]. Numerous other modulators of S1P 
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receptors are in development and include the S1P1 agonist SEW2781, S1P1 
antagonists VPC44116, VPC23019, and W146 (3-amino-4-3-hexylphenylamino)-4-
oxobutylphosphonic acid), and the multi-receptor antagonist VPC25239 which acts on 
S1P1 and S1P3 [220, 221]. These compounds have not yet been tested in cancer 
models and have been reviewed in Pyne and Pyne, 2011 [222]. 
 
Table 2.4. Currently available sphingosine kinase inhibitors. 
Agent Target Potency Stage of Development Comments 
SKI‑II 
 
2‑(p‑hydroxyanilino)‑4‑ 
(p‑chlorophenyl) 
thiazole) 
SphK1 
and 
SphK2 
Ki ~ 16 
µM for 
SphK1 
Ki ~ 8 
µM for 
SphK2 
In vitro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In vivo 
• Non‑competitive 
inhibition (ATP). No 
activity against ERK2, 
PI3K and PKCa  [130, 
223]. 
• Inhibition of 
proliferation and 
induction of apoptosis 
in various tumour cell 
lines [217]. 
• Inhibition of oestrogen 
receptor signalling in 
breast carcinoma cells 
[154]. 
 
• Inhibition of growth of 
syngeneic mammary 
adenocarcinoma cells. 
Oral biological 
availability [217]. 
SK1‑I 
 
(2R,3S,4E)‑N‑methyl‑ 
5‑(4‑pentylphenyl)‑ 
2‑aminopent‑4‑ene‑ 
1,3‑diol) 
 
SphK1 Ki ~ 10 
µM 
In vitro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In vivo 
• Sphingosine 
competitive inhibition. 
No activity against 
PKCα, PKCδ, PKA, 
AKT1, ERK1, EGFR, 
CDK2, IKKβ or 
CamK2b	  [195]. 
• Inhibition of growth 
and survival, induction 
of apoptosis in U937 
leukaemia, 
glioblastoma and lung 
cancer cells [128, 195, 
219]. 
 
• Inhibition of U937 
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AML, glioblastoma 
and lung tumour 
xenograft growth [128, 
195, 219]. 
• Increased survival of 
mice with orthotopic 
glioblastoma [219]. 
ABC294640 
 
(3‑(4‑chlorophenyl)‑ 
adamantane‑1‑carboxylic 
acid (pyridin‑4‑ylmethyl) 
amide 
 
 
SphK2 Ki ~ 9.8 
µM 
In vitro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In vivo 
• Sphingosine 
competitive inhibition. 
No activity against 20 
protein kinases. 
Inhibition of 
proliferation and 
migration of various 
tumour cell lines [150]. 
• Induction of 
autophagic cell death 
in kidney, prostate and 
breast tumour cell lines 
[151]. 
• Partial oestrogen 
receptor antagonist in 
breast carcinoma cells 
[155]. 
 
• Inhibition of tumour 
growth and induction 
of apoptosis in 
mammary 
adenocarcinoma 
xenografts	  [150]. 
• Inhibition of tumour 
growth and induction 
of autophagic cell 
death in kidney tumour 
xenografts. Oral 
biological availability 
[151]. 
FTY720 SphK1 
and 
SphK2 
Ki ~ 2 
µM for 
SphK1 
In vitro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Sphingosine 
competitive inhibition	  
[96]. 
• Inhibition of autotaxin 
[224], phospholipase 
A2 [225], SphK1 
[226], sphingosine 
lyase [227] and 
ceramide synthase	  
[228]. Activation of 
PP2A	  [204, 210]. 
• Inhibition of ERK1, 
ERK2 [229]	  and AKT 
phosphorylation [207, 
208]. Activation of 
caspases	  [230-232], 
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In vivo 
JNK [229]	  and 
PKCδ [231]. Increased 
ROS production [231]. 
• Phosphorylated by 
SphK2 [96]. 
• FTY720‑phosphate is 
agonist of S1P1,3,4,5 
[161]. 
• Growth arrest and 
apoptosis of various 
cancer cell lines	  [196, 
204-210, 229-231, 233, 
234]. 
 
• Growth inhibition in 
various animal tumour 
models	  [207-210, 233-
238]. Inhibition of 
tumour vascularisation 
and angiogenesis	  
[238]. 
• Reduced plasma LPA 
levels [224]. 
(s)-FTY720 vinyl 
phosphonate 
SphK1 Ki ~ 14.5 
µM 
In vitro • Sphingosine 
competitive inhibition 
[239, 240]. 
VPC94075 
 
((S)-N-(1-amino-1-
iminopropan-2-yl)-4-
octylbenzamide 
hydrochloride 
SphK1 Ki ~ 100 
nM 
In vitro • Sphingosine 
competitive inhibition 
[241]. 
• Reduced endogenous 
S1P in U937 cells but 
does not result in 
reduced proliferation 
[241]. 
PF-543 
SphK1 Ki = 3.6 
nM 
In vitro • Sphingosine 
competitive inhibition 
[242]. 
• Reduced endogenous 
S1P in head and neck 
carcinoma cells but no 
reduction in 
proliferation [242]. 
SLR080811 
 
((S)-2-[3-(4-
octylphenyl)-1,2,4-
oxadiazol-5-
yl]pyrrolidine-1-
carboximidamide) 
SphK2 Ki = 1.3 
µM 
In vitro • Sphingosine 
competitive inhibition 
[243]. 
• Reduces intra-cellular 
S1P [243]. 
• Increases plasma S1P 
levels in mice [243]. 
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Designing New Sphingosine Kinase Inhibitors with Nanomolar 
Potency 
 
Despite therapeutic pre-clinical in vivo efficacy, the current sphingosine kinase 
inhibitors exhibit Ki or IC50 values in the micromolar range, which may preclude their 
clinical use due to the requirement for unachievably high doses. Inhibitors that are 
highly potent and selective for each SphK isoform are beginning to emerge (Table 
2.4). The FTY720 analogue, (S)-FTY720 vinylphosphonate, inhibits purified SphK1 
and induces its proteosomal degradation by binding to the allosteric site of the 
enzyme and inhibiting its catalytic site [239, 240]. SphK1 inhibitors with nanomolar 
potency were recently developed by a series of modifications to sphingosine, 
however, to date have not undergone further pre-clinical testing [244]. Amidine-based 
SphK1 inhibitors with nanomolar potency that reduce endogenous S1P levels in 
human U937 leukaemia cells have recently been described [241]. The lead compound 
is the amidine analogue VPC94075 that exhibits selectivity for SphK1, with no 
activity against diacylglycerol kinase and protein kinase C. Selectivity for SphK1 over 
SphK2 was dependent on the length of the apolar tail, with those with a longer tail 
being selective for SphK1. Surprisingly, no anti-proliferative effects were found when 
the inhibitor was applied to U937 leukaemia cells, despite significantly reducing 
endogenous S1P levels. A selective SphK1 inhibitor with 100-fold selectivity for 
SphK1 over SphK2, PF-543, is another example of a recently developed agent [242]. 
On application of PF-543 to head and neck carcinoma cells, which have high 
endogenous SphK1 expression and S1P levels, a 10-fold reduction in S1P was 
observed. However in contrast to previous reports, no reduction in proliferation or 
survival was found [242]. 
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The potential for highly potent SphK2 inhibitors is currently being explored, largely 
by modifying FTY720. Varying the alkyl chain on the hydrophobic tail of the 
FTY720-derived cyclohexylamine scaffold imparts selectivity for SphK2 over 
SphK1, although these agents continue to have Kis in the low micromolar range [245, 
246]. SLR080811 is a guanidine-based SphK2 inhibitor. Although this molecule 
lowers S1P levels in cultured cells it had limited cytotoxic effects in vitro. 
Furthermore, it drove an SphK1-dependent increase in S1P plasma concentrations in 
mice, mimicking the elevated S1P levels observed in SphK2-null mice [243]. 
Whether these inhibitors will translate into clinically useful anti-cancer agents is yet 
to be determined. 
 
Concluding Remarks 
 
Numerous studies attest to SphK1 being important in promoting cellular proliferative 
and survival effects, with suppression of SphK1 by genetic ablation or chemical 
inhibition confirming this association. More recently, the design and synthesis of 
highly selective and potent SphK1 inhibitors have successfully reduced SphK1 
activity and intra-cellular S1P levels, although surprisingly did not result in anti-
proliferative or cytotoxic effects. This observation may be explained by potential off-
target effects, but is not in keeping with the cytotoxicity seen with interfering RNA or 
gene knockout murine models, suggesting SphK1 inhibition remains a viable anti-
cancer strategy. Furthermore, so little is known about SphK2, in particular its sub-
cellular localisation and compartmentalised production of S1P, that attempts to inhibit 
the enzyme result in seemingly contradictory pro-survival and cytotoxic effects with 
little mechanistic explanation. Highly selective and potent SphK2 inhibitors are 
eagerly anticipated to unravel the uncertainty surrounding this enzyme. SphK1 and 
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SphK2 themselves may not be the only anti-cancer targets since the pathways that 
regulate these enzymes and those regulated by them are also worthy of manipulation 
and the simultaneous inhibition of both SphK1 and SphK2 also warrants 
investigation.  
 
There is a paucity of studies investigating the roles these enzymes play in 
haematological malignancies with limited work conducted on any particular type. 
Given the numerous cellular signalling pathways that interact with sphingolipid 
metabolism, the potential for combining inhibitors of the SphKs or other sphingolipid 
pathway components with currently available agents as cytoreductive therapy holds 
significant promise of improved outcomes. However, reported combinatory effects 
are patchy and the rationale for the combinations tested not always clear. Much 
remains to be done before a compelling case is likely to emerge. The possible 
exception is in CML, which is the most widely studied model and it is here that 
perhaps the greatest translational in-roads will be made, given the impressive results 
with regard to the re-sensitisation of imatinib-resistant CML cells upon SphK 
inhibition. No doubt improved SphK inhibitors will be required to make the transition 
to the clinic but these are already in development and will hopefully be investigated in 
the form of a clinical trial in the not-too-distant future. 
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CHAPTER 3: MATERIALS AND METHODS 
 
 
MATERIALS 
 
Cells 
 
Ph+ cell lines: ALL1 (Dr Jerry Radich, Fred Hutchinson Cancer Research Centre, 
Seattle OR), 2070 [247], TOM1 (Prof Junia Melo, IMVS, Adelaide SA) and K562 
(American Tissue Culture Collection, ATCC). Ph- cell lines: REH (ATCC), NALM6 
(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, DSMZ) and 
LK63 (Prof Andrew Boyd, QIMR, Brisbane QLD). OP9 cells were purchased from 
ATCC. HEK293T and NIH3T3 cells were obtained from Dr Helen Rizos (Westmead 
Millennium Institute, Sydney, Australia). Cells were cultured in RPMI 1640 media 
with 10% foetal calf serum and 2 mM L-glutamine, Minimum Essential Medium 
Eagle Alpha Modification (αMEM) or Dulbecco’s Modified Eagle Medium (DMEM) 
at 37oC in an atmosphere of 5% CO2. 
 
Leukaemic blasts were obtained from patients with ALL after informed consent was 
obtained with institutional ethics committee approval from the Sydney West Area 
Health Service Human Research Ethics Committee. Cells recovered from the spleens 
of animals engrafted with these primary cells were used in the in vivo experiments 
described herein except sample 2070 where the cryopreserved patient cells were used. 
Xenografts were established in NOD/SCID mice. Xenografts ALL-3, ALL-55 and 
ALL-56 were previously established by Dr Vivek Bhadri (Children’s Cancer Institute 
Australia, Sydney). Information on all patient samples is summarised in Table 3.1. 
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Table 3.1. Human ALL cells used in this thesis.  
Patient 
ID Age/Sex Immunophenotype Cytogenetics 
ALL-3 12/F CD19+CD10- 46, XX, del(11;q23) 
ALL-55 14/M CD34+CD19+CD10+ 46, XY, t(9;22)(q34;q11.2) 
ALL-56 10/M CD34+CD19+CD10+ 
46, XY, t(9;22)(q34;q11.2)[6]/46idem, 
der(16)t(1;16)(q21;q12)[6]/46 idem +10, 
der(16)t(1;16) 
0398 15/M CD34+CD19+CD10- 46, XY, add(3)(q29), t(14:19)(q32p13) 
0533 19/F CD19+CD10+ 46, XX, t(9;22)(q34;q11.2) 
1345 5/F CD19+CD10+ 45, XX, dup(1)(q42 q25), del(3)(q21), -9, del(9)(p22), t(18;20)(q21q13.1) 
1809 12/M CD34+CD19+CD10+ 46, XY, del(4)(q21q25), -9, add(13)(q14), +add (22)(p13)[9]/46, XY[11] 
1999 14/F CD34-CD19+CD10+ 46, XX 
2032 12/M CD19+CD10+ 46, XY, add(9)(p24), del(9)(p21), del(13)(q11q21), del(19), t(1;19)(q23;p13) 
2070 65/M CD34+CD19+CD10+ 45, XY, t(9;22)(q34;q11.2), del(9)(p21) 
2286 11/M CD34+CD19+CD10+ 
46, XY, add(6)(p23), inv(8)(p12q11.2), 
der(14)?inv(14)(q11.2q32.1)del(q32.1q22), 
add(16)(q22)[20] 
2307 5/F CD19+CD10+ 46, XX, der(19)t(1;19)(q23;p13)[11]/46, XX[9] 
2313 13/M CD34+CD19+CD10+ 
46, XY, der(16)t(11;16)(q13;q22)[3]/ 
46, XY[17] 
2318 10/F CD34+CD19+CD10+ 46, XX[10] 
2319 1/F CD19+CD10+ 46, XX, der(19)t(1;19)(q23;p13)[7]/46, XX[13] 
2322 3/M CD19+CD10+ 47, XY, +X, t(11;19)(q23;p13.3)[8]/46, XY[12] 
2331 4/F CD34+CD19+CD10+ 46, XX[20] 
2337 4/M CD34+CD19+CD10+ 56, XY, +X, +5, +8, +10, +11, +12, +14, +18, +21, +22[6]/46, XY[4] 
2422 9/M CD34+CD19+CD10+ 46, XY 
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Tissue Culture 
 
RPMI 1640, DMEM and phosphate buffered saline (PBS) were obtained from Lonza 
(Basel, Switzerland). Foetal calf serum, αMEM and HEPES buffer were purchased 
from Sigma Aldrich (St Louis, MO). L-glutamine, 0.05% trypsin 
ethylenediaminetetraacetic acid (EDTA), 0.4% trypan blue and 
penicillin/streptomycin mixture were obtained from Invitrogen (Carlsbad, CA). 
Murine IL-3, murine IL-7, murine SCF and murine Flt-3 ligand were purchased from 
R&D Systems (Minneapolis, MN). 
 
Drugs and Inhibitors 
 
Doxorubicin and vincristine sulfate (Pfizer, Sydney, Australia) were obtained through 
the Westmead Hospital Pharmacy Department (Westmead, NSW, Australia). Z-VAD-
FMK was purchased from BD Biosciences (San Jose, CA). FTY720-P and SKI-II, 
also known as (p-hydroxyanilino)-4-(p-chlorophenyl)thiazol) were purchased from 
Cayman Chemical (Ann Arbor, MI). ABC294640 was purchased from Enzo Life 
Sciences (Basel, Switzerland). 6-carboxy-2′,7′-dichlorodihydrofluoresce in diacetate, 
di(acetoxymethyl ester), (carboxy-H2DCFDA) was purchased from Invitrogen. AR-
42, bortezomib, FTY720 and imatinib mesylate were purchased from Selleck 
Chemicals (Houston, TX). FTY720 was also provided by Novartis Pharmaceuticals 
(Basel, Switzerland). 3-methyladenine (3MA), 10058-F4 and okadaic acid were 
purchased from Sigma Aldrich. SK1-I ((2R,3S,4E)-N-methyl-5-(4′-pentylphenyl)-2-
aminopent-4-ene-1,3-diol.HCl) was purchased from Tocris Bioscience (Bristol, UK). 
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General Reagents and Consumables 
 
Tissue culture flasks, plates, needles, vacutainers, syringes, 40 µm spleen strainers 
and 0.4 µm transwell inserts were purchased from Falcon, BD Labware (Franklin 
Lakes, NJ, USA). Syringe filter units with 0.22 and 0.45 µm pore sizes were 
purchased from Millipore (Billerica, MA). Annexin V-FITC (fluorescein 
isothiocyanate) and propidium iodide (PI) were purchased from BD Biosciences. 
Polybrene, N-acetyl-cysteine (NAC), sodium chloride (NaCl), lithium chloride (LiCl), 
glycine, sodium deoxycholate, sodium orthovanadate (Na3VO4), sodium fluoride 
(NaF), aprotinin, leupeptin, phenylmethylsulfonyl fluoride (PMSF), sodium 
molybdite, tetramethylethylenediamine (TEMED), ammonium persulfate (APS), β-
mercaptoethanol and bromophenol blue were obtained from Sigma Aldrich. Agarose, 
bovine serum albumin (BSA), Tris-HCl, sodium dodecyl sulfate (SDS), glycerol, 
Triton X-100, Tween-20, EDTA, 1% (v/v) bis- 37.5% (v/v) acrylamide and Nonidet 
P-40 were purchased from Amresco (Solon, OH). Complete protease inhibitor tablets 
were obtained from Roche (Castle Hill, NSW, Australia), nitrocellulose membranes 
and molecular weight standards were from BioRad (Hercules, CA), skim milk powder 
from Diploma (Rowville, VIC, Australia). X-ray film was obtained from Kodak 
(Rochester, NY, USA), methanol from Fronine Lab Supply (Riverstone, NSW, 
Australia) and Whatman blotting paper from Whatman International (Maidstone, 
Kent, UK). Western blots performed using the Invitrogen iBlot system used the 
reagents specified by the manufacturer, including pre-cast gels and PVDF 
membranes. Betaplate Scint for Betaplate, glass fibre filters and microplates were 
purchased from PerkinElmer (Waltham, MA). Methyl 3H-thymidine was obtained 
from PerkinElmer. 
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Flow Cytometry 
 
Flow cytometry was performed using FACSCanto (6-colours), LSRII (12-colours) or 
LSRFortessa (10-colours) flow cytometers (BD Biosciences). 
 
Antibodies 
 
The following antibodies (catalogue number) were purchased from BD Biosciences: 
rabbit anti-human cleaved Caspase-3-FITC (559341), mouse anti-human CD19-PE 
(555413) and the following rat anti-mouse antibodies: CD45-PE (553081), 
CD45R/B220-PE-Cy5 (553091), CD19-PE (553786), CD11b-FITC (553310) and 
CD43-PE (553271). The following rabbit anti-human antibodies were purchased from 
Cell Signalling (Boston, MA): Caspase-3 (9662), LC3 (2775), Mcl-1 (4572), Beclin-1 
(3738), poly (ADP-ribose) polymerase (PARP) (9542), SphK1 (3297), c-Myc (5605) 
and histone H3 (Lys9) (9649). Invitrogen: rat anti-mouse CD45-FITC (MCD4501). 
Sigma Aldrich: mouse anti-human β-actin (A5441), α-tubulin (T9026), 
topoisomerase II (WH0007153M1) and HRP-conjugated goat anti-mouse 
immunoglobulins (A3682). Dako Denmark (Glostrup, Denmark): horseradish 
peroxidase (HRP)-conjugated swine anti–rabbit immunoglobulins (P0217) and 
biotinylated polyclonal goat anti-rabbit immunoglobulins (E0432). Santa Cruz (Santa 
Cruz, CA): rabbit anti-human S1P1 (sc-48356). ECM Biosciences (Versailles, KY): 
rabbit anti-human SphK1 (SP1621), rabbit anti-human pSphK1 (Ser225) (SP1641), 
rabbit anti-human SphK2 (SP4621) and rabbit anti-human pSphK2 (Thr538) 
(SP4631). Novus Biologicals (Littleton, CO): rabbit anti-human ABCA1 (NB400-
105). 
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Primers 
 
Table 3.2. Primers used in this thesis.  
Gene ID Forward Reverse 
BCR/ABL ACTGCCCGGTTGTCGTGT GGAGTGTTTCTCCAGACTGT 
(genomic DNA) 
 GACTGCAGCTCCAATGAGAAC GTTTGGGCTTCACACCATTCC 
(genomic DNA) 
 CTCCAGCGAGGAGGACTTC GGAACATGCGGTAGGTGGT  
PPP1R15A GCTTCTGGCAGACCGAAC GTAGCCTGATGGGGTGCTT 
SPHK1 TGTCACCCATGAACCTGCTGT 
CCCTGCACA 
AGAAGGCACTGGCTCCTCCA 
GAGGAACAAG (genomic DNA) 
 TCGTGCTTTACGGTATCGCCGC 
TCCCGATT 
 
SPHK2 GCACCCAGTGTGAATCGAGC TCTGGAGACGGGCTGCTTTA 
(genomic DNA) 
 CGCTATCAGGACATAGCGTT  
ABCA1 TCGACATGGTGAAAAACCAG AATGGTGACACAAAGCGATTC 
TRIB3 GTCTTCGCTGACCGTGAGA CAGTCAGCACGCAGGAGTC 
FAM129A ATGCTGTGGAGAGCTATGAGAA GGCTGGAAGAATTCGACATTTA 
MYC GCTGCTTAGACGCTGGATTT TAACGTTGAGGGGCATCG  
MYC 
Promoter 
ACACTAACATCCCACGCTCTG GATCAAGAGTCCCAGGGAGA 
(genomic DNA) 
NS near 
MYC 
TCCTGGGTAGGAACCAGTTG ACTCACCAAGAGCTCCTCCA 
(genomic DNA) 
NUP62 
Promoter 
AAGAAAGAAGGTGGGAGCGG CTGTAGCCTCGACCCCTTTG 
(genomic DNA) 
NME1 
Promoter 
CGCAGTCTTTGGGCTTTGTC TGCACACCAGGCTGACTTAG 
(genomic DNA) 
GAPDH GAGTCAACGGATTTGGTCGT GACAAGCTTCCCGTTCTCAG  
ABCG1 TATGGTTGGGGGTTTCCTG TTCCTTTCAGGAGGGTCTTGT  
NUP62 AAGACCTGCTGAGCCCACT GGTTTTCTCACGCTCCTCAT  
NME1 TTACCATCCCCGACCATCT AACCAACTCAATGAATCCTATGC  
Primers were designed to detect cDNA unless otherwise specified. 
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Mice 
 
This research was carried out in strict accordance with the recommendations in the 
National Health and Medical Research Council Guidelines and Policies to Promote 
the Wellbeing of Animals Used for Scientific Purposes and the Australian Code of 
Practice for the care and use of animals for scientific purposes. Protocols were 
approved by the Sydney West Area Health Service Animal Ethics Committee 
(Approval Nos. 5049.08-09 and 4172.04-11) and The University of New South Wales 
Animal Care and Ethics Committee (Approval No. 09/130A). NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NOD/SCIDγc-/-) mice were bred in-house and accommodated in 
sterile micro-isolator cages in ventilated racks. C57BL/6 mice were also bred in-house 
or purchased from the Animal Resource Centre (Perth, WA). The SphK1-/- mice were 
obtained from Prof J. Gamble (Centenary Institute, Sydney, Australia) with 
permission from Prof Proia (Bethesda, MD) and the SphK2-/- mice from Prof Proia. 
 
METHODS – Cell Biology 
 
Cell Counts and Viability 
 
Manual cell counts were performed using a haematocytometer following a 1:1 
dilution of cells in 0.4% trypan blue. Viable cells were identified by dye exclusion 
and percentage cell viability was calculated as number of live cells/total number of 
cells x 100. Automated cell counts were performed using the Beckman Coulter AcT 
Diff analyser (Brea, CA). 
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Passage of Cells 
 
Suspension cells were passaged three times per week by diluting flasks 1 in 2 to 1 in 5 
in RPMI 1640. For adherent cells, monolayers were washed once with PBS prior to 
incubation with 0.05% trypsin in EDTA at 37oC for 5 minutes to detach cells. An 
equal volume of appropriate medium was added to terminate the reaction. Detached 
cells were collected and washed by centrifugation at 180 x g for 5 minutes, then re-
suspended in appropriate medium prior to re-plating at the required cell concentration. 
 
Measurement of Cell Death 
 
Viability was usually measured by incubating cells with PI and annexin V-FITC 
according to the manufacturer’s instructions, at room temperature for 10 minutes prior 
to flow cytometric analysis. Cells negative for both annexin V and PI staining were 
considered viable. CytoTox-ONE kit (Promega, Madison, WI) is a fluorometric 
method for estimating the number of non-viable cells in a 96-well plate format, used 
as an alternative measure of cell viability. Apoptosis was measured by intra-cellular 
Caspase-3 staining. Cells were fixed and permeabilised using Cytofix/Cytoperm 
solution (BD Biosciences) according to the manufacturer’s instructions, followed by 
incubation with anti-cleaved Caspase-3-FITC antibody for 30 minutes at room 
temperature in the dark prior to flow cytometric analysis. Reactive oxygen species 
(ROS) were assessed following labelling of cells with 20 µM of carboxy-H2DCFDA 
dye in PBS for 30 minutes at 37oC in the dark. 
  
Measurement of Cellular Proliferation 
 
Proliferation was measured by 3H-thymidine incorporation [248]. Briefly, cells were 
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plated in quadruplicate and after 24 hours, 1 µCi of 3H-thymidine (PerkinElmer) was 
added per well. Following a further 6-hour incubation at 37oC, cells were harvested 
onto glass fibre filters and analysed on a MicroBeta2 2450 microplate reader 
(PerkinElmer). 
 
METHODS – Molecular Biology 
 
PCR, qPCR and qRT-PCR 
 
Genomic DNA PCRs were performed using genomic DNA collected using the DNA 
isolation kit (Promega) (BCR/ABL), the QIAmp DNA Mini Kit (Qiagen, Valencia 
CA) (SphK1 and SphK2) or the QIAquick PCR Purification Kit (Qiagen) (ChIP 
assay). The BCR/ABL genomic PCR used Takara Taq TM HS (Takara Bio Inc., Otsu, 
Japan) and primers specific for the e1a2 transcript of BCR/ABL: 5’-
ACTGCCCGGTTGTCGTGT-3’ (m-BCR) and 5’-GGAGTGTTTCTCCAGACTGT-
3’ (c-ABL). The PCR conditions were 98oC for 5”, then 98oC for 10”, 58oC for 20”, 
72oC for 30” for 40 cycles, 72oC for 5’. The SphK1/2 genomic PCRs were performed 
using the following primers and conditions: SphK1 - primer 1: 5’-
TGTCACCCATGAACCTGCTGTCCCTGCACA-3’, primer 2: 5’-
AGAAGGCACTGGCTCCTCCAGAGGAACAAG-3’ and primer neo: 5’-
TCGTGCTTTACGGTATCGCCGCTCCCGATT-3’ (40 cycles of 94oC for 1’, 65oC 
for 1’ and 72oC for 1’); SphK2 - primer 1: 5’-GCACCCAGTGTGAATCGAGC-3’, 
primer 2: 5’-TCTGGAGACGGGCTGCTTTA-3’, primer 3: 5’-
CGCTATCAGGACATAGCGTT-3’ (40 cycles of 94oC for 30”, 55oC for 30” and 
72oC for 2’). Products were separated on a 2% agarose gel and stained with ethidium 
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bromide (Amresco, Solon, OH) (BCR/ABL) or Midori Green (Nippon Genetics) and 
visualised using Molecular Imager Gel Doc TM XR (BioRad). 
 
For qRT-PCR, RNA was extracted using the Qiagen RNeasy Mini Kit and cDNA 
obtained using the AffinityScript QPCR cDNA Synthesis Kit (Agilent Technologies 
Australia, Mulgrave, VIC, Australia). Quantitative RT-PCR and q-PCR (ChIP assay 
using genomic DNA) were performed on a Corbett Rotor-Gene 3000 thermal cycler 
(Corbett Life Science, NSW, Australia) using SYBER Green Real-Time PCR Master 
Mix (Invitrogen) with thermal cycling conditions: 50oC for 2’, 95oC for 2’, 40 cycles 
of 95oC for 15”, 60oC for 15” and a final melt of 55-95oC. Amplification products 
were normalised to GAPDH and analysed on Rotor-Gene software. 
 
Pathway Analysis 
 
Signalling pathways were extracted from Metacore (GeneGo, Carlsbad, CA) using the 
Network Building function and identified interactions with known effects and curated 
links.  
 
Gene Expression Analysis 
 
Total RNA was extracted from cells using the Qiagen RNeasy Mini Kit. 
Amplification and biotinylation of the purified RNA was performed with the 
TargetAmpTM-Nano Labeling Kit (Epicenter Biotechnologies, Madison WI) for gene 
expression analysis using the Illumina HumanHT-12 v4.0 Whole-Genome Gene 
Expression BeadChip and GenomeStudio software (San Diego, CA). 
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The gene signatures were generated using data from cell lines treated with 
ABC294640 (ALL1 – 60 µM, TOM1 – 60 µM, NALM6 – 60 µM and REH – 80 µM) 
for 24 hours and the data normalised using GenomeStudio. The first method filtered 
the array data using a Diff p value of less than 0.01 in all cell lines. The second 
method used a 2-fold regulation filter followed by principal component analysis 
(Qlucore, Lund, Sweden) of the array data with a p value of < 0.005 and a false 
discovery rate of < 0.01. Hierarchical Clustering was performed using the 
GenePattern web site with Pearson correlation for the column distance measure and 
Pairwise complete-linkage method. The data was normalised for each row and centred 
on the mean.  Heat maps were generated using Java TreeView. The signal intensity 
for the genes in both signatures was extracted from the publically available dataset of 
newly-diagnosed paediatric ALL patients, GSE28497. The mean of the log2-
transformed data of the up-regulated genes was calculated and the signature intensity 
expressed as the change in this value in patient samples relative to that in the normal 
controls.  
 
METHODS – Microscopy 
 
Histology and Image Acquisition 
 
Cytospin slides of 1 x 105 control or drug treated leukaemia cells were prepared and 
stained with a Romanowsky (Wright’s) stain. Images were obtained using SPOT 
Version 4.6 software and a SPOT RTKE camera (Sterling Heights, MI) attached to an 
Olympus BX40 microscope (North Ryde, NSW, Australia). Images were compiled 
and annotated using Adobe Photoshop CS4. The objective lenses were Plan 20x/0.40 
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and UPlanFl 40x/0.75. All images were obtained in air at room temperature with no 
subsequent processing.	  
 
Electron Microscopy 
 
Electron microscopy was performed by Dr John Hewson as previously described 
[249]. Briefly, cells were fixed in modified Karnofsky fixative (2.5% formaldehyde 
prepared freshly from paraformaldehyde, 2% EM grade glutaraldehyde in 0.1 M 3-
[N-morpholino] propane sulphonic acid buffer, pH 7.4) for 2 hours. Cell blocks were 
post-fixed in osmium tetroxide, dehydrated in increasing concentrations of ethanol, 
and embedded in epoxy resin. Semi-thin (500 nm) sections were cut on a Reichert 
ultracut microtome and assessed by light microscopy. Ultrathin (80-90 nm) sections 
were cut and grid stained with 2% ethanolic uranyl acetate and then Reynolds lead 
citrate. The ultrastructure was examined using a Philips CM-10 transmission electron 
microscope (FEI, Portland OR) operated at 80 kV. Images were recorded with an 
Olympus SIS Megaview G2 CCD camera (Tokyo, Japan). 
 
Confocal Microscopy 
 
Acid vacuoles were quantitated as previously described [249]. Briefly, cells were 
labelled with 10 µM Lysosensor Blue DND-167 (Invitrogen) in RPMI containing 
10% foetal calf serum for 30 minutes and re-suspended in fresh medium before 
examination using an Olympus FV1000 confocal laser scanning microscope system, 
based on an Olympus IX-81 ZDC microscope, with BP 330- to 385-nm excitation and 
BA 420-nm emission filters. Images were captured using FV10-ASW 1.7 software 
(Olympus), and the number of acidic vacuoles in cells was enumerated using ImageJ 
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software (National Institutes of Health, Bethesda, MD). 
 
METHODS – Animal Models 
 
Induction of BCR/ABL-Positive ALL in Mice 
 
pMSCV retroviral vectors containing a 5’ LTR-driven p185 BCR/ABL and internal 
ribosome entry site (IRES) enhanced GFP (provided by Prof Charles Mullighan, St 
Jude Children’s Research Hospital, TN) were used to generate helper-free retrovirus 
 
Figure 3.1. Generation of p185 BCR/ABL-containing murine retrovirus. 
Plasmids were transfected into HEK293T cells and retroviral supernatant collected after 48 
hours. The success of viral production and titre calculation were determined by transducing 
NIH3T3 cells and monitoring GFP expression by flow ctometry. 
 
 
after transient transfection of HEK293T cells using Fugene 6 transfection reagent 
(Roche). Retroviral titres were determined by serial dilution and incubation for 72 
hours with NIH3T3 mouse fibroblasts prior to assessment of GFP positivity by flow 
cytometry (Figure 3.1). Titres were found to be in the range 0.5 to 1.0 x 106 viral 
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particles per mL. Bone marrow was harvested from C57BL/6 wild type, SphK1-/- and 
SphK2-/- mice and the B-cell progenitors collected by flow cytometric cell sorting for 
the CD11b-CD19+B220+ fraction. Dr Maggie Wang performed the cell sorting. There 
were no significant numerical differences in the proportions of B-cell progenitor 
fractions in the bone marrows of wild type, SphK1-/- and SphK2-/- mice (Figure 3.2). 
 
Figure 3.2. Bone marrow B-cell progenitor fractions in WT, SphK1-/- and SphK2-/- mice. 
Mature B-cells were defined as expressing surface IgM+B220+, Pre-B-cells as IgM-
B220+CD43-, and Pro-B-cells as IgM-B220+CD43+. The mean ± SD of 3 animals is shown. 
 
 
B-cell progenitors from each genotype were transduced in vitro on OP9 murine bone 
marrow stroma in the presence of 20 ng/mL IL-3, 30 ng/mL IL-7, 20 ng/mL SCF and 
10 ng/mL Flt-3 ligand (R&D Systems). Retroviral supernatant was added to the B-cell 
progenitors at 4 time points over 24 hours prior to harvesting and injection into 
cohorts of sub-lethally (5 Gy) irradiated wild type mice (Figure 3.3). 
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Figure 3.3. Overall schema for the generation of BCR/ABL+ murine ALL. 
Experimental design for transducing murine B-cell progenitors with the p185 BCR/ABL-
containing murine retrovirus followed by injection into WT recipients (see text for details). 
For sorting, cells falling in the viable cell gate (P1) were subjected to doublet exclusion using 
FSC-A vs FSC-H (P2), followed by exclusion of granulocytes using CD11b (P3). B-cell 
progenitors were identified using dual CD19 and B220 expression, excluding the B220bright 
mature B-cells. IL-3, interleukin-3; IL-7, interleukin-7; SCF, stem cell factor; Flt3-L, Fms-
related tyrosine kinase 3 ligand. 
 
 
Mice were monitored for the development of leukaemia by assessing CD45+GFP+ 
events at weekly tail vein bleeds, by flow cytometry (Figure 3.4).  
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Figure 3.4. Detection of murine ALL by flow cytometry. 
The flow plot represents a typical tail vein bleed of a mouse that developed leukaemia, 
indicated by the orange events (CD45+GFP+). 
 
 
Assessment of In Vivo Drug Efficacy 
 
Groups of 6 NOD/SCIDγc-/- mice were given 2-5 x 106 ALL cells by tail vein 
injection. FTY720 or ABC294640 was prepared daily in normal saline or PBS 
respectively and administered by intra-peritoneal (IP) injection for a total of 21 
consecutive days in all experiments. Mice commenced treatment 3 (xenograft 1345) 
or 7 (all other xenografts) days post injection of leukaemic cells. FTY720 was 
administered at 10 mg/kg daily in all experiments unless otherwise indicated (note the 
protocol used for Figure 5.1 is described in the associated text and figure legend). 
ABC294640 was administered at 50 mg/kg daily (xenograft 2070) or 100 mg/kg daily 
(xenografts 1345 and 1999). Control animals in all experiments received normal 
saline or PBS. For ABC294640 survival studies, mice commenced treatment with 100 
mg/kg of the drug when approximately 1% leukaemia was detected in the blood and 
continued for 21 days.  
 
Levels of leukaemia were measured by weekly tail vein bleeds and animals were 
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sacrificed after 21 days of treatment or, for survival studies, when deterioration of 
their health scores required humane sacrifice. The percentage of human cells in the 
peripheral blood, bone marrow and spleen was assessed by flow cytometry using 
antibodies to human CD19 and murine CD45. Total leukaemia was calculated based 
on the bone marrow from one femur representing 5.8% of the total bone marrow and a 
blood volume of 80 mL/kg of body weight [250]. 
 
Measurement of FTY720 in Plasma 
 
Blood was drawn by tail vein bleeding and immediately transferred to ice. A 50 µL 
aliquot was centrifuged at 1500 rpm for 10 minutes to pellet cells, and 20 µL of 
plasma was added to 380 µL ice-cold methanol. Extracts were spiked with 20 pmoles 
C17 sphingosine and C17 S1P (Avanti Polar Lipids, Alabaster, AL), which act as the 
internal standards for FTY720 and FTY720-phosphate (FTY720-P), respectively. 
Extracts were then vortexed, sonicated for 30 seconds in an ice bath, and centrifuged 
for 20 min at 14,000 rpm, at 4°C. Supernatants were transferred to 5 mL glass tubes, 
and the pellets were re-extracted as above with 600 µL ice-cold 80% methanol/20% 
water (v/v). The supernatants from both extraction steps were combined, dried in a 
SpeediVac, re-suspended in 200 µL 80% methanol/0.1% formic acid (v/v), and stored 
at -20°C for quantification of FTY720 and FTY720-P using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) by A/Professor Stuart Pitson (SA Pathology, 
Adelaide, Australia), as described previously [251]. 
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METHODS – Miscellaneous 
 
S1P Quantitation 
 
S1P concentrations in mouse plasma and cell lysates were determined using an S1P 
ELISA kit (Echelon Biosciences, Salt Lake City, UT) according to the manufacturer’s 
instructions. 
 
Western Blotting 
 
Five to ten million ALL cells were used for each condition. After incubation with or 
without drug for the appropriate time period the reaction was stopped by the addition 
of excess cold PBS containing 1 mM Na3VO4. Cell lysates were prepared in 10 mM 
Tris HCl, 150 mM NaCl (pH 7.5) containing 1 mM EDTA, 4 mM Na3VO4, 10 mM 
NaF, 1% Triton X-100, 4 µg/mL aprotinin, 1 mM phenylmethylsulfonyl fluoride, 0.1 
mg/mL leupeptin and protease inhibitor tablet, as per the manufacturer’s instruction, 
at 4oC for 30 minutes and the lysates clarified by centrifugation at 14,000 x g for 10 
minutes. The amount of protein in each lysate was quantified using the bicinchoninic 
(BCA) assay (Thermo Scientific, Rockford, IL) and equal amounts (20 µg) of protein 
were loaded in each lane of in-house or pre-cast (Invitrogen) gels and transferred to a 
nitrocellulose (BioRad) or PVDF (Invitrogen) membrane. Membranes were incubated 
with specific antibodies, followed by appropriate secondary antibodies conjugated to 
horseradish peroxidase and enhanced chemiluminescence (PerkinElmer). 
Densitometry was performed using a Kodak Imaging Station 4000MM (Rochester, 
NY). 
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Chromatin Immunoprecipitation (ChIP) Assay 
 
Acetylated histones were immunoprecipitated using specific antibodies and protein G 
immunomagnetic beads (Invitrogen) and associated chromatin assessed by qPCR with 
specific primers. In detail, protein was cross-linked to DNA for 10 minutes at 37oC 
with 1% formaldehyde then quenched with 125 mM glycine. Washed cells were lysed 
in 1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8 for 10 minutes on ice and 
sonicated using five 1 minute cycles at 40% amplitude with 60% duty from a Branson 
sonicator (Branson Ultrasonics, Danbury, CT). Lysates were clarified by 
centrifugation at 10,000 x g for 10 min at 4oC and diluted 10 fold in 
immunoprecipitation buffer (0.5% Nonidet P-40; 50 mM Tris, pH 8; 120 mM NaCl; 
0.5mM PMSF; Complete protease inhibitor cocktail (Roche)). The lysate was pre-
cleared for 1 hour at 4oC with protein G magnetic beads then incubated with primary 
antibody and protein G magnetic beads overnight at 4oC. Beads were sequentially 
washed with immunoprecipitation buffer, high salt wash buffer (immunoprecipitation 
buffer containing 500 mM NaCl), lithium wash buffer (250 mM LiCl; 0.5% NP-40; 
1% sodium deoxycholate; 1 mM EDTA, 10 mM Tris-HCl, pH 8) and Tris/EDTA (10 
mM Tris, 1 mM EDTA, pH 8). The protein–DNA complexes were eluted with 1% 
SDS in 0.1 M NaHCO3 at room temperature for 15 minutes. Crosslinks were then 
reversed in 50 mM NaCl at 65oC for 6 hours and DNA purified using Qiaquick PCR 
columns (Qiagen), prior to qPCR analysis. 
 
PP2A Activity Assay 
 
The protein phosphatase activity in cell lysates was determined by measuring the 
generation of free phosphate from a threonine phosphopeptide using the malachite 
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green-phosphate complex assay as described by the manufacturer (Millipore). Cell 
lysates were prepared in a low-detergent lysis buffer (1% Nonidet P-40, 10 mM 
HEPES, 150 mM NaCl, 10% glycerol, 1 mM PMSF, 5 mM benzamidine and 10 
µg/mL leupeptin). The phosphatase assay was performed in a PP2A-specific reaction 
buffer (Millipore) using 750 µM phosphopeptide substrate. After 10 minutes 
incubation at 30oC, malachite dye was added and free phosphate measured by optical 
density at 620 nm using a Wallac 1420 Multilabel Counter (PerkinElmer). 
 
METHODS – Statistics and Software 
 
Assessment of Drug Interactions 
 
Cells were cultured alone or with agents to be tested, at concentrations expected to 
produce less than 50% cell death when used singly. Viability was assessed using 
annexin V-FITC and PI staining by flow cytometry. The proportion of surviving cells 
expected if no interactive effects were observed was calculated according to the 
method of Webb [252]. Combinations with chemotherapeutic agents were assessed at 
24 hours due to excess toxicity at later time points. Combinations with other agents 
were assessed at 24, 48 and 72 hours. 
 
General Statistical Analysis 
 
The expression of the gene signatures in ALL cells was performed using the Mann-
Whitney test. The Fractional Product method [252] was used to discriminate between 
synergistic and antagonistic effects of drug combinations with a value of > 0.1 
indicating antagonism and < -0.1 synergy. Comparisons between two groups were 
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performed using the Student’s t test and between multiple groups using ANOVA 
analysis. A level of significance of < 0.05 was deemed significant. For survival 
studies Kaplan-Meier analysis was performed and a Log-rank test used to determine 
significance with Bonferoni’s correction for multiple comparisons. 
 
Software 
 
The following software was used for research and preparation of the thesis: 
Adobe Photoshop CS4 (San Jose, CA) 
GenePattern web site (Cambridge, MA) 
GenomeStudio software (San Diego, CA) 
GraphPad Prism software (La Jolla, CA) 
ImageJ software (National Institutes of Health, Bethesda, MD) 
Java TreeView 
Metacore (GeneGo, Carlsbad, CA) 
Microsoft Excel 
Microsoft Powerpoint	  
Microsoft Word 
Qlucore Software (Lund, Sweden) 
Rotor-Gene software (Qiagen) 
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CHAPTER 4: THE EFFECTS OF FTY720 IN ACUTE 
LYMPHOBLASTIC LEUKAEMIA CELLS 
 
 
The following manuscript has been published: Autophagy 2011;7:707-715. 
The Materials and Methods section has been placed in Chapter 3. 
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ALL  Acute lymphoblastic leukaemia 
AML  Acute myeloid leukaemia 
CLL  Chronic lymphocytic leukaemia 
CML  Chronic myeloid leukaemia 
FITC  Fluorescein isothiocyanate 
FTY720-P FTY720 phosphate 
MCL  Mantle cell lymphoma 
NAC  N-acetyl-cysteine 
PARP  anti-poly (ADP-ribose) polymerase 
Ph- ALL Philadelphia negative ALL 
Ph+ ALL Philadelphia positive ALL 
PI  Propidium Iodide 
PP2A  Protein phosphatase type 2A 
ROS  Reactive oxygen species 
S1P  Sphingosine 1-phosphate 
S1P1  Sphingosine 1-phosphate receptor 1 
SphK1  Sphingosine kinase 1 
SphK2  Sphingosine kinase 2 
3MA  3-Methyladenine 
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Abstract  
	  
Acute lymphoblastic leukaemia (ALL), the most common form of childhood cancer, 
usually responds to chemotherapy but patients who develop disease relapse have a 
poor prognosis. New agents to treat ALL are urgently required. FTY720 is an 
immunosuppressive drug that has promising in vitro activity in a number of 
malignancies, with the proposed mechanism being the re-activation of the protein 
serine/threonine phosphatase, PP2A. FTY720 reduced the proliferation and viability 
of Ph+ and Ph- ALL cell lines and patient samples with IC50 values for viability 
between 5.3 to 7.9 µM. Cell death was caspase-independent with negligible activation 
of Caspase-3 and no inhibition of FTY720-induced cell death by the caspase inhibitor 
Z-VAD-FMK. The cytotoxic effects of FTY720 were independent of PP2A re-
activation as determined by the lack of effect of the PP2A inhibitor okadaic acid. 
Features of autophagy, including autophagosomes and LC3II expression, were 
induced by FTY720. However the phosphorylated form of FTY720 (FTY720-P) 
similarly induced autophagy but not cell death. This suggests that autophagy is pro-
survival in this setting, a finding supported by protection from cell death induced by 
the cytotoxic agent vincristine. FTY720 also induced reactive oxygen species (ROS) 
and the antioxidant N-acetyl-cysteine (NAC) partially reversed the cytotoxic effects, 
demonstrating a role for ROS generation in the cell death mechanism. FTY720 is an 
active drug in vitro in ALL cell lines and patient samples. Evidence supports a 
caspase-independent mechanism of cell death with the occurrence of autophagy and 
necrosis. 
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Introduction 
 
Acute lymphoblastic leukaemia (ALL) is the most common form of childhood cancer 
and accounts for about 20% of cases of acute leukaemia in adults [58]. Although ALL 
is highly responsive to initial combination chemotherapy, about 25% of children and 
65% of adults develop disease relapse, with subsequent poor prognosis [253]. In 20-
40% of adults and 2-5% of childhood patients with ALL, the disease is caused by the 
BCR/ABL proto-oncogene (Philadelphia positive, Ph+ ALL), with a historically poor 
prognosis, although the introduction of tyrosine kinase inhibitors in combination 
chemotherapy has significantly improved survival [60]. In addition, current 
chemotherapeutic protocols for ALL are complex and prolonged, and result in 
significant toxicities in many patients. New therapeutic strategies are therefore 
required for ALL patients who relapse or who have high risk features for relapse at 
diagnosis. Targeting signalling pathways within leukaemic cells is a promising 
strategy, which seeks to exploit intra-cellular mechanisms responsible for cell 
replication and survival. 
 
The immunosuppressive drug FTY720 binds to four of five G protein-coupled 
sphingosine 1-phosphate (S1P) receptors resulting in receptor down regulation, 
rendering the cell unresponsive to S1P, an important lymphocyte chemoattractant 
[161]. S1P is responsible for the egress of lymphocytes from secondary lymphoid 
tissues into the circulation through binding to S1P1 [161]. Disruption of the S1P 
gradient therefore negates a major mechanism for stimulating the movement of 
lymphocytes from lymph nodes to the peripheral blood and results in a marked 
lymphopenia [103, 254, 255]. As such, FTY720 has been trialled in the prevention of 
graft rejection for renal transplantation [256-261] and in the treatment of autoimmune 
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disorders such as multiple sclerosis, although only the latter application remains 
viable at this point in time [163]. 
 
FTY720 also re-activates the protein phosphatase type 2A (PP2A), an essential 
protein serine/threonine phosphatase whose activity is reduced in certain malignancies 
[204, 262, 263]. PP2A is a key enzyme within various signal transduction pathways, 
regulating fundamental cellular activities such as DNA replication, cell cycle 
progression and apoptosis [264]. Studies have shown FTY720 to have activity against 
a number of haematological malignancies including multiple myeloma, chronic 
lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), acute myeloid 
leukaemia (AML) with c-kit mutations, and in mouse models of chronic myeloid 
leukaemia (CML) and Ph+ ALL [205-208, 210].  Such wide ranging efficacy has been 
attributed to PP2A re-activation and not to signalling through the S1P1 receptor. 
FTY720 is phosphorylated by sphingosine kinase 1 and 2 (SphK1 and SphK2) of 
which SphK2 is the most important isoform [96]. Only the phosphorylated form of the 
drug is able to bind to S1P receptors, an interaction thought to be distinct from its 
effect on PP2A [96, 206, 210]. The phosphorylated form of the drug is not seen as 
being involved in cell death and therefore not viewed as relevant in the treatment of 
malignancies. 
 
FTY720 appears to be a potentially valuable addition to the pharmacological 
repertoire available for the treatment of haematological malignancies. However, there 
have been no detailed reports of the effects of FTY720 in ALL. In this study, we 
assessed the efficacy of FTY720 on a wide range of Ph+ and negative ALL cells and 
investigated the associated mechanisms of cell death. 
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Results 
 
FTY720 Inhibits ALL Cell Proliferation and Survival  
 
FTY720 has been reported to induce cell death in a number of haematological 
malignancies including Ph+ ALL [210]. FTY720 produced a marked reduction in 
cellular proliferation of ALL cell lines as measured by 3H-thymidine incorporation, 
with IC50 values ranging from 1.4 µM for ALL1 to 4.0 µM for LK63 (Figure 4.1A). 
 
Figure 4.1. FTY720 results in reduction of cell proliferation and viability. 
A) ALL1, REH, NALM6 and LK63 cell lines were treated with indicated concentrations of 
FTY720 for 24 hours and proliferation measured using 3H-thymidine incorporation. Counts 
have been normalised to control values. The mean ± SD of quadruplicates is shown from one 
of two experiments. B) Viability of the same cell lines treated with FTY720 for 24 hours as 
assessed by flow cytometry. The mean ± SD of duplicate samples is shown from one of three 
experiments. Primary Ph- (C) and Ph+ (D) patient cells were treated with increasing 
concentrations of FTY720 for 16 hours and viability assessed by flow cytometry. The mean ± 
SD of duplicates is shown. 
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FTY720 also produced a profound reduction in cell viability with IC50 concentrations 
in the low micromolar range (1 µM – 10 µM) in all cell lines (Figure 4.1B).  The Ph+ 
cell line, ALL1, was more sensitive to FTY720 than other cell lines, with an IC50 of 
5.3 µM at 24 hours whilst LK63 cells appeared to be the most resistant to FTY720 
with a 24-hour IC50 of 7.9 µM. 
 
 
Figure 4.2. FTY720 induces release of LDH indicating loss of plasma membrane 
integrity. 
ALL1 and REH cells were treated with 7.5 µM and 10 µM FTY720 for 16 hours and released 
LDH determined as per the manufacturer’s instructions (Promega, G7890). The amount of 
fluorescence is proportional to the amount of released LDH from damaged cells. 100% - 
maximum LDH release (manufacturer’s positive control), Control – untreated ALL cells. The 
mean ± SD of triplicate determinations is shown. *p<0.05 compared to control. 
 
 
Cell death was further substantiated by measurement of lactate dehydrogenase (LDH) 
release from damaged cells (Figure 4.2). Primary patient ALL cells were also 
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sensitive to treatment with FTY720. Both Ph+ and Ph- cells showed a fall in viability 
of similar magnitude to that of ALL cell lines with IC50 values within the range of 5-
10 µM (Figure 4.1C and D).  
 
FTY720 Results in Caspase-Independent Cell Death 
 
FTY720 has been reported to induce apoptosis in lymphoid cells [265] but caspase-
independent cell death in chronic lymphocytic leukaemia and mantle cell lymphoma 
cells [206, 207]. Exposure of ALL cell lines to concentrations of FTY720 that induce 
cell death (Figure 4.3A) induced cleavage of Caspase-3 in only a minority of cells 
when assessed by flow cytometry (Figure 4.3B). Similarly, Western blotting failed to 
detect cleavage of Caspase-3 (Figure 4.3C). The absence of classical apoptosis was 
further supported by virtually absent PARP cleavage (Figure 4.3C), consistent with 
the small percentage of cells with cleaved Caspase-3 detected by flow cytometry. The 
pan-caspase inhibitor Z-VAD-FMK did not protect ALL cells from the cytotoxic 
effects of FTY720, demonstrating a caspase-independent mechanism of cell death 
whereas it protected against doxorubicin-induced apoptosis in REH and ALL1 cells 
(Figure 4.3D and data not shown) due to a reduction in Caspase-3 cleavage (data 
not shown). 
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Figure 4.3. FTY720 results in caspase-independent cell death. 
A) Viability of ALL1 and REH cells treated with 10 µM FTY720 for 6, 12 and 24 hours as 
determined by flow cytometry. The mean ± SD of duplicate assessments is shown from one 
of two experiments. B) Caspase-3 cleavage in ALL1 cells as determined by flow cytometry. 
Doxorubicin (Dox) 3 µM for 24 hours was used as a positive control. C) Western blots of 
Caspase-3 and PARP in cell lysates of cells treated with the indicated concentrations of 
FTY720 for designated time periods. The positive control (+) is NALM6 cells treated with 1 
µM doxorubicin for 6 hours. D) Caspase independence was determined by preincubating 
ALL1 and REH cells with 20 or 100 µM Z-VAD-FMK for 30 minutes prior to the addition of 
10 µM FTY720. Dox, positive control. Viability was assessed by flow cytometry following a 
further 12 hour incubation. The mean ± SD of duplicates is shown with values representative 
of two individual experiments. 
Chapter 4 The Effects of FTY720 in Acute Lymphoblastic Leukaemia Cells 
	  
	  
77	  
Activation of PP2A is not Required for FTY720-Induced Cell Death 
 
FTY720 is thought to elicit anti-leukaemic effects through activation of PP2A, which 
results in caspase-dependent cell death [204, 210]. Treatment with FTY720 activated 
PP2A by approximately 1.5 fold in ALL1 and REH cell lines as expected (Figure 
4.4A). However, pre-treatment with the PP2A inhibitor okadaic acid, which inhibits 
PP2A activity (Figure 4.4A), was not associated with an increase in the viability of 
either ALL1 or REH cells suggesting PP2A-independent cell death (Figure 4.4B). 
The lack of a role for PP2A is consistent with the absence of apoptosis.  
 
Figure 4.4. FTY720-mediated PP2A activation is not responsible for loss of cell viability. 
(A) ALL1 cells were treated with 10 µM FTY720 for 4 hours or 5 nM okadaic acid for 2 
hours and assessed for PP2A activity using the malachite green-phosphate complex assay. 
The mean ± SD of duplicate samples is shown from one of two individual experiments. (B) 
ALL1 and REH cells were treated with 7.5 µM or 10 µM FTY720 for 24 hours with or 
without pre-incubation for 2 hours with 5 nM okadaic acid. Cell viability was determined by 
flow cytometry. The mean ± SD of duplicate samples is shown from one of two 
representative experiments. *p<0.05 compared to control. 
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FTY720 Results in the Induction of Autophagy 
 
Consistent with the absence of caspase activation, light microscopic examination of 
ALL cell lines showed prominent cytoplasmic vacuolation with very few, if any, 
apoptotic cells (Figure 4.5A). Staining with Lysosensor Blue identified the vacuoles 
as being acidic in nature (Figure 4.5B). Detailed examination revealed a positive 
association between the number of acidic vacuoles and the dose of FTY720 applied to 
the cells (Figure 4.5C). 
 
FTY720 has been reported to induce autophagy in certain cell types through binding 
S1P receptors [90]. Consistent with these reports FTY720 induced the processing of 
LC3 suggesting the presence of autophagy (Figure 4.6A). To demonstrate that the 
increased LC3II was due to increased induction of autophagy as opposed to a block in 
the autophagic pathway, the autophagic flux was measured by inhibiting the late 
stages of autophagy with the vacuolar type H+-ATPase inhibitor bafilomycin A1 
[266]. In support of FTY720 as an inducer of autophagy, increased autophagic flux 
was visualised as increased LC3II when FTY720-treated ALL cells were co-incubated 
with bafilomycin A1 (Figure 4.6B). 
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Figure 4.5. FTY720 promotes autophagy in ALL cells. 
A) ALL1 cells were treated with 10 µM FTY720 for 16 hours. Cytospin slides were prepared 
and stained with a Wright’s stain. Original magnification x 600. The size bar in the lower 
right hand corner of each image represents 100 microns. B) ALL1 and REH cells were 
stained with Lysosensor Blue following treatment with indicated concentrations of FTY720 
for 16 hours and examined by confocal microscopy. Original magnification x 600. C) 
Histograms representing the proportion of cells containing specific numbers of acidic 
vacuoles is shown. Quantitation was obtained from the analysis of more than 120 cells for 
each condition. The mean ± SD of duplicate determinations is shown from one of two 
individual experiments.  
 
 
Inhibition of Beclin-1 by anti-apoptotic Bcl-2 family members is known to inhibit 
autophagy [267, 268]. Whilst levels of Beclin-1 remained constant following FTY720 
treatment, the anti-apoptotic Bcl-2 family member, Mcl-1, decreased in a 
concentration-dependent manner suggesting the inhibitory control of Beclin-1 was at 
least partially removed (Figure 4.6C). Bcl-2 protein levels did not change from 
baseline (data not shown). This is in agreement with findings by Lui et al, where 
FTY720 was reported to result in a reduction in Mcl-1 levels whilst maintaining 
baseline Bcl-2 levels [206]. 
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Figure 4.6. FTY720 increases autophagic flux in ALL cells. 
A) Western blot analysis of LC3 protein in cell lysates prepared from NALM6, ALL1 and 
REH cells treated as indicated. RAD001 was used as a positive control. B) Western blot of 
NALM6 cells treated with the indicated concentrations of FTY720 for 6 hours with or 
without 10 nM or 100 nM bafilomycin A1. Densitometry of LC3II bands was undertaken and 
values normalised to β-actin and control samples provided. C) Western blot of Beclin-1 and 
Mcl-1 expression in REH cells treated with the indicated concentrations of FTY720 for 6 
hours. Densitometry of Mcl-1 bands was undertaken and values normalised to β-actin and 
control samples provided. 
 
 
Electron microscopy confirmed the presence of autophagy, identifying the vacuoles as 
autophagosomes, containing mitochondria and other cellular organelle remnants 
(Figure 4.7). Necrotic cells were also observed alongside cells with autophagy. 
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Figure 4.7. Ultrastructural analysis by transmission electron microscopy. 
Ultrathin sections of ALL1 and REH cells treated as indicated for 16 hours. Necrotic cell 
indicated by arrow. The size bar in the lower right hand corner of each image represents 1 
micron. 
 
 
FTY720 does not Mediate Leukaemic Cell Death Through the S1P1 
Receptor 
 
FTY720 only activates S1P receptors following phosphorylation by one of the two 
sphingosine kinases [96]. This occurs in cell culture with poorly defined kinetics. To 
overcome this issue and examine the role of S1P receptors in ALL cell responses to 
FTY720 we used the phosphorylated form of FTY720 (FTY720-P). S1P1 was 
expressed in ALL1 and REH cells and was not altered by exposure to FTY720 
(Figure 4.8A). In contrast to FTY720, FTY720-P failed to induce cell death (Figure 
4.8B) demonstrating that activation of S1P receptors is not sufficient for leukaemic 
cell death. This is consistent with reports of FTY720-P having pro-survival effects in 
various cells including those of breast and colon cancer [229, 269]. FTY720-P 
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resulted in the processing of LC3, suggesting that autophagy was induced by the 
phosphorylated form, but that this did not cause cell death (Figure 4.8C). 
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Figure 4.8. FTY720-induced cell death is not mediated by S1P1 receptor signalling. 
A) Expression of S1P1 in ALL1 and REH cells by Western blotting. Cells were treated with 
the indicated concentrations of FTY720 for the indicated times. B) ALL1 and REH cells were 
treated with indicated concentrations of FTY720 or FTY720-P for 24 hours. Cell viability 
was determined by flow cytometry with annexin V-FITC and PI staining. The mean ± SD of 
duplicate determinations for each drug concentration is shown from one of two experiments. 
C) Western blot analysis of LC3 protein in cell lysates prepared from NALM6 cells treated as 
indicated with FTY720-P for 6 hours. RAD001 was used as a positive control. D) Viability of 
ALL1 and REH cells treated with 5 nM vincristine for 24 hours, either alone or in the 
presence of 5 µM FTY720 or FTY720-P. Viability was assessed with annexin V and PI 
staining by flow cytometry. The mean ± SD of duplicate experiments is shown from one of 
two experiments. # p<0.05 compared to vincristine alone. 
 
 
To clarify the role of FTY720-induced autophagy in ALL cell death, the effect of 
FTY720 and FTY720-P on vincristine-induced apoptosis was examined. A sub-
cytotoxic concentration of FTY720 and equivalent concentrations of FTY720-P 
partially rescued cells from vincristine-induced apoptosis, supporting a survival role 
for autophagy in this setting (Figure 4.8D). Similar results were obtained at a range of 
vincristine concentrations or when 2.5 µM FTY720 was used (data not shown).  
 
Furthermore, inhibition of autophagy with 3-methyladenine (3MA) resulted in a fall 
in cell viability when combined with FTY720 greater than the reduction seen with 
FTY720 alone (Figure 4.9A), confirming that autophagy is protective. The inhibitory 
effect of 3MA on autophagy was confirmed by Western blot as a reduction in LC3II 
formation (Figure 4.9B). 
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Figure 4.9. FTY720-induced autophagy is protective. 
A) ALL1 and REH cells were incubated with 5 µM FTY720 with or without 5 mM 3MA for 
24 hours. Cell viability was assessed by flow cytometry. The mean ± SD of duplicate 
determinations is shown. *p<0.05 compared to identically treated cells in the absence of 
3MA. B) Western blot analysis of LC3 protein in cell lysates prepared from NALM6, REH 
and ALL1 cells treated as indicated with FTY720 for 6 hours with or without 5 mM 3MA. 
Densitometry was used to quantitate LC3II bands and values are below corresponding lanes. 
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FTY720 Generates Reactive Oxygen Species 
 
Recently, caspase-independent cell death induced by FTY720 was reported to be 
dependent on the generation of ROS [207]. Similarly, we found that treatment of ALL 
cell lines with cytotoxic concentrations of FTY720 resulted in the production of ROS 
in a time and dose-dependent manner (Figure 4.10A). Pre-treatment of ALL cells 
with the antioxidant NAC resulted in the inhibition of both ROS generation (Figure 
4.10B) and the loss of viability following exposure to FTY720 (Figure 4.10C). This 
data demonstrates that FTY720-induced cell death is at least partially dependent on 
ROS generation.  
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Figure 4.10. FTY720 generates reactive oxygen species. 
A) ALL1 and REH cells were treated with 10 µM FTY720 for 0 to 10 hours. ROS generation 
was measured using carboxy-H2DCFDA. The mean ± SD of duplicates is shown from one of 
two representative experiments.  B) REH cells were untreated (Control) or treated with 10 
µM FTY720 for 6 hours with or without a 15 minute pre-incubation with 10 mM NAC. C) 
ALL1 and REH cells were treated with the indicated concentrations of FTY720 following a 
15 minute pre-incubation with 5 or 10 mM NAC. Viable cells were measured as annexin V 
and PI negative events by flow cytometry. The mean ± SD of duplicate determinations is 
shown from one of two experiments. *p<0.05 compared to identically treated cells in the 
absence of NAC. 
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Discussion 
 
Although FTY720 has been studied in several haematological malignancies, we report 
here the first detailed analysis of the effects of FTY720 in Ph+ and Ph- B lineage ALL. 
Currently, FTY720 appears extremely promising in treating relapsing/remitting 
multiple sclerosis as shown in a recent phase three randomised controlled trial [163]. 
In the haematological malignancies, FTY720 remains in pre-clinical development, 
however, it appears the drug is potentially efficacious in such conditions, including 
ALL, and it is anticipated that strong pre-clinical data will provide the platform to 
commence human trials in the future.  
 
FTY720 has been shown to be highly active in Ph+ haematological malignancies such 
as seen in mouse models of CML and Ph+ ALL [210]. In this study, we add to this list 
Ph- B lineage ALL. Firstly, we have shown a marked reduction in both cellular 
proliferation and viability in Ph+ and negative ALL cell lines and patient samples 
when exposed to FTY720. Secondly, we have observed that the mechanism of cell 
death is via a caspase-independent process and therefore strictly speaking, not 
apoptosis. A minor proportion of ALL cells demonstrated Caspase-3 cleavage. This 
explains why a very small amount of PARP cleavage is present in Figure 4.3C. While 
this caspase-independent mechanism contrasts with a number of reports, [204, 205, 
210, 262, 263] caspase-independent cell death has also been reported in chronic 
lymphocytic leukaemia and mantle cell lymphoma [206, 207].  
 
FTY720 has been shown to mediate its anti-malignant effect through mechanisms 
other than the binding of its phosphorylated form to the S1P1 receptor [204, 206, 210]. 
Such an effect on cell viability is thought to be through the interaction of the parent 
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drug with PP2A although the precise details of this interaction are unknown. 
Although FTY720 produced an increase in PP2A activity, the PP2A inhibitor okadaic 
acid failed to rescue the cells from the effects of the drug. This suggests that 
activation of PP2A is not required for FTY720-mediated cell death in ALL cells, in 
contrast to previous studies that report the dependence of FTY720 on PP2A 
activation. CML [210], Ph+ ALL [210], CLL [206] and most recently, AML with c-kit 
mutations [208] have all reported to undergo FTY720-mediated cell death via PP2A 
activation. PP2A is known to negatively regulate components of signalling pathways 
responsible for controlling cell cycle dynamics and proliferation [270]. In addition, 
PP2A interacts with a number of pro- and anti-apoptotic proteins thereby allowing 
cells to undergo programmed cell death [271]. Additionally, FTY720 resulted in 
BCR/ABL dephosphorylation in in vitro models of CML and Ph+ ALL in a PP2A-
dependent manner [210]. The involvement of PP2A when FTY720 is applied to cells 
from these haematological disorders is difficult to refute, however our data 
demonstrate that in B-lineage ALL cells, PP2A activation is insufficient to induce cell 
death.  
 
Autophagy is a process by which cells conserve and recycle their organelles when in a 
nutrient-deprived or stressed state. As such it can be thought of as a ‘self preservation’ 
mechanism [202]. If autophagy continues unabated, it too may result in cell death, 
although this process remains controversial, and whether cell death is ‘autophagic’ 
per se or the result of a switch to an alternate death pathway (apoptosis or necrosis) is 
the subject of ongoing investigation [272-275]. We demonstrated the increased 
presence of cells containing autophagosomes with biochemical evidence of increased 
autophagic flux, necrotic cells and a lack of classic apoptotic cells with FTY720, 
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concomitant with a progressive loss of cell viability. Whether this autophagy is 
required for cell death remains to be determined but inhibition of mTOR has also been 
shown to result in autophagy, but not apoptosis, in ALL cells. Like FTY720, mTOR 
inhibition induced a significant reduction of viability in vitro [249]. It is possible that 
ALL cells may be particularly prone to undergo autophagy and die by caspase-
independent mechanisms. Recently, autophagy was shown to be required for necrotic 
cell death induced by the Bcl-2 family inhibitor, obatoclax, in combination with 
dexamethasone in dexamethasone-resistant T-ALL cells [276], demonstrating that 
autophagy can play an active role in the demise of ALL cells.  
 
FTY720 is also known to bind and signal through four of the five known S1P 
receptors following phosphorylation, and this is the main mechanism by which it 
mediates its immunosuppressive activity. However, activation of S1P receptors by 
FTY720-P did not produce cytotoxic effects, suggesting that S1P signalling is not 
sufficient for FTY720-induced cell death in ALL cells. S1P signalling through S1P5, 
or activation of SPHK1, and subsequent S1P production, have been associated with 
the induction of autophagy [90, 91]. It is therefore possible that FTY720-induced S1P 
signalling also plays a role in the induction of autophagy in ALL cells. Indeed we 
observed LC3II induction following FTY720 and FTY720-P treatment suggesting 
that in this setting the induction of autophagy is not responsible for ALL cell death.  
Moreover, both FTY720 and FTY720-P protected ALL cells from the cytotoxic agent 
vincristine. Since both FTY720 and FTY720-P induced autophagy, and autophagy is 
known to have a pro-survival role [202], it is likely that these agents are providing 
protection from cell death via this mechanism, as demonstrated by a further increase 
in cell death in the presence of autophagy inhibition using 3MA. Recently, FTY720 
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was shown to induce autophagy and necrosis in ovarian cancer cells [277]. As in our 
study, autophagy was shown to be protective against the cytotoxic effects of FTY720. 
Although the cytotoxic effect of FTY720 was independent of S1P signalling in both 
ALL and ovarian cancer cells, we have shown that S1P signalling induces autophagy, 
which in turn exerts cell protection.  
 
We have shown that FTY720 induces the formation of ROS, which can result in cell 
death [278-281]. Incomplete reversal of leukaemic cell death by the antioxidant NAC 
suggests that FTY720 most likely has multiple effects culminating in cellular toxicity 
and ultimately cell death. ROS can be generated in apoptotic and non-apoptotic 
modes of cell death. The antiproliferative agent platycodon D was shown to produce 
ROS, altered mitochondrial membrane potential and Caspase-3 activation indicative 
of classical apoptosis with all features significantly reversed by NAC [278]. Under 
apoptosis-deficient conditions, death receptor signalling through, for example, TNF 
and FAS receptors, has been shown to induce cellular necrosis, ultimately mediated 
by the generation of ROS [281]. 
 
Although FTY720 was initially studied for its immunosuppressive actions, its 
potential role has now increased to include a number of malignancies. The treatment 
of human leukaemia, particularly ALL, is cumbersome and costly on many levels. 
Simplifying the complexity of years of multi-agent chemotherapy and reducing 
associated toxicities whilst maximising the chance of remission are of prime 
importance. FTY720 represents a potential new treatment for Ph+ and negative ALL, 
perhaps providing an opportunity to improve on current chemotherapeutic protocols.
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CHAPTER 5: IN VIVO EFFICACY OF FTY720 
 
 
The following manuscript has been published: PLoS ONE 2012;7(5): e36429. 
The Materials and Methods section has been placed in Chapter 3. 
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Abstract 
 
Most patients with acute lymphoblastic leukaemia (ALL) respond well to standard 
chemotherapy-based treatments. However a significant proportion of patients, 
particularly adult patients, relapse with the majority dying of leukaemia. FTY720 is 
an immunosuppressive drug that was recently approved for the treatment of multiple 
sclerosis and is currently under pre-clinical investigation as a therapy for a number of 
haematological malignancies. Using human ALL xenografts in NOD/SCIDγc-/- mice, 
we show for the first time that three Ph+ human ALL xenografts responded to 
FTY720 with an 80±12% (p=0.048) reduction in overall disease when treatment was 
commenced early. In contrast, treatment of mice with FTY720 did not result in 
reduced leukaemia compared to controls using four separate human Ph- ALL 
xenografts. Although FTY720 re-activated PP2A in vitro, this re-activation was not 
required for death of Ph- ALL cells. The plasma levels of FTY720 achieved in the 
mice were in the high nanomolar range. However, the response seen in the Ph+ ALL 
xenografts when treatment was initiated early implies that in vivo efficacy may be 
obtained with substantially lower drug concentrations than those required in vitro. Our 
data suggest that while FTY720 may have potential as a treatment for Ph+ ALL it will 
not be a useful agent for the treatment of Ph- B-ALL. 
 
Key Words 
Acute lymphoblastic leukaemia, NOD/SCIDγc-/-, FTY720, PP2A, Apoptosis. 
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Introduction 
 
Acute lymphoblastic leukaemia (ALL) represents approximately a quarter of all 
childhood cancers, and a similar proportion of cases of acute leukaemia in younger 
adults. Although the treatment of childhood ALL is one of the success stories of 
modern oncology, treatment protocols remain imperfect [282]. Approximately 15% of 
children and the majority of adults diagnosed with ALL relapse following treatment. 
The overall survival of the 60% of adults who relapse following treatment is only 7% 
at 5 years [60, 283]. Overall, once relapse occurs, the success of any further treatment, 
including haematopoietic stem cell transplantation, is poor.  
 
FTY720 is an immunosuppressive drug recently approved for the treatment of 
multiple sclerosis [163]. Once phosphorylated by sphingosine kinases, phosphorylated 
FTY720 (FTY720-P) down-regulates four of the five sphingosine 1-phosphate (S1P) 
receptors, trapping lymphocytes in secondary lymphoid organs [284]. More recently, 
FTY720 has been investigated for the treatment of malignancies and has documented 
in vitro and/or pre-clinical activity against a number of haematological disorders 
including T-cell acute lymphoblastic leukaemia (T-ALL), multiple myeloma, chronic 
lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), acute myeloid 
leukaemia (AML) with c-kit mutations, mouse models of chronic myeloid leukaemia 
(CML) and Ph+ (Philadelphia chromosome positive) ALL, Ph- ALL and NK cell 
leukaemia [196, 204-210]. 
 
The anti-leukaemic efficacy of FTY720 is thought to be due to re-activation of the 
protein phosphatase type 2A (PP2A), an essential protein serine/threonine 
phosphatase, the activity of which is reduced in certain malignancies [204]. The 
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involvement of PP2A re-activation in Ph+ disease has been well documented with 
interplay between PP2A and Bcr/Abl being clearly demonstrated [210]. Indeed PP2A 
activation and caspase-dependent cell death were required for its cytotoxic effect in 
AML, CML and Ph+ ALL [208, 210] whilst caspase-dependence without PP2A 
activation was recently reported for NK cell leukaemia [209]. However we, and 
others, have reported caspase-independent death mechanisms of FTY720, suggesting 
that the mechanism of action of FTY720 in malignant cell killing is varied and still 
unclear [196, 206, 207]. Regardless of the mechanism of cell death, the IC50 values 
have been similar between studies, ranging from 2.4 to 12 µM (Table 5.1). Study of 
the in vivo efficacy of FTY720 for the treatment of CLL, MCL, AML, CML, Ph+ 
ALL and NK cell leukaemia demonstrated increased survival of mice and/or reduced 
leukaemic cell burden [206-210]. 
 
We have previously reported the in vitro efficacy of FTY720 in Ph- ALL [196]. Here, 
consistent with reports by others in mouse models of Ph+ ALL [210], we show that 
FTY720 was effective in vivo in a human xenograft model of Ph+ ALL. On the other 
hand, we found that FTY720 had no therapeutic effect in vivo against Ph- ALL. This 
disparity in the in vivo response occurred despite Ph+ and Ph- ALL cells 
demonstrating similar in vitro sensitivities to FTY720. In some Ph- ALL xenografts 
FTY720 appeared to exacerbate the disease, suggesting that clinical trials of FTY720 
in Ph- ALL are unlikely to succeed. 
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Table 5.1. Studies of FTY720 in haematological malignancies.  
In vivo 
Study Cell Type 
Caspase-
dependent 
PP2A-
dependent 
IC50 range 
(µM) Daily 
Dose 
Increased 
Survival 
Matsuoka et al 
2003.	   
T-ALL Yes Yes ND ND ND 
Yasui et al 2005. Myeloma Yes ND 3.6 - 9.7 ND ND 
Wallington-
Beddoe et al 
2011.	   
Ph+ & Ph- 
ALL 
No No 5.3 - 7.9 ND ND 
Neviani et al 
2007.	   
CML, Ph+ 
ALL 
Yes Yes ND 10mg/kg Yes (32D & 
BaF3) 
Liu et al 2008.	   
CLL, Burkitt’s 
Lymphoma 
No (CLL), No 
(Raji), Yes 
(Ramos) 
Yes (CLL), 
ND (Raji), 
Yes (Ramos) 
4 - >10 
(CLL), 4 - 
>10 (Raji, 
Ramos) 
5mg/kg ND (CLL, 
Ramos), Yes 
(Raji) 
Liu et al 2010.	   MCL No ND 5 - 12 5mg/kg Yes (JeKo) 
Roberts et al 
2010.  
AML Yes Yes 2.4 - 7.5 
(48 h) 
10mg/kg Yes (FDC-P1 
with 
activated c-
kit)  
ND - Not determined. In vitro IC50 values were assessed at 24 hours unless otherwise 
indicated. FTY720 was administered by the intra-peritoneal route in all in vivo studies. Cell 
lines used for in vivo studies are indicated. 
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Results 
	  
FTY720 did not Reduce the Progression of a Ph- ALL In Vivo Using 
Multiple Treatment Dosing Schedules 
 
FTY720 has been reported to induce cell death in ALL cells in vitro [196] and inhibit 
the development of ALL in the murine cell line BaF3 transduced with Bcr/Abl in 
immuno-compromised mice [210]. Here we examined the effect of FTY720 on Ph- 
human ALL xenografts in NOD/SCID mice. In an initial experiment using xenograft 
ALL-3, we compared an advanced disease model, where treatment was not 
commenced until disease was clearly detectable in the blood, with an early disease 
model where treatment commenced only 4 days post engraftment. Mice were 
administered vehicle control or FTY720 by IP injection at 5 mg/kg/day in the early 
disease arm or 10 mg/kg/day in the late disease arm. Mice were treated for a total of 
18 days and the level of ALL in the blood assessed weekly. Although a trend towards 
reduced disease with FTY720 was observed, this did not achieve statistical 
significance (Figure 5.1A). To further escalate plasma concentrations of FTY720, 
this same xenograft was examined using orally administered FTY720 at 25 
mg/kg/day, with treatment commencing when human leukaemia cells were first 
detected in peripheral blood (advanced disease model). Again there was no reduction 
in disease observed in the FTY720-treated animals (Figure 5.1B). Assessment of 
FTY720 plasma levels revealed mice receiving the higher dose of drug by gavage had 
higher FTY720 levels (427.1±58 nM) than those receiving FTY720 by the IP route 
(205±58 nM) (Figure 5.1C). Consistent with previous reports, FTY720-P was present 
at higher levels than the parental drug in the plasma of treated mice [161, 251].   
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Figure 5.1. FTY720 does not reduce disease burden in a xenograft model of advanced 
human ALL. 
(A) Groups of 7-8 NOD/SCIDγc-/- mice were engrafted with xenograft ALL-3 and treated 
with vehicle control or FTY720 by IP injection 6 days a week for 3 weeks. The early disease 
arm received FTY720 at 5 mg/kg/day 6 days a week commencing on day 4 post engraftment, 
and the advanced disease arm at 10 mg/kg/day commencing in week 5. The mean ± SD of the 
percentage of ALL cells in the blood is indicated. (B) Groups of 4 mice were engrafted with 
ALL-3 and treated with 25 mg/kg/day of FTY720 or vehicle control by gavage, commencing 
in week 6 and continuing for 2 weeks. The mean ± SD of the percentage of ALL cells in the 
blood is indicated. (C) Plasma concentrations of FTY720 and FTY720-P were determined 2 h 
after IP administration and 6 h after oral administration of FTY720. 
 
 
FTY720 is Effective in Ph+ but not Ph- ALL Xenografts Using an Early 
Disease Model 
 
To further examine whether FTY720 may be effective when used earlier in the 
development of the disease, and in light of the possibility that the ALL-3 xenograft 
may have been resistant to FTY720, we engrafted NOD/SCIDγc-/- mice with three 
additional human Ph- ALL xenografts (1345, 0398 and 1999). Treatment was 
commenced on day 3 (xenograft 1345) or 7 (xenografts 0398 and 1999) post 
engraftment, when ALL cells were not yet detectable in the peripheral blood, and 
continued for 3 weeks. No significant reduction in disease was observed in any tissue 
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examined at the end of 3 weeks of treatment with FTY720. Indeed, the amount of 
ALL increased in the bone marrow from 2.7±2.3 to 9.8±3.3 x 106 cells/femur (3.7 
fold, p=0.004) and blood from 3.1±2.1 to 8.0±2.5 x 106 cells/mL (2.5 fold, p=0.01) of 
mice with xenograft 1345 treated with FTY720 and in the spleens, from 0.03±0.01 to 
0.30±0.24 x 106 cells (11.5 fold, p=0.02) of mice receiving xenograft 0398 (Figure 
5.2A). In the experiment using xenograft 1345 there were also two deaths in the 
FTY720 group prior to the three-week endpoint with very high levels of leukaemia in 
both animals (data not shown). In addition, the livers of mice engrafted with 
xenografts 1345 and 1999 also showed increased leukaemic cell infiltration (Figure 
5.2B). The dose of FTY720 was reduced from 10 mg/kg to 5 mg/kg in the experiment 
using xenograft 1999 due to concerns regarding toxicity of the drug, with extreme 
lethargy noted post injection in preceding xenografts. 
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Figure 5.2. FTY720 does not reduce ALL in a model of early disease. 
(A) Groups of 6 NOD/SCIDγc-/- mice were engrafted with the indicated human ALL 
xenografts. After 3 to 7 days, 10 mg/kg (1345, 1999, 2070, ALL-55 and ALL-56) or 5 mg/kg 
(0398) of FTY720, or 0.9% sodium chloride was administered daily by intra-peritoneal 
injection for three weeks. Surviving animals were sacrificed at the end of treatment and the 
level of leukaemia analysed by flow cytometry. The number of ALL cells x 106 in the bone 
marrow, spleen and blood is reported with each dot representing an individual animal and the 
bar the mean of the cohort. #p<0.05 indicating increased disease and §p<0.05 reduced disease 
compared to control. (B) Increased infiltration of the liver following FTY720 treatment. 
Livers collected at the time of sacrifice from the animals shown in (A) were formalin fixed 
and paraffin embedded. Sections were stained with hematoxylin and eosin and examined by 
light microscopy. Representative control and FTY720-treated sections are shown for 
xenografts 1345 and 1999. Xenografts 0398 and 2070 had minimal leukaemia in the liver. (C) 
Total ALL burden was calculated for each animal from the numbers of ALL cells in each 
compartment (peripheral blood, bone marrow and spleen). The number of ALL cells x 109 is 
reported with each dot representing an individual animal and the bar the mean of the cohort. 
#p<0.05 indicating increased disease and §p<0.05 reduced disease compared to control.  
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To confirm the validity of this model we examined the response of 3 Ph+ ALL 
samples, 2070, ALL-55 and ALL-56. Mice were engrafted and treated as described 
above with treatment commencing 7 days after the injection of cells. Consistent with 
reports on murine Ph+ ALL [210], FTY720 produced a significant reduction in 
disease burden in the Ph+ ALL xenografts using an early disease model (Figure 
5.2A). This decrease was most obvious in the blood (reduced from 0.15±0.04 to 
0.03±0.00 x 106/mL (p=0.0002), 0.01±0.00 to 0.00±0.00 x 106/mL (p=0.0009), and 
2.45±0.76 to 1.12±0.41 x 106/mL (p=0.005) respectively) and the bone marrow 
(reduced from 1.38±0.51 to 0.41±0.18 x 106/femur (p=0.003), 1.32±0.51 to 0.10±0.06 
x 106/femur (p=0.0002) and 3.63±1.16 to 0.96±0.51 x 106/femur (p=0.0004) 
respectively) with variable responses being noted in the spleens (from 1.53±0.87 to 
1.00±0.39 x 106/spleen (p=n.s.), 0.02±0.01 to 0.04±0.02 x 106/spleen (p=n.s.) and 
83.54±65.04 to 11.39±6.44 x 106/spleen (p=0.02) respectively). Overall the Ph+ 
xenografts were reduced from an estimated total disease burden of 25.48±9.06 to 
7.97±3.40 x 106 cells (p=0.002), 22.85±8.96 to 1.81±1.08 x 106 cells (p=0.0002) and 
from 149.96±74.08 to 29.92±13.36 x 106 cells (p=0.003) respectively. The response 
of Ph+ xenografts was significantly different from that observed in Ph- xenografts 
(p=0.029). 
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Figure 5.3. Induction of cell death in vitro of the indicated xenograft cells. 
ALL cells recovered from the spleens of untreated mice were cultured with the indicated 
concentrations of FTY720 for 16 hours and viability assessed by flow cytometry using 
annexin V and propidium iodide staining. The viability of cells in control cultures was 42% 
for xenograft 1345, 90% for xenograft 1999, 93% for xenograft 0398, 51% for xenograft 
ALL-3, 63% for xenograft ALL-55 and 34% for ALL-56. 
 
 
FTY720 Kills Ph- ALL Xenograft Cells In Vitro in a PP2A-Independent 
Manner 
 
We considered the possibility that the Ph- patient xenografts may have been resistant 
to FTY720 but in vitro culture demonstrated that 1345, 0398, 1999, ALL-3, ALL-55 
and ALL-56 were all sensitive, with comparable IC50 values to ALL cell lines and 
patient samples examined previously, including the Ph+ sample 2070 [196] (Figure 
5.3). FTY720 induced activation of PP2A in all xenografts which was inhibited by 5 
nM okadaic acid, a concentration previously shown to be optimal for specific 
inhibition of PP2A [206], However, FTY720-induced cell death was independent of 
PP2A activation (Figure 5.4). 
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Figure 5.4. FTY720 re-activates PP2A but induces PP2A-independent cell death. 
(A) Xenografts were treated with 10 µM FTY720 for 4 hours with or without a 2 hour pre-
incubation with 5 nM okadaic acid. Activation of PP2A was assessed as described in 
‘Materials and Methods’. (B) All xenografts were treated with the indicated concentrations of 
FTY720 with or without a pre-incubation with 5 nM okadaic acid. Viability was assessed by 
flow cytometry using annexin V and propidium iodide staining. The mean ± SD of duplicate 
determinations are shown. 
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Discussion 
 
The main findings of this study were that FTY720 was ineffective in treating human 
Ph- ALL xenografts whilst effective for Ph+ ALL in a clinically relevant mouse model 
of human ALL, implying that this drug is unlikely to be suitable for clinical trial 
development for Ph- disease. Overall there were no significant reductions in ALL in 
Ph- xenografts as a result of FTY720 treatment and in one xenograft we observed a 
clear and significant worsening of the disease. This lack of effect was observed not 
only when animals had advanced disease but also in an early disease model. The 
increased splenic infiltration observed in one xenograft could be due to FTY720-
induced loss of S1P1 expression and retention of ALL cells in the spleen as S1P1 is 
required for lymphocyte egress from the splenic white pulp [285]. The reduced 
efficacy of FTY720 on inhibiting the infiltration of two of the three Ph+ ALL into the 
spleens is also consistent with an effect on ALL cell trafficking. However, the 
increased splenic disease in xenograft 0398 was not associated with significantly 
reduced disease in the blood or bone marrow suggesting that altered trafficking was 
not the only cause of increased ALL in the spleens of FTY720-treated animals. We 
found FTY720 to be efficacious in a human xenograft model of Ph+ ALL in the early 
treatment model, consistent with previous reports in mouse models of Ph+ ALL [210]. 
 
It is not clear why FTY720 was not effective in vivo for Ph- disease but there are a 
couple of potential explanations. Firstly the bone marrow microenvironment has been 
reported to afford protection from the effects of a range of chemotherapeutic agents in 
a number of haematological malignancies including ALL [286]. Although the 
mechanism is not fully understood, stromal cells are known to provide factors that 
support ALL survival, activating pro-survival pathways such as the PI-3K/mTOR 
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pathway [287, 288]. It is also possible that FTY720 simply did not attain sufficient 
concentrations in the animals to produce the cytotoxic effects in ALL cells that we 
observed in vitro. Pharmacokinetic studies of FTY720 performed in rats suggest that 
micromolar concentrations may not be achievable [161, 289, 290]. In our study, 
plasma FTY720 levels were approximately 200 nM and 400 nM when administered at 
10 mg/kg/day by IP injection and 25 mg/kg/day oral, respectively. However, in vivo 
responses have been observed in a range of haematological malignancies where in 
vitro IC50 values were in the micromolar range (Table 5.1). The reasons for the 
discrepancies in effective drug concentrations in vitro and in vivo remain unclear. We 
have previously reported a similar situation with the mTOR inhibitor RAD001 in 
ALL [249], with IC50s in the low micromolar ranges, but in vivo responses observed 
at plasma concentrations ten-fold lower, and it is possible that effects on the 
microenvironment are contributing to the observed in vivo response. Lower 
concentrations of FTY720 appear to be required in vivo for Ph+ ALL than the in vitro 
studies would suggest. It is also possible that the previously reported accumulation of 
FTY720 in lymphoid tissues enhances its effective concentration on leukaemia cells, 
relative to the concentration measured in plasma [291]. This increases the likelihood 
of FTY720 being useful in the setting of malignant disease. Although this may 
explain greater than expected in vivo activity, it would not explain the discrepancy 
between Ph- and Ph+ ALL. While FTY720 has relatively low toxicity compared to 
standard chemotherapeutic agents, there are suggestions that long-term exposure 
produces macular degeneration [292] and conditions associated with increased 
vascular leak [293], as well as increased risk of viral infections and skin cancer [163]. 
FTY720 also induces transient bradycardia, which could explain the lethargy 
observed following injection [294]. 
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In contrast to most previous studies, the ultimate mechanism of cell death in vitro in 
Ph+ and Ph- ALL cells was both caspase- and PP2A-independent [196]. Although 
PP2A was activated by FTY720, inhibition of PP2A activity using okadaic acid did 
not impact on cell death. This finding contrasts with many previous studies including 
those in haematological malignancies [206, 208, 210]. The major exception was a 
study in natural killer cell leukaemia [209]. Despite reporting in vitro and in vivo 
efficacy, FTY720 was not found to activate PP2A and the PP2A inhibitor okadaic 
acid did not reverse FTY720-induced cell death. While our data is similar, in that cell 
death was PP2A independent, we did observe a significant activation of PP2A 
following FTY720 exposure. Our data also differs in that the mechanism of cell death 
was not caspase-dependent apoptosis. 
 
Our previous in vitro studies also demonstrated the production of reactive oxygen 
species in response to FTY720, a finding that is in keeping with previous reports [207, 
231]. In these studies blockade of ROS production by antioxidants partially reversed 
the cytotoxic effects of FTY720. In the study by Liao et al [209] it was suggested that 
ROS production down regulated the anti-apoptotic protein Mcl-1, the loss of which 
was required for cell death [209]. Similarly, we have shown that FTY720 reduced 
expression of Mcl-1, however we did not detect apoptosis as a result of FTY720 
exposure [196]. 
 
Mcl-1 also inhibits the development of autophagy through inhibition of Beclin-1 [295, 
296]. Although we did not detect induction of Beclin-1 expression with FTY720, 
reduced inhibition would be expected due to lower Mcl-1 protein levels thereby 
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permitting the development of autophagy. Furthermore, autophagy induced by a sub-
cytotoxic concentration of FTY720 partially counteracted the cytotoxic effects of 
agents such as vincristine supporting its cell protective role [196]. FTY720-induced 
autophagy is at least partly due to the induction of S1P signalling by FTY720-P [161, 
196]. Brinkmann et al noted that FTY720-P peaked at more than triple the peak levels 
of the cytotoxic unphosphorylated FTY720 [161]. In our study, the non-cytotoxic 
phosphorylated derivative was found to be approximately 1.5 and 6 fold higher than 
FTY720 in animals receiving FTY720 by the IP and oral route respectively. It 
therefore appears that the induction of autophagy may offer protection, which may 
have played a role in our animal experiments, potentially explaining the outcomes 
observed for Ph- disease. 
 
Our observation that a drug with excellent in vitro efficacy did not universally 
translate into positive effects in the in vivo setting was unexpected. The disparity 
between the in vivo responses of Ph- ALL samples to FTY720, despite good in vitro 
efficacy currently lacks an adequate explanation, but highlights the importance of 
conducting well-designed pre-clinical studies prior to initiating clinical trials. In 
conclusion, we present here the first report of FTY720, in a relevant human xenograft 
model, demonstrating differential efficacy in Ph+ versus Ph- B-lineage ALL, a finding 
which questions the utility of further testing of FTY720 in the latter form of the 
disease. 
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CHAPTER 6: SPHINGOSINE KINASE 2 IN ACUTE 
LYMPHOBLASTIC LEUKAEMIA 
	  
 
 
This chapter is a manuscript submitted to Blood, which has undergone first 
round peer-review and will be accepted for publication pending satisfactory 
responses to reviewers’ requests. The responses to these reviewers have been 
mostly addressed and included in this version of the manuscript, with the 
exception of two additional experiments, which are currently being performed 
by Rana Baraz and Linda Bendall. These experiments and future directions 
from this work will be the subject of further discussion in Chapter 8. The 
Materials and Methods section has been placed in Chapter 3. 
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Key Points: 
Sphingosine kinase 2 protein is increased in acute lymphoblastic leukaemia and its 
inhibition suppresses c-Myc and its target genes. 
Inhibition/loss of sphingosine kinase 2 impedes the development of murine leukaemia 
and extends survival in mice with human leukaemia. 
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Abstract  
 
We show that sphingosine kinase 2 plays an oncogenic role in acute lymphoblastic 
leukaemia by influencing the expression of the oncogene MYC. Genetic loss of 
sphingosine kinase 2 impaired leukaemia development in a murine model, while 
pharmacological inhibition significantly extended survival in mouse xenograft models 
of human disease. Inhibition or genetic deletion of sphingosine kinase 2 reduced 
expression of MYC in leukaemic cells. This was associated with reduced association 
of acetylated histone H3 with the MYC gene and lower expression of the Myc proto-
oncogene protein (c-Myc) and c-Myc regulated genes. This demonstrates that 
sphingosine kinase 2 can regulate MYC, which plays an important role in 
haematological malignancies, and therefore this pathway may prove a useful 
therapeutic target in this disease.  
 
Introduction 
	  
Sphingosine kinases catalyse the synthesis of sphingosine 1-phosphate (S1P) from 
sphingosine [69]. Over-expression of sphingosine kinase (SphK) 1 has indisputable 
tumour-promoting properties [222] and has been associated with poor survival solid 
tumour patients [120, 121, 127], resistance to imatinib in chronic myeloid leukaemia 
(CML) [134, 135, 192] and to daunorubicin in acute myeloid leukaemia (AML) cells 
[125]. In contrast, the role of SphK2 in cancer is less clear. While over-expression 
suppressed cell growth and induced apoptosis [69], knockdown of SPHK2 in 
glioblastoma cells inhibited proliferation more effectively than knockdown of SPHK1, 
and SPHK2-deficient breast cancer cells proliferated poorly in vivo [121, 147, 149]. 
SphK2 has basal enzyme activity that is further activated by ERK-mediated 
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phosphorylation [138], placing it downstream of signalling pathways frequently 
activated in malignancies including B-Raf, Ras, Jak and Flt3 [297-299] all of which 
can activate ERK [300]. 
 
S1P is best known for its extra-cellular effects mediated through the G protein-
coupled receptors, S1P1 to S1P5. S1P can also act intra-cellularly by direct modulation 
of histone deacetylase activity and the ubiquitin ligase activity of tumour necrosis 
factor receptor-associated factor 2 (TRAF2) [69]. In the nucleus SphK2 binds directly 
to histone deacetylases (HDAC) where locally produced S1P inhibits HDAC1 and 2, 
increasing acetylation of histone H3 on Lys9, H4 on Lys5 and H2B on Lys12 [82]. 
Gene expression of the cell cycle inhibitor p21 and transcriptional regulator c-fos is 
subsequently increased, providing an explanation for the reported growth inhibitory 
effects of SphK2.  
 
The Myc proto-oncogene protein (c-Myc) is over-expressed across a diverse range of 
human cancers [301], including haematological malignancies, playing a role in both 
tumour initiation and maintenance [302]. In acute lymphoblastic leukaemia (ALL), 
the role of c-Myc has not been extensively explored, however, translocations 
involving MYC have been reported in some cases [303, 304]. Under normal 
circumstances MYC expression is tightly controlled by transcriptional regulatory 
motifs in its proximal promoter region [305], however epigenetic modifications can 
also influence the expression of MYC, including in ALL [306]. 
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Here we demonstrate that a gene signature consistent with increased SphK2 activity is 
present in ALL patient diagnostic samples and that SphK2 protein is over-expressed 
and activated in ALL cells. Inhibition of SphK2 kills B-lineage ALL cells and 
synergises with the proteasome inhibitor bortezomib and with imatinib in Ph+ cells in 
vitro. Inhibition of SphK2 reduced expression of MYC mRNA, protein and c-Myc 
target genes. Reduced association of acetylated histone H3 with MYC was observed, a 
finding consistent with the effect being mediated by the reported role of SphK2 in 
histone acetylation. In vivo, SphK2 inhibition showed significant anti-leukaemic 
effects in a human xenograft model of ALL, and enhanced the efficacy of imatinib 
resulting in increased survival in mice bearing a Ph+ xenograft. Furthermore, gene 
deletion of Sphk2 significantly reduced leukaemia development in a murine model of 
BCR/ABL-driven ALL.  
 
Results 
 
Pharmacological Inhibition of SphK2 Reduces ALL Cell Proliferation and 
Survival In Vitro and Induces Caspase-Independent Cell Death 
 
Here we show that ABC294640 reduced S1P production in leukaemic cell lines but 
did not affect SPHK1 protein expression (Figure 6.1A and 6.S1A). SphK2 inhibition 
consistently reduced cell proliferation (Figure 6.1B and data not shown), and 
induced cell death (Figure 6.1C) in a time-dependent manner (Figure 6.1E) with IC50 
values at 24 hours being significantly higher than those measured at later time points 
(p<0.001, Annova test with repeated measures). Furthermore, SphK2 inhibition also 
induced cell death in primary ALL cells (Figure 6.1D) while IC50 concentrations for 
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normal bone marrow mononuclear cells and B-cell progenitors were not achieved 
even after 72 hours (Figure 6.S2). 
 
Inhibition of SphK2 resulted in externalisation of phosphatidylserine (Figure 6.1F), 
however a transition from annexin V+/PI- (early apoptosis) to annexin V+/PI+ (late 
apoptosis) was not clear (Figure 6.1F). Apoptotic cells, as defined by nuclear 
condensation and apoptotic bodies on examination by light microscopy, were largely 
absent in ABC294640-treated cultures (Figure 6.S3) despite cleavage of Caspase-3 
(Figure 6.1G). While caspase inhibition significantly inhibited apoptosis induced by 
doxorubicin, it did not significantly reduce ABC294640-induced cell death (p=0.18, 
n=8, Figure 6.1H). Although LC3-I was processed to LC3-II following SphK2 
inhibition (Figure 6.1I) the autophagy inhibitor 3MA did not diminish ABC294640-
induced cell death (Figure 6.1J), despite reducing LC3 processing (data not shown). 
Overall, cell death following SphK2 inhibition was largely caspase-independent and 
lacked morphological features of apoptosis. Although autophagy was occurring 
following ABC294640 treatment, this was not the mechanism of cell death. 
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Figure 6.1. SphK2 inhibition suppresses proliferation and induces caspase-independent 
cell death in ALL cells. 
(A) ALL cell lines were cultured with 60 µM ABC294640 or vehicle for 24 or 48 h and 
cellular S1P concentrations determined. (Mean ± SD from 3 cell lines). *p<0.05. (B - E) ALL 
cell lines (B, C & E) or patient cells (D) were cultured with ABC294640 or vehicle for 48 h 
(B), 72 h (C) or 16 h (D). (B) The proliferation (B) or viability (C - E), was normalised to 
control cultures. (F) ALL cell lines were cultured with 75 µM (REH) or 100 µM (ALL1) 
ABC294640 for 24 h and annexin V and PI staining assessed. (G) ALL cell lines were 
cultured with 100 µM ABC294640 or vehicle for 72 h, except for NALM6 cells (analysed at 
24 h), and Caspase-3 cleavage measured.  isotype control,   cleaved 
Caspase-3. (H) ALL cell lines were cultured with 0.25 µg/mL of doxorubicin, 80 µM or 90 
µM ABC294640 or vehicle with or without pre-incubation with 100 µM Z-VAD-FMK and 
viability assessed after 16 h. (Mean ± SD from ≥ 3 experiments). *p<0.05 comparing cells 
pre-incubated with Z-VAD to those without. (I) Cell lines were treated with ABC294640 and 
cell lysates analysed for LC3 protein. (J) ALL cell lines were treated with vehicle (Control) 
or 50 µM ABC294640 for 24 h with or without 5 mM 3MA, except for ALL1 where 48 h 
treatment with ABC294640 was used. (Mean ± SD). 
 
 
Sphingosine Kinase 2 Expression in ALL 
 
To establish a gene signature for activation of SphK2, we treated ALL cell lines with 
the SphK2 specific inhibitor ABC294640 and analysed gene expression by 
microarray. A Diff p value filter, produced a list of 12 probes representing 11 genes, 
and principal component analysis, identified 40 probes representing 35 genes (Figure 
6.2A). These genes were not regulated in cells treated with the SphK1 inhibitor SK1-I 
(data not shown) demonstrating specificity of the signature to SphK2. Regulation of 
selected genes was confirmed by qRT-PCR (Figure 6.S4). Both SphK2 gene 
signatures segregated control and drug treated cell lines using Hierarchical Clustering 
and Qlucore software (Figure 6.2A and data not shown) and were validated using an 
additional 5 cell lines (Figure 6.S5). The SphK2 signatures were used to interrogate a 
large publicly available gene expression dataset obtained from paediatric ALL 
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patients at the time of diagnosis (GSE28497) [307]. SphK2 activity signatures were 
higher in ALL samples (p=0.001 and p=0.027) (Figure 6.2C and data not shown) 
than normal B-cell progenitors. The SPHK2 gene was not over-expressed (GSE28497 
- data not shown), however, increased SphK2 protein was detected (Figure 6.2D) 
with increased phosphorylation, suggesting increased enzymatic activity (Figure 
6.2D). Together these data show activation of SphK2 without increased gene 
expression.  
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Figure 6.2. The expression and activity of the sphingosine kinases in ALL. 
(A) Hierarchical clustering of control and SphK2 inhibitor treated ALL cell lines using gene 
expression changes resulting from inhibition of SphK2 by ABC294640 60 µM (REH 80 µM) 
Mfor 24 hours, detected by filtering on the Diff p value (left panel) or principal component 
analysis (right panel). (B) Principal component analysis of the SphK2 signature produced by 
Diff p value filtering. (C) Gene expression array data from ALL samples were interrogated 
for the presence of the SPHK2 gene signature relative to normal B-cell progenitors. The 
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signature intensity is shown and patient subtypes are indicated. (D) Expression of 
phosphorylated and total SphK2 in ALL cell lines, 5 patient samples, peripheral blood 
mononuclear cells (PBMC) from normal donors and normal CD34+CD19+ bone marrow B-
cell progenitors. 
 
 
SphK2 Inhibition in ALL Inhibits Expression of MYC and c-Myc 
Regulated Genes 
 
In order to determine the mechanism by which inhibition of SphK2 induced cell death 
in ALL we undertook microarray analysis of control and ABC294640-treated cells at 
the earlier time point of 6 hours. Only 5 genes were consistently regulated across all 
cell lines (Figure 6.3A). Examination of the diagnostic paediatric ALL gene 
expression dataset, GSE28497 [307] revealed MYC to be more than 2 fold over-
expressed (p=0.03) affecting all sub-classifications (Figure 6.3B). FAM129A was 
slightly over-expressed (log2 fold change 0.84, p=0.0001) and DDIT3 under-
expressed (log2 fold change -0.73, p=0.001) while TSC22D3 and TRIB3 were within 
normal limits. MYC remained significantly decreased at 24 hours in all 9 cell lines and 
metacore analysis identified c-Myc as the transcription factor most significantly 
associated with the changes in gene expression in these cell lines (p<1.0e-250, z-
Score=90.57, g-Score=93.07) (Table 6.S1). Down regulation of MYC expression was 
confirmed by qRT-PCR (Figure 6.3C), with c-Myc protein markedly reduced 
(Figure 6.3D). c-Myc was also decreased following knockdown of SphK2 by siRNA 
(Figure 6.S6). Despite recent reports of increased Sphk1 expression in the absence of 
Sphk2 [308], SPHK1 gene expression was not increased by SphK2 inhibition as 
determined by microarray analysis. 
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We questioned whether changes in c-Myc regulated genes could segregate SphK2 
inhibitor-treated ALL cells from their respective controls. To this end we extracted 
three previously published c-Myc gene signatures [306, 309, 310], from the original 
and the validation microarray data sets. Unsupervised hierarchical clustering 
separated the SphK2 inhibitor-treated cells from control treated cells (Figure 6.3E 
and Figure 6.S7).  
 
Chapter 6 Sphingosine Kinase 2 in Acute Lymphoblastic Leukaemia 
	  
	  
121	  
 
Chapter 6 Sphingosine Kinase 2 in Acute Lymphoblastic Leukaemia 
	  
	  
122	  
Figure 6.3. Inhibition of SphK2 suppresses expression of MYC and c-Myc regulated 
genes. 
(A) Changes in gene expression in NAM6, ALL1, REH and TOM1 cells lines following 6 h 
of SphK2 inhibition. (Mean ± SD)  (B) Gene expression array data from ALL samples were 
interrogated for MYC expression. The signal intensity is shown for each patient and 4 normal 
donors and patient subtypes are indicated. (C) qRT-PCR analysis of MYC expression in ALL 
cell lines following a 24 h incubation with ABC294640 60 µM or vehicle. The mean ± SD of 
3 experiments is shown. *p<0.05. (D) Western blots showing expression of c-Myc following 
incubation with ABC294640 at the indicated concentrations and time periods. (E) 
Hierarchical clustering of control and SphK2 inhibitor treated ALL cell lines using a c-Myc 
gene signature. (F) Gene set enrichment plots were generated using the indicated gene sets 
and the array data from each of the stromal-dependent cell lines treated with ABC294640. 
NES=normalised enrichment score, q=false discovery rate, p=significance. (G) Gene 
expression array data from ALL samples interrogated for the presence of the MYC gene 
signature [310] relative to normal B-cell progenitors. The signature intensity is shown and 
patient subtypes are indicated. 
 
 
Gene Set Enrichment Analysis (GSEA) demonstrated a significant negative 
enrichment of both the Bild and Schuhmacher c-Myc signatures in SphK2 inhibited 
cells. The specificity of this effect was apparent from the lack of any consistent 
association between NF-κB or PI-3K/AKT pathway members or SP1 targets (Figure 
6.3F and Table 6.S2). This suggests that regulation of MYC plays a significant role in 
the response of ALL cells to SphK2 inhibition. Interrogation of the GSE28497 dataset 
using the Schuhmacher et al [310] c-Myc signature found c-Myc targets to be 
increased in diagnostic patient samples (p=0.019) consistent with the over-expression 
of MYC in these patient samples (Figure 6.3G).  
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SphK2 Inhibition Reduces the Association of Histone H3 Acetylated on 
Lysine 9 with the MYC Promoter 
 
It has been reported that SphK2 binds to HDAC in the nucleus and that locally 
produced S1P inhibits HDAC activity resulting in increased acetylation of histones 
including histone H3 on Lys9 (H3K9ac) [82]. ENCODE/Broad [311] report that 
H3K9ac associates with MYC (Figure 6.4A) and using ChIP followed by qPCR of 
MYC promoter elements, SphK2 inhibition was found to reduce the association of 
MYC with H3K9ac (Figure 6.4B). In support of a role for c-Myc suppression in ALL 
cell death following SphK2 inhibition, the c-Myc inhibitor 10058-F4 induced cell 
death in ALL cell lines in a time-dependent manner similar to that observed following 
SphK2 inhibition (Figure 6.4C). The association of NME1 and NUP62 promoters 
(Figure 6.4D) with H3K9ac were significantly reduced following inhibition of SphK2 
(Figure 6.4E) consistent with their reduced expression.  
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Figure 6.4. SphK2 inhibition regulates MYC expression via deacetylation of histones. 
(A) Schematic diagram showing the H3K9ac track on the MYC gene as determined in 
GM12878 cells, a B-lymphoblastoid cell line. (B) REH and TOM1 cells were treated with 80 
µM ABC294640 for the indicated times. ChIP analysis of the MYC promoter was performed 
using anti-H3K9ac as the precipitating antibody. Primers in the MYC promoter or an 
unrelated inter-genic region were used to amplify co-precipitated DNA. The mean ± SD of 3 
experiments is shown. *p<0.05. (C) TOM1 and REH cells were cultured with the indicated 
concentrations of the c-Myc inhibitor 10058-F4 for the indicated times and analysed for 
viability using annexin V/PI staining and flow cytometry. The mean ± SD of duplicates for 
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each cell lines are shown. (D) Schematic diagram showing the H3K9ac track on the NME1, 
SLC29A1 and NUP62 genes as determined in GM12878 cells (Note NUP62 is encoded on the 
reverse strand). (E) ChIP analysis of NME1 and NUP62 in REH and TOM1 cells treated with 
80 µM ABC294640 for the indicated times using anti-H3K9ac as the precipitating antibody. 
The mean ± SD of 3 experiments is shown. *p<0.05. 
 
 
Concurrent Bcr/Abl and SphK2 inhibition Produces Synergistic Effects 
in Ph+ ALL 
 
New therapies for ALL will almost certainly be employed in combination with 
established chemotherapy regimens. No significant interactive effects between SphK2 
inhibition and vincristine or doxorubicin were observed, with the Fractional Product 
method showing at best additive effects (Figure 6.5A and Figure 6.S8). In contrast, 
synergistic cell death was observed at all time points when inhibition of SphK2 was 
combined with the proteosome inhibitor bortezomib (Figure 6.5B). Imatinib inhibited 
proliferation, but had little effect on the viability of Ph+ ALL cell lines (Figure 6.5C 
and D). However, known resistance-inducing mutations in BCR/ABL were not 
detected. Resistance to imatinib-induced cell death was overcome by concurrent 
SphK2 inhibition and clear synergistic interactions were observed in almost all 
conditions tested (Figure 6.5E and Figure 6.S8). 
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Figure 6.5. SphK2 inhibition synergises with bortezomib and imatinib. 
The indicated cell lines were cultured with (A) vehicle, 31.25 ng/mL doxorubicin or 1 nM 
vincristine or (B) vehicle or bortezomib (7.5 nM for NALM6, 5 nM for ALL1), with or 
without the addition of 50 µM ABC294640 for 24 h (A) or the indicated time (B) and 
analysed for viability. The mean and standard deviation 2 experimental replicates is shown. 
The indicated cell lines were incubated with increasing concentrations of imatinib for 72 h 
and assessed for proliferation (C) or survival (D). The mean and standard deviation of four 
(C) and two (D) experimental replicates is shown. (E) The indicated cell lines were cultured 
with vehicle, or 50 µM ABC294640 with or without the addition of 5 µM imatinib for 48 h or 
72 h and analysed for viability. The mean and standard deviation of 2 experimental replicates 
is shown. In A, B and E the hatched bar represents the calculated additive effect based on the 
effect of each agent alone. # Indicates a synergistic interaction between the agents as 
determined by the Fractional Product method. 
 
 
SphK2 Inhibition is Effective in a Human Xenograft Model of B-lineage 
ALL 
 
Intra-peritoneal injection of NOD/SCID IL2γc-/- mice with ABC294640 reduced 
plasma S1P concentrations by 23% after 2 hours, with a further decrease (45%) by 6 
hours, and levels remained significantly suppressed for at least 24 hours (Table 6.S3). 
This indicates that ABC294640 significantly inhibits SphK2 activity, reducing S1P 
plasma levels in vivo, consistent with findings by Beljanski et al [152]. NOD/SCID 
IL2γc-/- mice engrafted with human ALL cells were treated with 100 mg/kg/day 
ABC294640 or vehicle by intra-peritoneal injection for 21 days after which all 
animals were sacrificed. The percentage of ALL cells in the BM and blood was 
significantly reduced in SphK2 inhibitor-treated mice, while the contribution to the 
spleen was significantly reduced in xenograft 1999 only (Figure 6.6A-C upper 
panels). Average absolute levels of leukaemia in the BM of SphK2 inhibitor-treated 
mice were reduced by between 40 and 60% (p≤0.004) (Figure 6.6A lower panel). 
Reductions in the blood were between 60% and 67% (p<0.002) and in the spleen by 
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38% and 79% (p<0.0001) for xenografts 1999 and 1345 (Figures 6.6B and C lower 
panels). Overall, inhibition of SphK2 decreased the level of disease in all xenografts 
between 40 and 78% (p≤0.00005) (Figure 6.6E). No overt toxicity was noted, with 
the murine WBC being higher in SphK2 inhibitor-treated animals bearing xenograft 
1999 (p=0.018), consistent with reduced disease, and not significantly different in the 
other xenografts (Figure 6.6D). 
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Figure 6.6. ABC294640 shows in vivo efficacy in Ph+ and Ph- ALL. 
(A-E) Groups of 6 IL2γc-/- NOD/SCID mice engrafted with xenografts 1999, 2070 or 1345 
were treated with 100 mg/kg of ABC294640 daily by IP injection commencing 3 days for 
1345 or 7 days for 1999 and 2070 after receiving ALL cells and continuing for 21 days when 
all animals were culled. The percentage (upper panels) and absolute number (lower panels) of 
ALL cells detected in the BM (A), spleen (B) and peripheral blood (C) are shown. The 
murine WBC is shown in (D) and the total leukaemic burden (E) are also shown. Each dot 
indicates data from an individual animal and the line the mean of the cohort. Significance 
levels comparing vehicle to ABC294640-treated mice are indicated on the graphs. (F and G) 
Groups of 6 NOD/SCID IL2γc-/- mice were engrafted with ALL xenografts 1999 (F) or 2070 
(G). 100 mg/kg of ABC294640 was administered for 21 days by IP injection and in xenograft 
2070 100 mg/kg of imatinib was given alone or in addition to ABC294640 by daily intra-
peritoneal injection. The shaded area on each graph indicates the period of treatment. At the 
end of the treatment period mice were monitored for disease and culled as required. 
 
 
Inhibition of SphK2 significantly slowed the increase in circulating ALL cells, 
prolonging the survival of mice bearing xenograft 1999 (p=0.0012, Figure 6.6F and 
G) from a median of 30 days for control mice (95% CI 29-30 days) to 41 days (95% 
CI 32-38 days) for the treated group. Concurrent inhibition of SphK2 and Bcr/Abl 
with imatinib also significantly improved the survival of mice engrafted with a Ph+ 
ALL (2070) (Figure 6.6G). In this experiment the median survival of control mice 
was 49 days (95% CI 47.5-50.5 days) with imatinib extending survival to a median of 
65 days (95% CI 63.4-96.6 days). Concurrent inhibition of SphK2 further extended 
survival to a median of 104.5 days (95% CI 91.1-117.9 days, p=0.004 compared to 
imatinib alone and p=0.044 compared to ABC294640 alone).  
 
SphK2 Contributes to ALL Development in Mice  
 
Twenty-two of 29 mice receiving BCR/ABL transduced B-cell progenitors from WT 
animals developed ALL, with a median survival of 42 days (95% CI 32-52 days). 
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Absence of SphK2 reduced the incidence of BCR/ABL-driven ALL to 16 of 29 
animals (median survival of 58 days, 95% CI 47-69 days) (p=0.002) (Figure 6.7A). 
In contrast to reports by Liang et al [308], the absence of SphK2 did not result in 
increased SphK1 expression (Figure 6.S1B). The presence of BCR/ABL and the 
expected deletion of Sphk2 were confirmed by PCR in all murine leukaemias 
examined (Figure 6.7B and C). All leukaemias demonstrated a B-cell progenitor 
phenotype (Figure 6.7D), with the majority being pre-B-ALL, lacking CD43 
expression. Lymphoblasts were present in blood films and livers from all animals 
(Figure 6.7E and F). Cells recovered from the spleens of leukaemic mice 
demonstrated reduced c-Myc expression in leukaemias arising in SphK2-/- cells as 
compared to those derived from WT B-cell progenitors (Figure 6.7G). These data 
demonstrate a role for SphK2 in the development of BCR/ABL-driven ALL. ALL 
cells recovered from mice receiving BCR/ABL transduced WT B-cell progenitors 
were sensitive to ABC294640 while those from SphK2-/- B-cell progenitors were 
resistant, confirming that the cytotoxic effects of ABC294640 were mediated through 
SphK2 (Figure 6.7H).  
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Figure 6.7. SphKs are important in murine ALL development. 
(A) Kaplan-Meier survival analysis of WT mice injected with BCR/ABL-transduced B-cell 
progenitors from a total of nineteen WT and SphK2-/- animals. Significance using Cox 
Regression analysis relative to mice receiving WT cells is indicated. The experiment was run 
on three separate occasions. (B) PCR detection of BCR/ABL in the leukaemias harvested from 
mice. The positive and negative controls consisted of p190 positive and negative ALL cell 
lines. (C) PCR assessment of Sphk2 deletion in murine ALL cells. The PCR product from WT 
cells is 680 bp in WT and 310 bp in SphK2-/- cells (right panel). Note the WT band is detected 
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in residual normal cells in the harvested tissue containing ALL. The heavy band in the 100 bp 
DNA ladder is 500 bp. (D) Representative immunophenotype of a murine ALL sample 
showing B220 expression and lack of surface IgM. (E) Romanowsky stain of peripheral 
blood from a mouse with BCR/ABL-driven ALL. Original magnification 400x. Bar indicates 
50 µm. (F) Representative haematoxylin and eosin stained, paraffin embedded liver sections 
showing intra- and perivascular ALL infiltration. Original magnification 200x (upper panel) 
400x (lower panel). Bar indicates 100 µm. (G) Western blot of c-Myc in murine ALL 
recovered from secondary recipients. Values below the gels indicate the density of the c-Myc 
band relative to β-actin. Spleen cells recovered from 3 independent leukaemias is shown. The 
mean±SD of the data from the gel is shown in the graph. *p<0.05 compared to WT ALL. (H) 
ALL cells recovered from the spleens of mice receiving WT or SphK2-/- ALL were plated on 
OP9 stroma to minimise cell death. Cells were treated with the indicated concentrations of 
ABC294640 for 24 h and viability assessed by annexin V/PI staining. The mean ± SD of 
duplicates is shown. 
 
 
Discussion 
 
The oncogenic role of SphK1 has been demonstrated in a range of malignancies, 
however the role of SphK2 in cancer is largely unknown. Over-expression of SphK2 
can be pro-apoptotic via binding to BclXL [140] and by its role in sphingolipid 
metabolism resulting in increased levels of pro-apoptotic ceramide [98]. Recently 
sphingolipid metabolism was shown to be required for activation of BAK and BAX 
and apoptosis induction [312]. However, recent studies using pharmacological and 
molecular methods have demonstrated a role for SphK2 in tumour promotion [149, 
152]. In this study, we examined the effects of Sphk2 deletion in the development of 
BCR/ABL-driven ALL and inhibition of SphK2 in ALL cells in vitro and in vivo. 
Despite a recent report showing increased SphK1 in tissues from Sphk2 gene-deleted 
mice, we did not detect changes in SphK1 in Sphk2-/- ALL cells or following 
inhibition of SphK2 by ABC294640 (Figure 6.S1). We also explored the mechanism 
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by which SphK2 inhibition mediates its anti-cancer activity, revealing suppression of 
c-Myc as a key mechanism. 
 
A role for SphK2 in ALL biology was suggested by the presence of a gene signature 
consistent with increased SphK2 activity in a large cohort of paediatric ALL samples 
collected at diagnosis. This was supported by the reduced incidence of ALL in a 
BCR/ABL-driven model of murine ALL in the absence of Sphk2, suggesting that 
SphK2 plays a role in disease initiation in this setting. However, the efficacy of 
SphK2 inhibition in established human leukaemia indicates that it is also important in 
disease progression. Overall, this is the first report on the effect of genetic deletion or 
pharmacological inhibition of SphK2 in the development of leukaemia and firmly 
demonstrates the tumour promoting effects of SphK2 in leukaemia.  
 
While over-expression of SphK2 has been reported to produce anti-proliferative 
effects and result in cell death, it is clear that SphK2 can also promote cell growth. 
The reasons for these discrepant effects are not entirely clear. The sub-cellular 
localisation of SphK2 may be important for the ultimate function of this enzyme 
[113]. A recent study showed that siRNA knockdown of SPHK2 inhibited breast 
cancer cell proliferation despite increasing S1P production [313], speaking strongly to 
the importance of the localised activity of these enzymes over global S1P production. 
When associated with the endoplasmic reticulum SphK2 induced apoptosis via 
production of ceramide [95], while translocation to the cytoplasm results in survival 
promoting effects in colon cancer cells [314], SphK2 also has demonstrated protective 
effects at the mitochondria following ischemia reperfusion injury in a number of 
tissues including cardiomyocytes [315]. In this study it appears that the nuclear 
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localisation of SphK2 and its effects on histone H3-histone deacetylase (HDAC)1/2 
were the dominant mechanism of action. In ALL cells SphK2 increases expression of 
oncogenic c-Myc, presumably through localised S1P production, promoting survival 
and proliferation. Consistent with this, ALL patient samples have increased MYC 
expression, increased expression of c-Myc regulated genes and are killed by c-Myc 
inhibition.  
 
SphK2 inhibition has been associated with both caspase-dependent [150] and -
independent cell death [151] with autophagy being involved in the latter. Autophagy 
also has cell survival roles [202] and although SphK2 inhibition induced autophagy in 
ALL cells, this was not the cause of cell death, a situation similar to that following 
FTY720 exposure [196]. Consistent with the lack of apoptosis, genes involved in 
apoptosis were not over-represented in the microarray data (data not shown). 
Inhibition of SphK2 has been shown to synergise with chemotherapeutic agents in 
breast cancer cell lines in vitro, via inhibition of NF-κB mediated survival signals 
[153]. However, our attempts at combining conventional chemotherapeutic agents 
such as vincristine and doxorubicin were disappointing with no significant synergy 
seen. The lack of an effect on NF-κB signalling in ALL cells when SphK2 is inhibited 
(Table S2) may explain this result. We therefore turned our attention to the biological 
response modifier bortezomib, after reports of efficacy in lymphoid malignancies 
[316, 317] and found the combination of ABC294640 and this agent to be superior to 
conventional drugs. In addition, inhibition of SphK2 also synergised with imatinib in 
Ph+ disease, reminiscent of work published with SphK1 inhibitors [135]. Overall this 
suggests that combination treatments including SphK2 inhibitors may have potential 
as therapeutic strategies. 
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A major novel finding in this study is the down-regulation of the MYC gene and c-
Myc target genes as a result of SphK2 inhibition. Increased MYC and c-Myc target 
gene expression in ALL samples from patients and the ability of a c-Myc inhibitor to 
kill ALL cells provides evidence for a role for c-Myc in ALL cell biology. These data 
potentially explain the often opposing roles of SphK2 in cell growth and survival, 
inhibiting growth and survival via effects on p21 and fos, while promoting these 
features by increasing expression of c-Myc. They also highlight a potentially under-
appreciated role of c-Myc in ALL biology and identify potential therapeutic strategies 
for the treatment of ALL and other c-Myc-driven malignancies.  
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Table 6.S1. Regulation of c-Myc target genes by SphK2 inhibition. 
Network 
Object 
Object 
Type Gene ID ALL1 2032 2070 LK63 1809 TOM1 NALM6 REH 1345 Mean 
E-FABP BP FABP5 -2.66 -2.61 -1.96 -3.73 -1.39 -7.07 -7.40 -1.74 -2.10 -3.41 
NDPK A Kinase NME1 -2.88 -2.93 -2.45 -3.11 -1.76 -1.18 -1.99 -2.10 -2.57 -2.33 
c-Myc TF MYC -1.84 -1.32 -3.80 -4.58 -1.75 -2.58 -1.02 -2.14 -1.36 -2.27 
ANKRD41 Protein 
ANKLE1; 
ANKRD41 -1.21 -2.97 -1.45 -2.03 -1.21 -3.76 -1.60 -2.64 -1.89 -2.08 
HSPC111 Protein 
HSPC111;NO
P16 -1.56 -1.97 -1.72 -2.57 -1.25 -2.08 -1.78 -2.22 -1.45 -1.84 
Bystin BP BYSL -1.38 -2.50 -1.61 -3.10 -1.26 -1.39 -1.39 -1.52 -2.04 -1.80 
PUS7 Enzyme PUS7 -1.47 -2.12 -1.71 -1.80 -1.65 -2.10 -1.07 -1.73 -2.04 -1.74 
MRPL12 BP MRPL12 -1.62 -2.35 -1.33 -2.55 -1.56 -1.03 -1.88 -1.56 -1.63 -1.72 
RRP46 Enzyme EXOSC5 -1.18 -4.08 -1.27 -2.24 -1.00 -1.01 -1.54 -1.02 -1.46 -1.64 
SLC3A2 Channel SLC3A2 1.87 1.26 2.22 1.92 1.89 2.11 1.43 1.75 1.67 1.79 
C/EBPβ TF CEBPB 2.82 2.43 1.92 2.69 1.96 1.47 2.18 1.80 1.65 2.10 
ABCA1 LGIC ABCA1 5.26 6.08 6.55 2.53 4.61 5.37 4.96 1.66 4.81 4.65 
BP – Binding protein, TF – Transcription factor, LGIC – Ligand-gated ion channel. Log2 fold change is shown for each cell line. Only 2-fold regulated genes 
expressed by all cell lines are shown. 
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Table 6.S2. Gene enrichment analysis for all nine cell lines. 
Cell Line ALL1 LK63 REH NALM6 TOM1 2032 2070 1809 1345 
BILD_MYC_ONCOGENE_SIGNATURE (206 genes) [309] 
NES -2.47* -2.59* -2.68* -2.69* -2.25* -2.46* -2.55* -1.90* -2.13* 
q 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
SCHUHMARCHER_MYC_SIGNATURE_UP (69 genes) [310] 
NES -2.98* -3.25* -2.69* -3.12* -2.68* -3.12* -3.16* -2.26* -2.77* 
q 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
V$NFKAPPAB (194 genes) 
NES 1.56 1.28 -1.11 1.25 -0.86 -1.17 -1.21 -1.32 -1.11 
q 0.02 0.04 0.24 0.16 0.73 0.13 0.05 0.03 0.24 
V$SP1_01 (184 gene) 
NES 0.98 -1.21 -1.40 -1.18 1.11 -1.23 -1.18 -1.35 -1.35 
q 0.51 0.09 0.01 0.17 0.28 0.09 0.10 0.04 0.03 
PARENT_MTOR_SIGNALLING_UP (580 genes) [318] 
NES 1.19 1.28 1.30 1.40 1.29 1.18 1.34* -0.93 -1.55* 
q 0.07 0.01 0.02 0.00 0.02 0.06 0.00 0.71 0.00 
BIOCHARTER_AKT_PATHWAY (22 genes) 
NES -0.65 1.64 -1.02 1.06 1.18 1.34 1.41 -0.49 -1.16 
q 0.91 0.02 0.42 0.39 0.27 0.11 0.08 0.99 0.28 
REACTOME_PI3K_CASCADE (38 genes) 
NES 0.97 1.64 1.31 1.26 1.29 0.83 1.14 -1.10 -0.85 
q 0.51 0.02 0.16 0.19 0.02 0.76 0.26 0.32 0.71 
NES – normalised enrichment score, q – False discovery rate, *p<0.05 following correction 
for multiple comparisons using Bonferoni’s method. 
Chapter 6 Sphingosine Kinase 2 in Acute Lymphoblastic Leukaemia 
	  
	  
140	  
 
 
 
Table 6.S3. Effect of ABC294640 on S1P plasma levels in mice. 
 
Time (h) S1P Concentration (µM) 
0 1.424 ± 0.058 
2 1.103 ± 0.140* 
6 0.784 ± 0.088* 
24 1.195 ± 0.122* 
Mean and standard deviation of 
samples from 3 mice at each time point 
is shown. *p<0.05 compared to 
control. 
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Figure 6.S1. Regulation of SphK1 by SphK2. 
Western blots showing expression of SphK1 in ALL1 cells following treatment with the 
indicated concentrations of ABC294640 for the times shown (A) and in murine ALL cells 
generated from WT or SphK2-/- B-cell progenitors (B). Blots of prepared lysates were 
performed by Ms Rana Baraz. 
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Figure 6.S2. Effects of ABC294640 on normal bone marrow cells. 
The indicated concentrations of ABC294640 were incubated with bone marrow mononuclear 
cells (upper panel) for 24, 48 and 72 h. Cell viability was measured by annexin V and PI 
staining and analysed by flow cytometry. CD19+ B-cell progenitors were analysed separately 
(lower panel). 
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Figure 6.S3. Morphology of SphK2 inhibitor-treated ALL cells. 
The indicated cell lines were cultured with 100 µM ABC294640 or vehicle for 24 h and 
cytospin preparations stained with Romanowsky stain. The arrow indicates an apoptotic cell. 
Representative fields of view obtained using SPOT Version 4.6 software and a SPOT RTKE 
camera (Sterling Heights, MI) attached to an Olympus BX40 microscope (North Ryde, NSW, 
Australia) with a Plan 20x/0.40 and UPlanFl 40x/0.75 lens in air at room temperature are 
shown. Original magnification of 400x. Images were compiled and annotated using Adobe 
Photoshop CS4. 
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Figure 6.S4. qRT-PCR of selected genes. 
The indicated cell lines treated with 60 µM ABC294640 for 24 h. The mean±SD of three 
independent experiments is shown. 
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Figure 6.S5. Validation of the SphK2 gene signature. 
Hierarchical clustering of the gene expression microarray data produced by a validation 
cohort of 5 ALL cell lines treated with ABC294640 for 24 h using the SPHK2 gene signature 
defined in Figure 6.2A. 
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Figure 6.S6. Knockdown of SphK2 reduces c-Myc expression in K562 cells. 
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Figure 6.S7. Hierarchical clustering using published MYC gene signatures. 
Hierarchical clustering of the gene expression microarray data using the MYC gene signatures 
defined by Bild (left panel) [309] and Schuhmacher (right panel) [310]. 
Chapter 6 Sphingosine Kinase 2 in Acute Lymphoblastic Leukaemia 
	  
	  
148	  
 
 
Figure 6.S8. Interactions between various agents and SphK2 inhibition. 
The indicated cell lines were treated as described in Figure 6.5. The Fractional Product, 
calculated according to Webb [252] is shown. Values of less than -0.1 and greater than 0.1 
indicate synergistic and antagonistic interactions respectively. Values between -0.1 and 0.1 
indicate no interaction (i.e. additive effects).  
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Figure 6.S9. ABC294640 synergises with the HDAC1/2 inhibitor, AR-42. 
The indicated cell lines were cultured with vehicle or AR-42 (250 nM for NALM6, 125 nM 
for ALL1) with or without the addition of 50 µM ABC294640 for the indicated time periods 
and analysed for viability by flow cytometry using annexin V and PI staining. The mean and 
standard deviation of the viability of 2 experimental replicates is shown. The hatched bar 
represents the calculated additive effect based on the effect of each agent alone. # Indicates a 
synergistic interaction between the agents as determined by the Fractional Product method 
[252]. This figure is not part of the submitted manuscript. 
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CHAPTER 6 APPENDIX: ABCA1 AND SPHINGOSINE 
KINASE 2 INHIBITION 
 
 
Introduction 
 
ATP-binding cassette, sub-family A, member 1 (ABCA1) is a transmembrane protein 
involved in the secretion of excess cholesterol from cells into the high-density 
lipoprotein (HDL) metabolic pathway, giving rise to the commonly used term “good 
cholesterol” [319]. ABCA1 not only transports cholesterol out of cells, termed reverse 
cholesterol transport [320], but also transports phospholipids [321], sphingolipids [73, 
75] and other lipophilic substances across the plasma membrane where they are 
sequestered by apolipoproteins (e.g. HDL) containing little or no lipid. Mutations in 
the ABCA1 gene result in Tangier disease, characterised by reduced plasma HDL 
cholesterol and premature, accelerated atherosclerosis, often resulting in myocardial 
infarction and stroke [322]. 
 
This appendix presents very preliminary observations, which suggest ABCA1 is 
involved in cellular processes subsequent to the inhibition of SphK2 in ALL cells and 
is a direct result of the initial experiments performed in Chapter 6. Furthermore, 
these observations present exciting new opportunities to investigate the numerous 
paths these preliminary experiments may lead to in manipulating ABCA1 to further 
increase SphK2 inhibitor-mediated cell death. 
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Results 
 
Inhibition of Sphingosine Kinase 2 Dramatically Increases ABCA1 
Expression 
 
One of the completely unexpected findings to emerge from the analysis of the gene 
microarray data presented in Chapter 6, pertaining to inhibition of SphK2 by 
ABC294640 in ALL cells, was the striking increase in the expression of ABCA1. 
Expression of the ABCA1 gene was dramatically increased following exposure to 
ABC294640 in all cell lines tested, as validated by qRT-PCR (Figure 6App.1 upper 
panel). Furthermore, validation of the microarray data was obtained by Western blot, 
revealing markedly increased ABCA1 protein expression in ALL cells upon SphK2 
inhibition (Figure 6App.1 lower panel). 
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Figure 6App.1. ABCA1 gene and protein expression in SphK2 inhibitor-treated cells. 
(Upper panel) Quantitative real-time PCR of ALL cell lines (NALM6, REH, ALL1 and 
TOM1) treated with 60 µM ABC294640 or vehicle (Control) for 24 hours relative to 
GAPDH. The mean and standard deviation of three independent experiments is shown. 
(Lower panel) The indicated ALL cell lines were treated with increasing concentrations of 
ABC294640 for 24 hours and ABCA1 protein expression was determined by Western blot.	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The fact that SphK2 resides in the nucleus and endoplasmic reticulum suggests that 
the observed increases in ABCA1 expression may be occurring at these locations and 
perhaps not at the cell membrane, the most recognised site. However, increased 
ABCA1 protein was found to predominantly occur in the cytoplasm (which includes 
cell membrane components and possibly endoplasmic reticulum), as fractionation of 
cell lysates into nuclear and cytoplasmic components did not consistently reveal 
increased ABCA1 expression in the nucleus (Figure 6App.2). 
 
Figure 6App.2. ABCA1 does not consistently increase in the nucleus. 
The indicated ALL cell lines were treated with the increasing concentrations of ABC294640 
for 48 hours. Nuclear and cytoplasmic protein lysates were obtained and analysed for ABCA1 
expression by Western blot. Tubulin is expressed only in the cytoplasm and was used as a 
cytoplasmic loading control. The faint tubulin bands in the nucleus lanes could represent 
cytoplasmic contamination in the nuclear lysates. Topoisomerase II was used as a nuclear 
loading control.	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Co-inhibition of Sphingosine Kinase 2 and ABCA1 Results in Synergistic 
Cell Death of ALL cells 
 
It is possible that increased ABCA1 expression resulting from SphK2 blockade forms 
part of a protective response, the inhibition of which could be exploited to increase 
ALL cell death. Since ABCA1 is expected to remove excess intra-cellular lipid, 
inhibition of this process may result in greater cytotoxicity upon inhibition of SphK2, 
which should produce increased levels of cytotoxic sphinglipid precursors, such as 
pro-apoptotic ceramide. 
 
Probucol is a lipid lowering drug known to reduce plasma HDL levels by inhibition of 
ABCA1 [323, 324]. Interestingly, the addition of probucol to ABC294640-treated 
ALL cells enhanced the efficacy of the sphingosine kinase 2 inhibitor (Figure 
6App.3), thereby supporting the hypothesis that ABCA1 may be rescuing cells from a 
build-up of toxic intra-cellular mediators. Of note, probucol itself was only minimally 
cytotoxic. 
Chapter 6 Appendix ABCA1 and Sphingosine Kinase 2 Inhibition 
	  
	  
155	  
 
 
Figure 6App.3. SphK2 and ABCA1 inhibition produces synergistic cell death. 
ALL1 (A) and NALM6 (B) cells were treated with the indicated concentrations of 
ABC294640 for 72 hours, with or without increasing concentrations of probucol. Cell 
viability was determined by flow cytometry with viable cells being dual annexin V/PI 
negative. The mean and SD of duplicate measurements are shown. (C) The determination of 
synergy by the Fractional Product method at 72 hours, calculated according to Webb is shown 
[252]. Values of less than -0.1 and greater than 0.1 indicate synergistic and antagonistic 
interactions respectively. Values between -0.1 and 0.1 indicate no interaction (i.e. additive 
effects). 
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Discussion 
 
The hypothesis underpinning these experiments is that inhibiting SphK2 results in the 
accumulation of pro-apoptotic sphingolipid metabolic pathway precursors, such as 
ceramide, within cells. Indeed, ceramide itself has been shown to increase expression 
of ABCA1 [325]. These toxic precursors would normally be exported from the cell by 
ABCA1 thereby preventing cell death. Should ABCA1 function be blocked, these 
substances would produce cell death, however, this effect is not seen in all 
malignancies, with down-regulation of ABCA1 in prostate cancer correlating with 
tumour agressiveness [326]. 
 
Further detailed experiments need to be performed with elucidation of the precise role 
ABCA1 is playing in this setting a priority. Firstly, increased transport of sphingolipid 
precursors by ABCA1 following SphK2 inhibition needs to be demonstrated. This 
could be shown by inhibiting SphK2 with or without chemical or genetic inhibition of 
ABCA1 and measuring intra-cellular sphingolipids such as ceramide, sphingosine and 
S1P. Secondly, ABCA1 is part of a large family of transporters many of which are 
responsible for the efflux of drugs [327]. It is certainly possible that the observed 
increase in ABCA1 in response to SphK2 inhibition is primarily an attempt by the cell 
to pump out the offending drug (ABC294640) rather than the ensuing build up of 
cytotoxic lipids, as is the case in lung tumour cells treated with alpha-tocopheryl 
succinate [328], although both processes may be occuring simultaneously. 
 
In summary, inhibition of ABCA1 might further enhance the efficacy of sphingosine 
kinase 2 inhibitors by preventing the removal of cell death associated lipids and the 
combination of a SphK2 inhibitor and an inhibitor of ABCA1 may be a novel and less 
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toxic approach for the treatment of ALL. These findings should be further 
investigated as a result of this preliminary work and may be more broadly applicable 
to other malignancies, haematological or otherwise, where sphingosine kinase 2 is 
over-expressed.
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CHAPTER 7: SPHINGOSINE KINASE 1 IN ACUTE 
LYMPHOBLASTIC LEUKAEMIA 
 
 
Introduction 
 
The oncogenic role of SphK1 has been most conclusively demonstrated in solid organ 
malignancies, however, there is much less information relating to haematopoietic 
tumours. Studies to date describe the in vitro effects of SphK1 inhibition in CML, 
AML and multiple myeloma [134, 191, 199] and although a selective SphK1 inhibitor 
was efficacious in a human AML xenograft model, the leukaemia was not blood 
borne and therefore may not represent the natural history of the disease [195]. 
Furthermore, gene knockout studies examining the involvement of this enzyme in 
leukaemia initiation and progression are lacking. In this Chapter, the in vivo effects of 
SphK1 gene deletion in the development of BCR/ABL-positive ALL and in vitro 
SphK1 and dual SphK1/2 enzyme inhibition are examined to complement the SphK2 
studies presented in Chapter 6.	  
 
Results 
 
Sphingosine Kinase 1 Expression in ALL 
 
Published gene signatures for activation of SphK1 are not available, so ALL cell lines 
were treated with the SphK1 specific inhibitor SK1-I for 6 and 24 hours and gene 
expression analysed by microarray. Unfortunately, attempts to extract a signature for 
SphK1 were unsuccessful, most likely due to at least two factors: (1) SphK1 is 
primarily located in the cytoplasm where it interacts with numerous cell signalling 
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pathways at a post-translational not genetic level, and (2) inhibition of SphK1 with 
SK1-I results in relatively rapid induction of cell death. This is in contrast to SphK2 
(Chapter 6). Although SPHK1 was not over-expressed in the dataset of paediatric 
ALL patients at diagnosis (GSE28497) (Figure 7.1A), similar to SPHK2, increased 
protein expression and activity was found in ALL cell lines and patient ALL samples 
compared to normal B-cell progenitors and peripheral blood mononuclear cells 
(Figure 7.1B). This suggests post-translational protein modifications are significant. 
 
Figure 7.1. SphK1 gene and protein expression in ALL. 
(A) Expression of SPHK1 in patient ALL samples and CD19+CD10+ B-cells from normal 
controls from GSE28497 is shown. The shaded area indicates expression levels greater than 
twice the mean of the normal samples. (B) Expression of pSphK1 (ser225) and total SphK1 
protein in Ph- (NALM6, REH and LK63), Ph+ (ALL1 and TOM1) cell lines (left panel), 5 
patient samples (right panel), CD34+CD19+ B-cell progenitors and peripheral blood 
mononuclear cells (PBMC) from 3 normal donors as determined by Western blotting.  
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Sphingosine Kinase 1 Contributes to ALL Development in Mice 
 
Ecotropic retroviruses containing the ALL associated p185 form of the oncogenic 
fusion gene BCR/ABL were generated and transduced into B-cell progenitors from 
C57BL/6 WT, SphK1-/- and SphK2-/- mice, as described in Chapter 3 (Materials and 
Methods) and Chapter 6. Recipients of WT-transduced cells tended to develop 
leukaemia earlier compared to recipients of SphK1-/--transduced cells. Clinically, the 
leukaemias in both groups often resulted in bilateral hind limb paralysis and several 
mice developed extramedullary leukaemic deposits, most notably in the flank regions. 
The presence of BCR/ABL (Figure 7.2A) and the expected deletion of Sphk1 were 
confirmed by PCR in all murine leukaemias examined (Figure 7.2B). 
 
 
Figure 7.2. Evaluation of BCR/ABL and Sphk1 in murine leukaemias. 
(A) PCR detection of BCR/ABL in the leukaemias harvested from mice. The positive and 
negative controls consisted of p190 positive and negative patient samples (Sphk2-/- included). 
(B) PCR assessment of Sphk1 deletion in murine ALL cells. The PCR product from WT cells 
is 350 bp and that from Sphk1-/- cells 300 bp. Note the WT band is detected in residual normal 
cells in the harvested spleens of mice with ALL. The heavy band in the 100 bp DNA ladder is 
500 bp. 
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All SphK1-/- leukaemias demonstrated a pre-B-cell progenitor phenotype (B220+, 
CD19+, IgM-, CD11b-, CD43-), Figure 7.3A. Lymphoblasts were present in blood 
films and livers from all animals (Figure 7.3B, C). Cells recovered from leukaemic 
mice produced a rapidly fatal ALL in secondary recipients within two weeks of 
injection of leukaemic cells. 
 
Figure 7.3. Murine ALL characterisation and morphology. 
(A) Representative immunophenotype of a murine ALL sample showing B220 expression and 
lack of surface IgM. (B) Romanowsky stain of peripheral blood films from mice with 
BCR/ABL-driven ALL. Original magnification 400x. Bar indicates 50 µm. (C) Representative 
haematoxylin and eosin stained, paraffin embedded liver sections showing intra- and 
perivascular ALL infiltration. Original magnification 200x (left and middle panels) 400x 
(right panel). Bar indicates 100 µm. 
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Twenty-two of 29 mice receiving cells from wild type animals developed ALL, with a 
median survival of 42 days (95% CI 32-52 days). Absence of SphK1 reduced the 
incidence of BCR/ABL-driven ALL to 14 of 30 (mean survival 100 days, 95% CI 89-
111 days, p=0.017 compared to WT mice) (Figure 7.4). 
 
Figure 7.4. Genetic deletion of Sphk1 reduces ALL development. 
Kaplan-Meier survival analysis of WT mice injected with BCR/ABL-transduced B-cell 
progenitors from a total of 29 WT and 30 SphK1-/- animals. Significance using Cox 
Regression analysis relative to mice receiving WT cells is indicated. The experiment was 
performed on three separate occasions. The SphK2-/- ALL survival curve is shown for 
comparison. 
 
 
Importantly, no significant numerical differences were found for the B-cell progenitor 
populations between wild type and SphK1-/- mice, thereby excluding potential 
differences in B-cell progenitor populations in these genotypes as contributing to the 
observed differences in ALL development and progression (Figure 7.5). These data 
demonstrate a role for SphK1 in the development of BCR/ABL-driven ALL. 
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Figure 7.5. No difference in B-cell progenitor fractions between WT and SphK1-/- mice. 
B-cell progenitor fractions from the bone marrow of WT and SphK1-/- mice were determined 
by flow cytometry. Mature B-cells were defined as expressing surface IgM+B220+, pre-B 
cells as IgM-B220+CD43-, and pro-B cells as IgM-B220+CD43+. The mean ± SD of 3 animals 
is shown. SphK2-/- mice are shown for comparison. 
 
 
Pharmacological Inhibition of Sphingosine Kinase 1 Reduces ALL Cell 
Proliferation and Survival In Vitro 
 
The activity of the selective SphK1 inhibitor, SK1-I, and the dual SphK1 and SphK2 
inhibitor, SKI-II, in ALL cell lines was confirmed by measuring intra-cellular S1P 
concentrations in cells cultured for 24 and 48 hours. While both agents suppressed 
S1P production in all cell lines (Figure 7.6A, B), statistical significance was attained 
only for SK1-I (p=0.017 and p=0.003 at 24 and 48 hours respectively) where 3 cell 
lines had been analysed (Figure 7.6C). 
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Figure 7.6. SphK inhibitors reduce intra-cellular S1P. 
ALL cell lines were cultured with (A) 12 µM SK1-I or (B) 2 µM SKI-II for NALM6 and 10 
µM SKI-II for ALL1 or vehicle for 24 or 48 hours. Cell lysates were prepared and S1P 
concentrations determined by ELISA. The mean and SD of duplicate measurements is shown. 
(C) Measurements from all cell lines for each inhibitor were analysed together. The mean and 
standard deviation from 3 cell lines (SK1-I) or the mean and standard error from 2 cell lines 
(ALL1 and NALM6 only for SKI-II) is shown. *p<0.05. Statistical analysis was not 
performed for SKI-II as only 2 cell lines had been examined. 
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SK1-I and SKI-II consistently reduced cell proliferation, with IC50 values from 4 to 10 
µM, and 2 to 5 µM, respectively, when assessed at 48 hours (Figure 7.7A). The IC50 
values at 24 and 72 hours were not significantly different from those at 48 hours. 
SK1-I and SKI-II induced cell death, with IC50 values at 72 hours ranging from 12 
µM to 18 µM and 2 µM to > 10 µM respectively (Figure 7.7B). The Ph+ cell lines 
ALL1, 2070 and TOM1 tended to be more resistant to the cytotoxic effects of SKI-II 
compared to Ph- ALL cells, with only TOM1 cells obtaining a 72 hour IC50 of 7.6 µM 
(Figure 7.7B). Both inhibitors also induced cell death in primary patient ALL cells 
over a 16 hour incubation (Figure 7.7C).  
 
Chapter 7 Sphingosine Kinase 1 in Acute Lymphoblastic Leukaemia 
	  
	  
166	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Figure 7.7. SphK inhibitors suppress proliferation and induce cell death in ALL cells. 
(A) The indicated ALL cell lines (A & B) or patient ALL cells (C) were cultured with 
increasing concentrations of SK1-I, SKI-II or vehicle for 48 hours (A), 72 hours (B) or 16 
hours (C). (A) Proliferation was assessed using 3H-thymidine incorporation. The CPM were 
normalised to control cultures. (B & C) Viability was assessed by annexin V and PI staining, 
analysed by flow cytometry. The mean ± SD of duplicate measurements is shown. 
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Sphingosine Kinase Inhibition Results in Caspase-Dependent and 
Independent Cell Death 
 
SK1-I and SKI-II both resulted in externalisation of phosphatidylserine with a clear 
transition of cells from annexin V+/PI- (early apoptosis) to annexin V+/PI+ (late 
apoptosis) (Figure 7.8). 
 
Figure 7.8. Assessment of apoptosis by flow cytometry for the SphK inhibitors. 
The indicated ALL cell lines were cultured with 20 µM SK1-I or 10 µM SKI-II for 24 hours 
and cell viability analysed by flow cytometry. The proportion of annexin V+/PI- and annexin 
V+/PI+ cells is shown. The presented plots are representative of duplicate measurements. 
 
 
SKI-II induced apoptosis in Ph-, but not Ph+ ALL cells, with nuclear condensation and 
apoptotic bodies being evident by light microscopy (Figure 7.9), consistent with the 
relative lack of cell death in Ph+ cell lines. Apoptotic cells were largely absent in 
SK1-I-treated cultures (Figure 7.9), with cells treated with SK1-I showing 
morphological signs suggestive of autophagy, visualised as cytoplasmic vacuolation. 
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Figure 7.9. Morphology of SphK inhibitor-treated ALL cells. 
The indicated ALL cell lines were cultured with 20 µM SK1-I or 10 µM SKI-II for 24 hours. 
Cytospins were prepared and stained with a Wright’s stain. The thin arrows indicate 
cytoplasmic vacuolation whilst the thick arrows point to apoptotic cells. 
 
 
SKI-II resulted in cleavage of Caspase-3 in sensitive cells (Figure 7.10). In contrast, 
SK1-I only induced Caspase-3 cleavage in NALM6 cells but not the other five cell 
lines despite inducing cell death. 
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Figure 7.10. Assessment of Caspase-3 activation in SphK inhibitor-treated cells. 
The indicated ALL cell lines were cultured with 25 µM SK1-I for 24 hours, 10 µM SKI-II or 
vehicle for 72 hours, except for NALM6 cells that were analysed at 24 hours, and labelled for 
cleaved Caspase-3. The thin line represents the isotype control, and the heavy line cleaved 
Caspase-3 staining. The percentage of cleaved Caspase-3 ± SD of duplicate measurements is 
indicated. Representative histograms are shown. 
 
 
In order to definitively determine the dependence of the SphK inhibitors on caspase 
activation for inducing cell death, the pan-caspase inhibitor Z-VAD-FMK was 
employed. Pre-incubation of Ph- ALL cells with Z-VAD-FMK significantly reduced 
SKI-II-induced cell death (p=0.02, n=3), confirming a caspase-dependent cell death 
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mechanism (Figure 7.11, upper panels). As SKI-II had little cytotoxic effects on Ph+ 
ALL cells, caspase-dependence testing was not performed for these cells. Although Z-
VAD-FMK slightly reduced SK1-I-induced cell death in some cell lines, this effect 
did not achieve statistical significance (p=0.45, n=4 SK1-I) and thus the cytotoxicity 
induced by inhibiting SphK1 was deemed caspase-independent (Figure 7.11, upper 
and lower panels). Doxorubicin induces classical apoptosis (caspase-dependence) in 
ALL cells and was therefore used as a positive control. 
 
Figure 7.11. Caspase-dependence testing of SphK inhibitors. 
ALL cell lines were cultured with 0.25 µg/mL of doxorubicin, 12.5 µM (NALM6 and ALL1), 
20 µM (REH), 25 µM (TOM1) SK1-I, or 2.5 µM (NALM6), 10 µM (REH) SKI-II or vehicle 
with or without a 1 hour pre-incubation with 100 µM Z-VAD-FMK. Annexin V-/PI- cells 
were considered viable. The mean and standard deviation from duplicate determinations is 
shown. 
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Consistent with induction of autophagy, LC3-I was processed to LC3-II following 
exposure to SK1-I, and to a much lesser extent following exposure to SKI-II (Figure 
7.12A). However, pre-treatment with the autophagy inhibitor 3MA did not inhibit cell 
death in response to SK1-I, suggesting that neither classical apoptosis nor autophagy 
were responsible for cell death with this agent (Figure 7.12B). 
 
 
Figure 7.12 SphK inhibitors induce autophagy but this is not responsible for cell death. 
(A) The indicated cell lines were treated with the specified concentrations of each SphK 
inhibitor and cell lysates analysed by Western blotting for LC3 protein. (B) NALM6 (left) and 
ALL1 (right) cells were treated with vehicle (Control) or 12 µM SK1-I for 24 hours with or 
without 5 mM 3MA. The mean and standard deviation are shown for duplicate measurements 
and similar data was obtained using a range of SK1-I concentrations. 
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Overall, while SKI-II induced caspase-dependent apoptosis, SK1-I-induced cell death 
was at best partially caspase-dependent and largely lacked morphological features of 
apoptosis. Although autophagy was clearly occurring following SK1-I treatment, this 
was not the mechanism of cell death and is most likely acting to promote cell survival. 
 
Concurrent Bcr/Abl and SphK1 Inhibition Produces Synergistic Effects 
in Ph+ ALL 
 
Inhibition of SphKs has been shown to result in greater inhibition of Bcr/Abl and 
increased cell death by imatinib in CML and K562 cells [110, 135, 191]. In order to 
assess the effects of concurrent SphK inhibition on responses to imatinib in ALL 
cells, Ph+ cell lines were co-incubated with SK1-I or SKI-II with or without the 
addition of imatinib. Although imatinib inhibited the proliferation of ALL1, 2070 and 
TOM1, it had little effect on the viability of these cells (Figure 7.13, upper panels). 
However we did not detect mutations in BCR/ABL that should provide resistance to 
imatinib in these cell lines (performed by A/Prof Susan Branford, SA Pathology). 
Resistance to cell death with imatinib was overcome by the addition of SK1-I or SKI-
II (Figure 7.13, lower panels). Clear synergistic interactions were observed at 48 
hours and 72 hours in all cell lines with the exception of imatinib and SK1-I in 2070 
at all time points tested, where additive effects were observed (Figure 7.13, lower 
panels and data not shown). 
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Figure 7.13. SphK inhibitors synergise with imatinib. 
The indicated cell lines were incubated with increasing concentrations of imatinib for 72 
hours and assessed for proliferation by 3H-thymidine incorporation (upper left panel) or 
survival by flow cytometry with annexin V/PI double negative cells being considered viable 
(upper right panel). The mean and standard deviation of four (upper left panel) and two 
(upper right panel) experimental replicates is shown. (Lower panels) The indicated cell 
lines were cultured with vehicle, 5 µM (2070) or 12.5 µM (ALL1 and TOM1) SK1-I or 5 µM 
SKI-II with or without the addition of 5 µM (0.5 µM for SK1-I experiments) imatinib for 72 
hours and analysed for viability by flow cytometry using annexin V and PI staining. The 
mean and standard deviation of 2 experimental replicates is shown. The hatched bar 
represents the calculated additive effect based on the effect of each agent alone. # Indicates a 
synergistic interaction between the agents as determined by the Fractional Product method. 
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Conventional Chemotherapeutic Agents Fail to Synergise with SphK1 
Inhibition 
 
Chemotherapeutic drugs are given together in various combinations so the selective 
SphK1 inhibitor SK1-I was combined with two commonly used anti-tumour agents, 
doxorubicin and vincristine. 
 
Figure 7.14. SphK1 inhibition does not synergise with conventional agents. 
NALM6 cells (upper panel) and ALL1 cells (lower panel) were incubated with the indicated 
concentrations of SK1-I for 24 hours with or without increasing concentrations of 
doxorubicin or vincristine. Viability was measured by flow cytometry staining with annexin 
V and PI. The mean and SD of duplicate measurements is shown. 
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Unexpectedly, SK1-I resulted in at best additive cell death when combined with 
increasing concentrations of doxorubicin or vincristine (Figure 7.14). 
 
Discussion 
 
The series of experiments presented in this Chapter clearly demonstrate a role for 
SphK1 in ALL. Although a gene signature consistent with increased SphK1 activity 
could not be determined, elevated and active SphK1 protein was found in ALL cells. 
Importantly, gene deletion of SphK1 significantly impaired the development of 
BCR/ABL-driven ALL further supporting a role for SphKs in promoting ALL. 
Consistent with these data, genetic loss of SphK1 has previously been shown to 
reduce the incidence of 4-NQO-induced head and neck squamous cell carcinoma 
[329] and azoxymethane-induced colon cancer [123]. However, the size but not 
incidence of intestinal adenomas was reduced in ApcMin/+;SphK1-/- mice, suggesting 
a role for SphK1 in disease progression [131]. Overall, this is the first demonstration 
of the effect of genetic deletion of SphK1 in the development of Ph+ ALL and 
highlights the involvement of SphK1 in ALL more generally. 
 
Inhibition of SphK1 has previously been associated with apoptosis in a range of cell 
types including leukaemias [195], although reports in B-lineage ALL are lacking. 
Despite the SphK1 inhibitor SK1-I efficiently killing ALL cells, the lack of Caspase-3 
activation (with the exception of NALM6 cells) and the minimal effect of pan-caspase 
inhibition, demonstrates that in ALL cells SK1-I does not induce classical apoptosis. 
Although autophagy induction was detected, this was not the cause of cell death, 
results similar to those obtained following FTY720 exposure [196]. Inhibition of both 
SphK isoforms has uniformly been reported to induce apoptosis [135, 136, 217] as we 
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observed here. Why the inhibition of both isoforms changes the death mechanism is 
not clear, but both enzymes produce S1P, which has well established anti-apoptotic 
effects [222]. Possibly, inhibition of both isoforms is required to suppress S1P 
concentrations to levels permissive of apoptosis. However, as a greater reduction in 
intra-cellular S1P concentrations was not detected with the dual SphK1/SphK2 
inhibitor compared to the individual SphK1 inhibitor, this explanation appears 
unlikely. 
 
It was surprising that Ph+ ALL cells were relatively resistant to combined 
SphK1/SphK2 inhibition compared to Ph- ALL whereas selective SphK1 inhibition 
was equally effective in all ALL cell lines. The role of SphK1 in Ph+ leukaemias has 
been well described with Bcr/Abl reported to increase expression of SphK1 in murine 
lymphoid and human myeloid leukaemia cell lines, with over-expression of SphK1 
leading to resistance to imatinib [191]. Although higher SphK1 protein levels in the 
Ph+ ALL cell lines as compared to Ph- cell lines were not found, at least additive cell 
death in all Ph+ cell lines with imatinib and each SphK inhibitor occurred. This was 
particularly evident for SKI-II, which was relatively ineffective in Ph+ ALL as a 
single agent. As SphK1 has been shown to enhance Bcr/Abl stability [192], the 
increased cytotoxic effects seen in ALL cells with dual enzyme inhibition are not 
unexpected. However, attempts at combining conventional chemotherapeutic agents 
such as doxorubicin and vincristine with the SphK inhibitors were disappointing with 
no significant synergy seen. 
 
Although SphK1 inhibition has been considerably investigated, most conclusions are 
based on in vitro studies using either siRNA or chemical-mediated SphK1 knockdown 
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with no in vivo studies assessing effects the genetic loss of this enzyme on leukaemia 
initiation and progression. These results present important preliminary findings, 
demonstrating the significance of SphK1 in ALL cells and warrant future studies 
exploring these and mechanistic concepts in greater detail. 
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CHAPTER 8: DISCUSSION AND FUTURE DIRECTIONS 
 
 
Introduction 
 
Sphingolipid signalling is increasingly recognised as important in malignancies and 
research to unravel the significance and intra-cellular interactions of components of 
this pathway is currently underway. Whilst S1P and its receptors have been the 
subject of most of the initial work undertaken in this area, the lipid precursors and the 
enzymes responsible for S1P production are now receiving attention. This Chapter 
discusses the key experimental findings presented in this thesis with an outline of 
future directions this research may take. 
 
The first agent to manipulate sphingolipid metabolism and be successfully translated 
to the clinic was FTY720 [161, 163]. The interaction of FTY720 with S1P receptors 
and the effect of this on lymphocyte trafficking have been extensively studied [161]. 
While numerous studies have attested to the cytotoxicity of higher doses of FTY720 
in a range of cancers [210] the mechanism remains unclear.  Moving on from 
FTY720, the sphingosine kinases gained significance in the field and SphK1 in 
particular received much attention for its tumour-promoting roles [69]. The enigmatic 
SphK2, on the other hand, seemed to resist attempts at classification, possibly due to 
its sub-cellular compartmentalisation compared to SphK1 and less well developed 
reagents with which to study it. Only recently, with the advent of selective SphK2 
inhibitors, new reagents such as detection antibodies, and the finding of tumour-
promoting effects in some circumstances, has this enzyme hit the spotlight. 
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FTY720 in ALL 
 
FTY720 induced in vitro cytotoxicity in ALL cells but also induced autophagy as a 
survival mechanism (Chapter 4), consistent with the known induction of autophagy 
by S1P interacting with its receptors [90]. Given this strong FTY720-induced 
autophagy in ALL cells, it was of interest to inhibit this process concurrently with 
FTY720 administration, as a means to increasing cell death. This was seen with 
inhibition of tyrosine kinase inhibitor-induced autophagy in CML cells by 
chloroquine, which enhanced cell death [330]. Accordingly, the autophagy inhibitors 
3MA and chloroquine, the latter being an anti-malarial drug, were employed for this 
purpose (chloroquine data was not published and is not shown in the thesis). Unlike 
the situation in CML cells, enhanced cell death was not observed with chloroquine but 
was found when 3MA was used. Chloroquine may not have been acting as an 
effective autophagy inhibitor in ALL cells despite being used at reported 
concentrations for autophagy inhibition [331, 332]. Inhibition of LC3 protein 
processing by Western blot was not performed in chloroquine-treated cells but could 
have illustrated this point. Chloroquine is in widespread clinical use and would have 
facilitated translation of FTY720 into the clinic for the treatment of ALL.    
 
The mechanism by which FTY720 induces cytotoxic effects is unclear though PP2A 
activation and inhibition of SphK1 are candidates [192, 210]. In ALL cells, induction 
of PP2A activity, although present, was not required for cell death, contrary to the 
majority of previous reports [206, 208, 210]. In Ph+ leukaemias, Bcr/Abl increases 
expression of SET [210], a known inhibitor of PP2A [333, 334], but where FTY720 
was shown to inhibit SET in lung tumour cells [335], this relationship remains to be 
examined in ALL. Certainly, the sensitivity of Ph+ ALL xenografts to FTY720 
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deserves further examination in terms of both mechanistic exploration and 
translational approaches. In contrast, Ph- xenografts were resistant to FTY720, 
demonstrating that FTY720 will not be helpful in this setting. Importantly, animals 
receiving FTY720 appeared profoundly lethargic and were generally in poor 
condition suggesting more work needs to be done to determine an effective 
therapeutic window in the setting of Ph+ disease. 
 
SphK2 and the SphK2-MYC Hypothesis 
 
Exciting novel data has been presented in this thesis concerning the role of SphK2 in 
ALL cells, not only suggesting translational potential with the demonstration of a 
selective SphK2 inhibitor showing in vitro and in vivo efficacy in human disease but 
also proposing the mechanism involved. Specifically, this body of work presents 
convincing evidence for a relationship between nuclear SphK2 and the MYC proto-
oncogene with the following hypothesis proposed. Under basal conditions in ALL 
cells, activated SphK2 produces nuclear S1P, which as previously reported [82] 
inhibits HDAC1/2 (Figure 8.1, left column). This work proposes that this results in 
acetylation of histone H3 associated with the MYC promoter, increasing MYC 
transcription, c-Myc protein production and altered target gene expression, 
contributing to the survival of ALL cells. Inhibition of SphK2 reduces nuclear S1P 
allowing HDAC1/2 to inhibit acetylation of histone H3. This attenuates MYC 
transcription, protein production and activation of downstream survival pathways, 
resulting in ALL cell death (Figure 8.1, right column).  
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Figure 8.1. Postulated mechanism relating nuclear SphK2 to MYC signalling. 
SphK2 is over-expressed in ALL cells and maintains cell viability through induction of MYC 
signalling by S1P-mediated suppression of HDAC activity. Ac, acetylated; HDAC, histone 
deacetylase; H3, histone H3; Sph, sphingosine. 	  
 
 
While most steps in this hypothesis have been demonstrated in this thesis, it has not 
been conclusively established that the observed ALL cell death upon SphK2 
inhibition is dependent on MYC inhibition. This could be demonstrated by over-
expressing MYC in ALL cells (using MYC expressing retroviral particles) and 
showing that this provides protection from SphK2 inhibitor treatment. The potential 
caveat is that SphK2 inhibition could also decrease expression of ectopic MYC, as 
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binding sites for acetylated Histone H3 occur within the MYC cDNA sequence 
(Chapter 6 Figure 4A). Further support for the hypothesis is provided by the 
demonstration of decreased c-Myc expression in murine SphK2-/- ALL compared to 
WT ALL, similar to that seen in vitro with human ALL cell lines treated with 
ABC294640 (Chapter 6, Figures 3D and 7G). To further validate these findings, 
detection of the SphK2 gene signature identified in ABC294640-treated ALL cell 
lines, and published MYC signatures, could be determined by microarray analysis of 
murine SphK2-/- ALL.  
 
The development of ALL in a proportion of BCR/ABL-transduced SphK2-/- B-cell 
progenitors raises further questions regarding the biology of ALL. These leukaemias 
may arise by the activation of alternative mechanisms compensating for reduced c-
Myc expression and/or function with a recent study demonstrating increased c-Myc 
due to over-expressed SphK1 [336]. However, gene deletion or inhibition of SphK2 
did not appear to regulate total SphK1 protein in this thesis (Chapter 6, Figure S1). 
Examination of gene expression data from SphK2-/- and WT ALL for the presence of 
signatures indicative of activation of other pathways could be undertaken. These 
pathways could include the PI-3K/AKT pathway, which activates SphK1 but not 
SphK2 [337] and can induce cell proliferation independently of c-Myc [338], NF-κB 
which is regulated by SphK1 [83], and Wnt signalling as this can activate c-Myc 
expression, potentially increasing c-Myc in the absence of SphK2 activity [339].  
 
The interaction between SphK2 and MYC expression was demonstrated in this thesis, 
but SphK2 inhibition also affected genes not thought to be regulated by MYC. 
Performing ChIP-seq on complexes immunoprecipitated with SphK2 will provide a 
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global picture of which genes may be directly regulated by this enzyme. This study 
focused on histone H3 acetylated on K9 but the involvement of other histones could 
also be assessed. Histone H2B acetylated on K12 (H2BK12ac) and histone H4 
acetylated on K5 (H4K5ac) are also reportedly modified by SphK2 [82]. Similarly the 
HDACs involved have not been identified and while HDAC1/2 have been shown to 
bind SphK2 by Hait et al, the role of HDACs 3, 7 and 9 are of interest as these are 
over-expressed in ALL and associated with outcome [339].  
 
It was surprising that the pan-HDAC inhibitor AR-42 synergised with SphK2 
inhibition (Chapter 6, Figure S9). This suggests that histone deacetylation resulting 
from SphK2 inhibition is not reversed by HDAC inhibitors. This observation could be 
confirmed genetically by comparing the sensitivity of WT and SphK2-/- ALL to 
HDAC inhibitors. While many questions remain regarding which histones and 
HDACs are involved here, the potential clinical application of combining SphK2 
inhibition with HDAC inhibition could be evaluated using in vivo models. 
  
Sphingosine Kinase Inhibition in ALL 
 
Similar to the overall format and design of experiments presented in Chapter 6 
concerning SphK2, inhibition of SphK1, presented in Chapter 7, was efficacious in 
vitro and synergised with imatinib in Ph+ ALL cells. However, recently-developed 
highly selective and potent SphK1 inhibitors have controversially reduced SphK1 
activity and intra-cellular S1P levels without anti-proliferative or cytotoxic effects 
[241, 242, 340]. These observations, however, are not in keeping with the cytotoxicity 
seen with siRNA or gene knockout murine models [110, 195], suggesting SphK1 
inhibition remains a viable anti-cancer strategy. Cell death occurred faster with 
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SphK1 inhibition than with SphK2 inhibition using ABC294640. This is consistent 
with the apparent respective dependence and independence on altered gene expression 
following SphK2 and SphK1 inhibition. Genetic deletion of SphK1 increased the 
latency and reduced the penetrance of BCR/ABL-driven murine ALL in vivo. 
However, due to the lack of a sufficient quantity of the specific SphK1 inhibitor, 
human ALL xenograft experiments were not undertaken. Overall, these results 
confirm SphK1 and SphK2 as important oncogenic targets in ALL.  
 
Given that SphK1 and SphK2 can compensate for each other in some settings, it 
would be interesting to examine the effect of loss of both SphK1 and SphK2. The 
embryonic lethality of Sphk1-/-.Sphk2-/- animals [99] makes these experiments 
challenging. While foetal livers from these animals may provide a source of B-cell 
progenitors for transduction, the time of foetal loss is very close to when these cells 
first emerge [99, 341]. Alternatively Sphk1fl/fl.Sphk2-/- mice could be generated 
(Sphk1fl/fl mice are available) permitting deletion of Sphk1 in adult animals following 
activation of a suitable Cre construct. The role of SphK1 in ALL could also be 
examined in the reciprocal experiment using mice that have been engineered to over-
express Sphk1 in haematopoietic and endothelial cells under regulation of Tie2 
(Sphk1tg), with the prediction of increased penetrance and/or reduced disease latency 
in this model.  
 
The role of SphKs in Ph- ALL should be evaluated using genetic models since only a 
Ph+ model is presented in this work. There are a growing number of potential models 
that could be used such as the p19ARF-/-.Rag1-/- model of pro-B ALL [342] which 
spontaneously develop ALL with 80% penetrance. p19ARF-/-.Rag1-/- mice could be 
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crossed onto Sphk1-/-, Sphk2-/- and Sphk1tg mice and the progeny monitored for ALL 
development and overall survival. Moreover, B-cell progenitors from p19ARF-/- also 
lacking Sphk1, Sphk2 or expressing Sphk1tg could be retrovirally transduced with 
mutations common in ALL such as oncogenic NRas (G13D), KRas (D12), or CRLF2 
and Jak2 (R683G) [299, 343, 344]. 
 
Elevated plasma S1P levels have been reported in some malignancies such as ovarian 
cancer [86] and SphK1 expression correlated with invasiveness, metastatic potential 
and treatment failure in oesophageal carcinoma [345]. To assess sphingosine 
metabolism in the clinical setting, some simple initial experiments could be conducted 
such as the evaluation of plasma S1P at diagnosis and in response to treatment and the 
assessment of SphK activity and S1P production in patient ALL cells. This would 
provide insights into whether there is a direct correlation between plasma S1P 
concentrations and the extent of disease. Furthermore, the effect of SphK inhibitors on 
S1P production and SphK enzyme activity in ALL cells from patients could be 
evaluated. 
 
Lastly, synergistic cell death was found with imatinib, bortezomib and the HDAC 
inhibitor, AR-42 using human ALL cell lines in combination with the SphK inhibitors 
SK1-I, SKI-II and ABC294640. In contrast, these SphK inhibitors did not increase 
sensitivity to vincristine or doxorubicin. To examine this in a more stringent model 
system, ALL generated from transduced WT, Sphk1tg, Sphk1-/-, Sphk2-/- and if 
obtained Sphk1-/-.Sphk2-/- cells could be treated with a range of agents. These agents 
could include the mTOR inhibitor RAD001, MEK inhibitor PD-325901, PI-3K 
inhibitor BKM120, Jak inhibitor INCB018424 and the Ras inhibitor Tipifarnib, all of 
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which are in clinical or pre-clinical studies for the treatment of ALL. Where increased 
in vitro sensitivity is found, in vivo experiments could be conducted and the data used 
to plan future clinical trials. 
 
In conclusion, the field of sphingolipid signalling in malignancies is ever expanding 
and the sphingosine kinases play a central role. These enzymes are becoming 
increasingly important in haematopoietic tumours and their complex sub-cellular 
interactions are progressively being unraveled. This thesis has presented novel data on 
the roles of SphK1 and SphK2 in B-lineage ALL and has introduced concepts which 
will result in further research effort. It is hoped that this work will not only contribute 
to our understanding of sphingosine kinase biology but also support the translation of 
sphingosine kinase inhibitors from the laboratory to the clinic, for the treatment of 
ALL.
 	  
	  
188	  
      APPENDIX 1 
 
 
Appendix 1 
	  
	  
189	  
 
Appendix 1 
	  
	  
190	  
 
Appendix 1 
	  
	  
191	  
 
Appendix 1 
	  
	  
192	  
 
Appendix 1 
	  
	  
193	  
 
Appendix 1 
	  
	  
194	  
 
 	  
	  
195	  
REFERENCES 
 
1. Cavazzana-Calvo, M., A. Fischer, F.D. Bushman, E. Payen, S. Hacein-Bey-
Abina, and P. Leboulch, Is normal hematopoiesis maintained solely by long-
term multipotent stem cells? Blood, 2011. 117(17): p. 4420-4. 
2. Arai, F., A. Hirao, and T. Suda, Regulation of hematopoiesis and its 
interaction with stem cell niches. Int J Hematol, 2005. 82(5): p. 371-6. 
3. Osawa, M., K. Hanada, H. Hamada, and H. Nakauchi, Long-term 
lymphohematopoietic reconstitution by a single CD34-low/negative 
hematopoietic stem cell. Science, 1996. 273(5272): p. 242-5. 
4. Bethel, C.A., T. Steinkirchner, E.D. Zanjani, and A.W. Flake, Stromal 
microenvironment of human fetal hematopoiesis: in vitro morphologic studies. 
Pathobiology, 1994. 62(2): p. 99-103. 
5. Pahal, G.S., E. Jauniaux, C. Kinnon, A.J. Thrasher, and C.H. Rodeck, Normal 
development of human fetal hematopoiesis between eight and seventeen weeks' 
gestation. Am J Obstet Gynecol, 2000. 183(4): p. 1029-34. 
6. Cheshier, S.H., S.J. Morrison, X. Liao, and I.L. Weissman, In vivo 
proliferation and cell cycle kinetics of long-term self-renewing hematopoietic 
stem cells. Proc Natl Acad Sci U S A, 1999. 96(6): p. 3120-5. 
7. Arai, F., A. Hirao, M. Ohmura, H. Sato, S. Matsuoka, K. Takubo, et al., 
Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in 
the bone marrow niche. Cell, 2004. 118(2): p. 149-61. 
8. Yoshihara, H., F. Arai, K. Hosokawa, T. Hagiwara, K. Takubo, Y. Nakamura, 
et al., Thrombopoietin/MPL signaling regulates hematopoietic stem cell 
quiescence and interaction with the osteoblastic niche. Cell Stem Cell, 2007. 
1(6): p. 685-97. 
9. Cheng, T., N. Rodrigues, H. Shen, Y. Yang, D. Dombkowski, M. Sykes, et al., 
Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science, 
2000. 287(5459): p. 1804-8. 
10. Schofield, R., The relationship between the spleen colony-forming cell and the 
haemopoietic stem cell. Blood Cells, 1978. 4(1-2): p. 7-25. 
11. Calvi, L.M., G.B. Adams, K.W. Weibrecht, J.M. Weber, D.P. Olson, M.C. 
Knight, et al., Osteoblastic cells regulate the haematopoietic stem cell niche. 
Nature, 2003. 425(6960): p. 841-6. 
 	  
	  
196	  
12. Kiel, M.J., O.H. Yilmaz, T. Iwashita, O.H. Yilmaz, C. Terhorst, and S.J. 
Morrison, SLAM family receptors distinguish hematopoietic stem and 
progenitor cells and reveal endothelial niches for stem cells. Cell, 2005. 
121(7): p. 1109-21. 
13. Sugiyama, T., H. Kohara, M. Noda, and T. Nagasawa, Maintenance of the 
hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone 
marrow stromal cell niches. Immunity, 2006. 25(6): p. 977-88. 
14. Zhang, J., C. Niu, L. Ye, H. Huang, X. He, W.G. Tong, et al., Identification of 
the haematopoietic stem cell niche and control of the niche size. Nature, 2003. 
425(6960): p. 836-41. 
15. Bonig, H. and T. Papayannopoulou, Hematopoietic stem cell mobilization: 
updated conceptual renditions. Leukemia, 2013. 27(1): p. 24-31. 
16. Li, L. and W.B. Neaves, Normal stem cells and cancer stem cells: the niche 
matters. Cancer Res, 2006. 66(9): p. 4553-7. 
17. Yin, T. and L. Li, The stem cell niches in bone. J Clin Invest, 2006. 116(5): p. 
1195-201. 
18. Hardy, R.R., C.E. Carmack, S.A. Shinton, J.D. Kemp, and K. Hayakawa, 
Resolution and characterization of pro-B and pre-pro-B cell stages in normal 
mouse bone marrow. J Exp Med, 1991. 173(5): p. 1213-25. 
19. Oettinger, M.A., D.G. Schatz, C. Gorka, and D. Baltimore, RAG-1 and RAG-
2, adjacent genes that synergistically activate V(D)J recombination. Science, 
1990. 248(4962): p. 1517-23. 
20. Schatz, D.G., M.A. Oettinger, and D. Baltimore, The V(D)J recombination 
activating gene, RAG-1. Cell, 1989. 59(6): p. 1035-48. 
21. Meffre, E., R. Casellas, and M.C. Nussenzweig, Antibody regulation of B cell 
development. Nat Immunol, 2000. 1(5): p. 379-85. 
22. Alt, F.W., G.D. Yancopoulos, T.K. Blackwell, C. Wood, E. Thomas, M. Boss, 
et al., Ordered rearrangement of immunoglobulin heavy chain variable region 
segments. EMBO J, 1984. 3(6): p. 1209-19. 
23. ten Boekel, E., F. Melchers, and A. Rolink, The status of Ig loci 
rearrangements in single cells from different stages of B cell development. Int 
Immunol, 1995. 7(6): p. 1013-9. 
 	  
	  
197	  
24. Hermanson, G.G., D. Eisenberg, P.W. Kincade, and R. Wall, B29: a member 
of the immunoglobulin gene superfamily exclusively expressed on beta-lineage 
cells. Proc Natl Acad Sci U S A, 1988. 85(18): p. 6890-4. 
25. Hombach, J., L. Leclercq, A. Radbruch, K. Rajewsky, and M. Reth, A novel 
34-kd protein co-isolated with the IgM molecule in surface IgM-expressing 
cells. EMBO J, 1988. 7(11): p. 3451-6. 
26. Nagata, K., T. Nakamura, F. Kitamura, S. Kuramochi, S. Taki, K.S. Campbell, 
et al., The Ig alpha/Igbeta heterodimer on mu-negative proB cells is competent 
for transducing signals to induce early B cell differentiation. Immunity, 1997. 
7(4): p. 559-70. 
27. Tonegawa, S., Somatic generation of antibody diversity. Nature, 1983. 
302(5909): p. 575-81. 
28. Hess, J., A. Werner, T. Wirth, F. Melchers, H.M. Jack, and T.H. Winkler, 
Induction of pre-B cell proliferation after de novo synthesis of the pre-B cell 
receptor. Proc Natl Acad Sci U S A, 2001. 98(4): p. 1745-50. 
29. Kitamura, D., A. Kudo, S. Schaal, W. Muller, F. Melchers, and K. Rajewsky, 
A critical role of lambda 5 protein in B cell development. Cell, 1992. 69(5): p. 
823-31. 
30. Kitamura, D. and K. Rajewsky, Targeted disruption of mu chain membrane 
exon causes loss of heavy-chain allelic exclusion. Nature, 1992. 356(6365): p. 
154-6. 
31. Maki, K., K. Nagata, F. Kitamura, T. Takemori, and H. Karasuyama, 
Immunoglobulin beta signaling regulates locus accessibility for ordered 
immunoglobulin gene rearrangements. J Exp Med, 2000. 191(8): p. 1333-40. 
32. Reth, M., E. Petrac, P. Wiese, L. Lobel, and F.W. Alt, Activation of V kappa 
gene rearrangement in pre-B cells follows the expression of membrane-bound 
immunoglobulin heavy chains. EMBO J, 1987. 6(11): p. 3299-305. 
33. Schlissel, M.S. and D. Baltimore, Activation of immunoglobulin kappa gene 
rearrangement correlates with induction of germline kappa gene 
transcription. Cell, 1989. 58(5): p. 1001-7. 
34. LeBien, T.W. and T.F. Tedder, B lymphocytes: how they develop and function. 
Blood, 2008. 112(5): p. 1570-80. 
35. Busslinger, M., Transcriptional control of early B cell development. Annu Rev 
Immunol, 2004. 22: p. 55-79. 
 	  
	  
198	  
36. Georgopoulos, K., M. Bigby, J.H. Wang, A. Molnar, P. Wu, S. Winandy, et 
al., The Ikaros gene is required for the development of all lymphoid lineages. 
Cell, 1994. 79(1): p. 143-56. 
37. Winandy, S., P. Wu, and K. Georgopoulos, A dominant mutation in the Ikaros 
gene leads to rapid development of leukemia and lymphoma. Cell, 1995. 
83(2): p. 289-99. 
38. DeKoter, R.P. and H. Singh, Regulation of B lymphocyte and macrophage 
development by graded expression of PU.1. Science, 2000. 288(5470): p. 
1439-41. 
39. Zhuang, Y., P. Soriano, and H. Weintraub, The helix-loop-helix gene E2A is 
required for B cell formation. Cell, 1994. 79(5): p. 875-84. 
40. Vilagos, B., M. Hoffmann, A. Souabni, Q. Sun, B. Werner, J. Medvedovic, et 
al., Essential role of EBF1 in the generation and function of distinct mature B 
cell types. J Exp Med, 2012. 209(4): p. 775-92. 
41. Nutt, S.L., B. Heavey, A.G. Rolink, and M. Busslinger, Commitment to the B-
lymphoid lineage depends on the transcription factor Pax5. Nature, 1999. 
401(6753): p. 556-62. 
42. Nutt, S.L., C. Thevenin, and M. Busslinger, Essential functions of Pax-5 
(BSAP) in pro-B cell development. Immunobiology, 1997. 198(1-3): p. 227-
35. 
43. Ramirez, J., K. Lukin, and J. Hagman, From hematopoietic progenitors to B 
cells: mechanisms of lineage restriction and commitment. Curr Opin Immunol, 
2010. 22(2): p. 177-84. 
44. Mullighan, C.G., C.B. Miller, I. Radtke, L.A. Phillips, J. Dalton, J. Ma, et al., 
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. 
Nature, 2008. 453(7191): p. 110-4. 
45. Mullighan, C.G., X. Su, J. Zhang, I. Radtke, L.A. Phillips, C.B. Miller, et al., 
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J 
Med, 2009. 360(5): p. 470-80. 
46. Roessler, S., I. Gyory, S. Imhof, M. Spivakov, R.R. Williams, M. Busslinger, 
et al., Distinct promoters mediate the regulation of Ebf1 gene expression by 
interleukin-7 and Pax5. Mol Cell Biol, 2007. 27(2): p. 579-94. 
 	  
	  
199	  
47. Dougall, W.C., M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De 
Smedt, et al., RANK is essential for osteoclast and lymph node development. 
Genes Dev, 1999. 13(18): p. 2412-24. 
48. Whitlock, C.A. and O.N. Witte, Long-term culture of B lymphocytes and their 
precursors from murine bone marrow. Proc Natl Acad Sci U S A, 1982. 
79(11): p. 3608-12. 
49. Hannum, C., J. Culpepper, D. Campbell, T. McClanahan, S. Zurawski, J.F. 
Bazan, et al., Ligand for FLT3/FLK2 receptor tyrosine kinase regulates 
growth of haematopoietic stem cells and is encoded by variant RNAs. Nature, 
1994. 368(6472): p. 643-8. 
50. Funk, P.E., R.P. Stephan, and P.L. Witte, Vascular cell adhesion molecule 1-
positive reticular cells express interleukin-7 and stem cell factor in the bone 
marrow. Blood, 1995. 86(7): p. 2661-71. 
51. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., 
Thiele, J., Vardiman, J.W, WHO Classification of Tumours of Haematopoietic 
and Lymphoid Tissues. Fourth ed2008, Lyon, France: IARC. 
52. Mullighan, C.G., The molecular genetic makeup of acute lymphoblastic 
leukemia. Hematology Am Soc Hematol Educ Program, 2012. 2012: p. 389-
96. 
53. Mullighan, C.G., Molecular genetics of B-precursor acute lymphoblastic 
leukemia. J Clin Invest, 2012. 122(10): p. 3407-15. 
54. Mullighan, C.G. and J.R. Downing, Genome-wide profiling of genetic 
alterations in acute lymphoblastic leukemia: recent insights and future 
directions. Leukemia, 2009. 23(7): p. 1209-18. 
55. Greaves, M.F., Biological models for leukaemia and lymphoma. IARC Sci 
Publ, 2004(157): p. 351-72. 
56. Mori, H., S.M. Colman, Z. Xiao, A.M. Ford, L.E. Healy, C. Donaldson, et al., 
Chromosome translocations and covert leukemic clones are generated during 
normal fetal development. Proc Natl Acad Sci U S A, 2002. 99(12): p. 8242-7. 
57. Redaelli, A., B.L. Laskin, J.M. Stephens, M.F. Botteman, and C.L. Pashos, A 
systematic literature review of the clinical and epidemiological burden of 
acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl), 2005. 14(1): 
p. 53-62. 
 	  
	  
200	  
58. Pui, C.H., W.E. Evans, and M.V. Relling, Are children with lesser-risk B-
lineage acute lymphoblastic leukemia curable with antimetabolite therapy? 
Nat Clin Pract Oncol, 2008. 5(3): p. 130-1. 
59. Fielding, A.K. and A.H. Goldstone, Allogeneic haematopoietic stem cell 
transplant in Philadelphia-positive acute lymphoblastic leukaemia. Bone 
Marrow Transplant, 2008. 41(5): p. 447-53. 
60. Gokbuget, N. and D. Hoelzer, Treatment of adult acute lymphoblastic 
leukemia. Semin Hematol, 2009. 46(1): p. 64-75. 
61. Stanulla, M. and M. Schrappe, Treatment of childhood acute lymphoblastic 
leukemia. Semin Hematol, 2009. 46(1): p. 52-63. 
62. Lukenbill, J. and A.S. Advani, The treatment of adolescents and young adults 
with acute lymphoblastic leukemia. Curr Hematol Malig Rep, 2013. 8(2): p. 
91-7. 
63. Fielding, A.K., S.M. Richards, R. Chopra, H.M. Lazarus, M.R. Litzow, G. 
Buck, et al., Outcome of 609 adults after relapse of acute lymphoblastic 
leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood, 2007. 109(3): 
p. 944-50. 
64. Era, T. and O.N. Witte, Regulated expression of P210 Bcr-Abl during 
embryonic stem cell differentiation stimulates multipotential progenitor 
expansion and myeloid cell fate. Proc Natl Acad Sci U S A, 2000. 97(4): p. 
1737-42. 
65. Smith, C.C. and N.P. Shah, Tyrosine kinase inhibitor therapy for chronic 
myeloid leukemia: approach to patients with treatment-naive or refractory 
chronic-phase disease. Hematology Am Soc Hematol Educ Program, 2011. 
2011: p. 121-7. 
66. Lee, S.J. and J.Y. Wang, Exploiting the promiscuity of imatinib. J Biol, 2009. 
8(3): p. 30. 
67. Czuczman, M.S. and S.A. Gregory, The future of CD20 monoclonal antibody 
therapy in B-cell malignancies. Leuk Lymphoma, 2010. 51(6): p. 983-94. 
68. Dy, G.K. and A.A. Adjei, Systemic cancer therapy: evolution over the last 60 
years. Cancer, 2008. 113(7 Suppl): p. 1857-87. 
69. Pitson, S.M., Regulation of sphingosine kinase and sphingolipid signaling. 
Trends Biochem Sci, 2011. 36(2): p. 97-107. 
 	  
	  
201	  
70. Bandhuvula, P. and J.D. Saba, Sphingosine-1-phosphate lyase in immunity and 
cancer: silencing the siren. Trends Mol Med, 2007. 13(5): p. 210-7. 
71. Brindley, D.N., Lipid phosphate phosphatases and related proteins: signaling 
functions in development, cell division, and cancer. J Cell Biochem, 2004. 
92(5): p. 900-12. 
72. Kobayashi, N., T. Nishi, T. Hirata, A. Kihara, T. Sano, Y. Igarashi, et al., 
Sphingosine 1-phosphate is released from the cytosol of rat platelets in a 
carrier-mediated manner. J Lipid Res, 2006. 47(3): p. 614-21. 
73. Kobayashi, N., N. Kobayashi, A. Yamaguchi, and T. Nishi, Characterization 
of the ATP-dependent sphingosine 1-phosphate transporter in rat 
erythrocytes. J Biol Chem, 2009. 284(32): p. 21192-200. 
74. Mitra, P., C.A. Oskeritzian, S.G. Payne, M.A. Beaven, S. Milstien, and S. 
Spiegel, Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. 
Proc Natl Acad Sci U S A, 2006. 103(44): p. 16394-9. 
75. Sato, K., E. Malchinkhuu, Y. Horiuchi, C. Mogi, H. Tomura, M. Tosaka, et 
al., Critical role of ABCA1 transporter in sphingosine 1-phosphate release 
from astrocytes. J Neurochem, 2007. 103(6): p. 2610-9. 
76. Takabe, K., R.H. Kim, J.C. Allegood, P. Mitra, S. Ramachandran, M. 
Nagahashi, et al., Estradiol induces export of sphingosine 1-phosphate from 
breast cancer cells via ABCC1 and ABCG2. J Biol Chem, 2010. 285(14): p. 
10477-86. 
77. Kawahara, A., T. Nishi, Y. Hisano, H. Fukui, A. Yamaguchi, and N. 
Mochizuki, The sphingolipid transporter spns2 functions in migration of 
zebrafish myocardial precursors. Science, 2009. 323(5913): p. 524-7. 
78. Osborne, N., K. Brand-Arzamendi, E.A. Ober, S.W. Jin, H. Verkade, N.G. 
Holtzman, et al., The spinster homolog, two of hearts, is required for 
sphingosine 1-phosphate signaling in zebrafish. Curr Biol, 2008. 18(23): p. 
1882-8. 
79. Fukuhara, S., S. Simmons, S. Kawamura, A. Inoue, Y. Orba, T. Tokudome, et 
al., The sphingosine-1-phosphate transporter Spns2 expressed on endothelial 
cells regulates lymphocyte trafficking in mice. J Clin Invest, 2012. 122(4): p. 
1416-26. 
 	  
	  
202	  
80. Venkataraman, K., S. Thangada, J. Michaud, M.L. Oo, Y. Ai, Y.M. Lee, et al., 
Extracellular export of sphingosine kinase-1a contributes to the vascular S1P 
gradient. Biochem J, 2006. 397(3): p. 461-71. 
81. Rosen, H. and E.J. Goetzl, Sphingosine 1-phosphate and its receptors: an 
autocrine and paracrine network. Nat Rev Immunol, 2005. 5(7): p. 560-70. 
82. Hait, N.C., J. Allegood, M. Maceyka, G.M. Strub, K.B. Harikumar, S.K. 
Singh, et al., Regulation of histone acetylation in the nucleus by sphingosine-
1-phosphate. Science, 2009. 325(5945): p. 1254-7. 
83. Alvarez, S.E., K.B. Harikumar, N.C. Hait, J. Allegood, G.M. Strub, E.Y. Kim, 
et al., Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin 
ligase TRAF2. Nature, 2010. 465(7301): p. 1084-8. 
84. Strub, G.M., M. Maceyka, N.C. Hait, S. Milstien, and S. Spiegel, 
Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp 
Med Biol, 2010. 688: p. 141-55. 
85. Xu, Y., Y.J. Xiao, L.M. Baudhuin, and B.M. Schwartz, The role and clinical 
applications of bioactive lysolipids in ovarian cancer. J Soc Gynecol Investig, 
2001. 8(1): p. 1-13. 
86. Sutphen, R., Y. Xu, G.D. Wilbanks, J. Fiorica, E.C. Grendys, Jr., J.P. LaPolla, 
et al., Lysophospholipids are potential biomarkers of ovarian cancer. Cancer 
Epidemiol Biomarkers Prev, 2004. 13(7): p. 1185-91. 
87. Baudhuin, L.M., Y. Jiang, A. Zaslavsky, I. Ishii, J. Chun, and Y. Xu, S1P3-
mediated Akt activation and cross-talk with platelet-derived growth factor 
receptor (PDGFR). FASEB J, 2004. 18(2): p. 341-3. 
88. Maceyka, M., S.E. Alvarez, S. Milstien, and S. Spiegel, Filamin A links 
sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 at lamellipodia 
to orchestrate cell migration. Mol Cell Biol, 2008. 28(18): p. 5687-97. 
89. Shida, D., X. Fang, T. Kordula, K. Takabe, S. Lepine, S.E. Alvarez, et al., 
Cross-talk between LPA1 and epidermal growth factor receptors mediates up-
regulation of sphingosine kinase 1 to promote gastric cancer cell motility and 
invasion. Cancer Res, 2008. 68(16): p. 6569-77. 
90. Chang, C.L., M.C. Ho, P.H. Lee, C.Y. Hsu, W.P. Huang, and H. Lee, S1P(5) 
is required for sphingosine 1-phosphate-induced autophagy in human prostate 
cancer PC-3 cells. Am J Physiol Cell Physiol, 2009. 297(2): p. C451-8. 
 	  
	  
203	  
91. Lavieu, G., F. Scarlatti, G. Sala, S. Carpentier, T. Levade, R. Ghidoni, et al., 
Regulation of autophagy by sphingosine kinase 1 and its role in cell survival 
during nutrient starvation. J Biol Chem, 2006. 281(13): p. 8518-27. 
92. Sukocheva, O., L. Wang, E. Verrier, M.A. Vadas, and P. Xia, Restoring 
endocrine response in breast cancer cells by inhibition of the sphingosine 
kinase-1 signaling pathway. Endocrinology, 2009. 150(10): p. 4484-92. 
93. Leclercq, T.M. and S.M. Pitson, Cellular signalling by sphingosine kinase and 
sphingosine 1-phosphate. IUBMB Life, 2006. 58(8): p. 467-72. 
94. Liu, H., M. Sugiura, V.E. Nava, L.C. Edsall, K. Kono, S. Poulton, et al., 
Molecular cloning and functional characterization of a novel mammalian 
sphingosine kinase type 2 isoform. J Biol Chem, 2000. 275(26): p. 19513-20. 
95. Okada, T., G. Ding, H. Sonoda, T. Kajimoto, Y. Haga, A. Khosrowbeygi, et 
al., Involvement of N-terminal-extended form of sphingosine kinase 2 in 
serum-dependent regulation of cell proliferation and apoptosis. J Biol Chem, 
2005. 280(43): p. 36318-25. 
96. Billich, A., F. Bornancin, P. Devay, D. Mechtcheriakova, N. Urtz, and T. 
Baumruker, Phosphorylation of the immunomodulatory drug FTY720 by 
sphingosine kinases. J Biol Chem, 2003. 278(48): p. 47408-15. 
97. Igarashi, N., T. Okada, S. Hayashi, T. Fujita, S. Jahangeer, and S. Nakamura, 
Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol 
Chem, 2003. 278(47): p. 46832-9. 
98. Maceyka, M., H. Sankala, N.C. Hait, H. Le Stunff, H. Liu, R. Toman, et al., 
SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in 
sphingolipid metabolism. J Biol Chem, 2005. 280(44): p. 37118-29. 
99. Mizugishi, K., T. Yamashita, A. Olivera, G.F. Miller, S. Spiegel, and R.L. 
Proia, Essential role for sphingosine kinases in neural and vascular 
development. Mol Cell Biol, 2005. 25(24): p. 11113-21. 
100. Lim, K.G., F. Tonelli, E. Berdyshev, I. Gorshkova, T. Leclercq, S.M. Pitson, 
et al., Inhibition kinetics and regulation of sphingosine kinase 1 expression in 
prostate cancer cells: Functional differences between sphingosine kinase 1a 
and 1b. Int J Biochem Cell Biol, 2012. 44(9): p. 1457-64. 
101. Kihara, A., Y. Anada, and Y. Igarashi, Mouse sphingosine kinase isoforms 
SPHK1a and SPHK1b differ in enzymatic traits including stability, 
 	  
	  
204	  
localization, modification, and oligomerization. J Biol Chem, 2006. 281(7): p. 
4532-9. 
102. Pitson, S.M., P.A. Moretti, J.R. Zebol, P. Xia, J.R. Gamble, M.A. Vadas, et 
al., Expression of a catalytically inactive sphingosine kinase mutant blocks 
agonist-induced sphingosine kinase activation. A dominant-negative 
sphingosine kinase. J Biol Chem, 2000. 275(43): p. 33945-50. 
103. Takabe, K., S.W. Paugh, S. Milstien, and S. Spiegel, "Inside-out" signaling of 
sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev, 2008. 60(2): p. 
181-95. 
104. Hannun, Y.A. and L.M. Obeid, Principles of bioactive lipid signalling: lessons 
from sphingolipids. Nat Rev Mol Cell Biol, 2008. 9(2): p. 139-50. 
105. Xia, P., J.R. Gamble, L. Wang, S.M. Pitson, P.A. Moretti, B.W. Wattenberg, 
et al., An oncogenic role of sphingosine kinase. Curr Biol, 2000. 10(23): p. 
1527-30. 
106. Le Stunff, H., A. Mikami, P. Giussani, J.P. Hobson, P.S. Jolly, S. Milstien, et 
al., Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth 
factor-induced chemotaxis. J Biol Chem, 2004. 279(33): p. 34290-7. 
107. Bergom, C., C. Gao, and P.J. Newman, Mechanisms of PECAM-1-mediated 
cytoprotection and implications for cancer cell survival. Leuk Lymphoma, 
2005. 46(10): p. 1409-21. 
108. Buehrer, B.M., E.S. Bardes, and R.M. Bell, Protein kinase C-dependent 
regulation of human erythroleukemia (HEL) cell sphingosine kinase activity. 
Biochim Biophys Acta, 1996. 1303(3): p. 233-42. 
109. Pitson, S.M., P.A. Moretti, J.R. Zebol, H.E. Lynn, P. Xia, M.A. Vadas, et al., 
Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. 
EMBO J, 2003. 22(20): p. 5491-500. 
110. Marfe, G., C. Di Stefano, A. Gambacurta, T. Ottone, V. Martini, E. 
Abruzzese, et al., Sphingosine kinase 1 overexpression is regulated by 
signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic 
myeloid leukemia cells. Exp Hematol, 2011. 39(6): p. 653-665 e6. 
111. Gault, C.R., S.T. Eblen, C.A. Neumann, Y.A. Hannun, and L.M. Obeid, 
Oncogenic K-Ras regulates bioactive sphingolipids in a sphingosine kinase 1-
dependent manner. J Biol Chem, 2012. 287(38): p. 31794-803. 
 	  
	  
205	  
112. Barr, R.K., H.E. Lynn, P.A. Moretti, Y. Khew-Goodall, and S.M. Pitson, 
Deactivation of sphingosine kinase 1 by protein phosphatase 2A. J Biol Chem, 
2008. 283(50): p. 34994-5002. 
113. Wattenberg, B.W., S.M. Pitson, and D.M. Raben, The sphingosine and 
diacylglycerol kinase superfamily of signaling kinases: localization as a key to 
signaling function. J Lipid Res, 2006. 47(6): p. 1128-39. 
114. Pitson, S.M., P. Xia, T.M. Leclercq, P.A. Moretti, J.R. Zebol, H.E. Lynn, et 
al., Phosphorylation-dependent translocation of sphingosine kinase to the 
plasma membrane drives its oncogenic signalling. J Exp Med, 2005. 201(1): 
p. 49-54. 
115. Vadas, M., P. Xia, G. McCaughan, and J. Gamble, The role of sphingosine 
kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim Biophys 
Acta, 2008. 1781(9): p. 442-7. 
116. Cuvillier, O., G. Pirianov, B. Kleuser, P.G. Vanek, O.A. Coso, S. Gutkind, et 
al., Suppression of ceramide-mediated programmed cell death by sphingosine-
1-phosphate. Nature, 1996. 381(6585): p. 800-3. 
117. Olivera, A., T. Kohama, L. Edsall, V. Nava, O. Cuvillier, S. Poulton, et al., 
Sphingosine kinase expression increases intracellular sphingosine-1-
phosphate and promotes cell growth and survival. J Cell Biol, 1999. 147(3): p. 
545-58. 
118. Cuvillier, O., Sphingosine kinase-1--a potential therapeutic target in cancer. 
Anticancer Drugs, 2007. 18(2): p. 105-10. 
119. Huwiler, A. and J. Pfeilschifter, Altering the sphingosine-1-
phosphate/ceramide balance: a promising approach for tumor therapy. Curr 
Pharm Des, 2006. 12(35): p. 4625-35. 
120. Li, J., H.Y. Guan, L.Y. Gong, L.B. Song, N. Zhang, J. Wu, et al., Clinical 
significance of sphingosine kinase-1 expression in human astrocytomas 
progression and overall patient survival. Clin Cancer Res, 2008. 14(21): p. 
6996-7003. 
121. Van Brocklyn, J.R., C.A. Jackson, D.K. Pearl, M.S. Kotur, P.J. Snyder, and 
T.W. Prior, Sphingosine kinase-1 expression correlates with poor survival of 
patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in 
growth of glioblastoma cell lines. J Neuropathol Exp Neurol, 2005. 64(8): p. 
695-705. 
 	  
	  
206	  
122. Bayerl, M.G., R.D. Bruggeman, E.J. Conroy, J.A. Hengst, T.S. King, M. 
Jimenez, et al., Sphingosine kinase 1 protein and mRNA are overexpressed in 
non-Hodgkin lymphomas and are attractive targets for novel pharmacological 
interventions. Leuk Lymphoma, 2008. 49(5): p. 948-54. 
123. Kawamori, T., T. Kaneshiro, M. Okumura, S. Maalouf, A. Uflacker, J. 
Bielawski, et al., Role for sphingosine kinase 1 in colon carcinogenesis. 
FASEB J, 2009. 23(2): p. 405-14. 
124. Johnson, K.R., K.Y. Johnson, H.G. Crellin, B. Ogretmen, A.M. Boylan, R.A. 
Harley, et al., Immunohistochemical distribution of sphingosine kinase 1 in 
normal and tumor lung tissue. J Histochem Cytochem, 2005. 53(9): p. 1159-
66. 
125. Sobue, S., S. Nemoto, M. Murakami, H. Ito, A. Kimura, S. Gao, et al., 
Implications of sphingosine kinase 1 expression level for the cellular 
sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of 
leukemia cells. Int J Hematol, 2008. 87(3): p. 266-75. 
126. Li, W., C.P. Yu, J.T. Xia, L. Zhang, G.X. Weng, H.Q. Zheng, et al., 
Sphingosine kinase 1 is associated with gastric cancer progression and poor 
survival of patients. Clin Cancer Res, 2009. 15(4): p. 1393-9. 
127. Ruckhaberle, E., A. Rody, K. Engels, R. Gaetje, G. von Minckwitz, S. 
Schiffmann, et al., Microarray analysis of altered sphingolipid metabolism 
reveals prognostic significance of sphingosine kinase 1 in breast cancer. 
Breast Cancer Res Treat, 2008. 112(1): p. 41-52. 
128. Song, L., H. Xiong, J. Li, W. Liao, L. Wang, J. Wu, et al., Sphingosine kinase-
1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-kappaB 
pathway in human non-small cell lung cancer. Clin Cancer Res, 2011. 17(7): 
p. 1839-49. 
129. Park, Y.S., S. Hakomori, S. Kawa, F. Ruan, and Y. Igarashi, Liposomal 
N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell 
growth and metastasis with reduced toxicity and enhanced drug efficacy 
compared to free TMS: cell membrane signaling as a target in cancer therapy 
III. Cancer Res, 1994. 54(8): p. 2213-7. 
130. French, K.J., R.S. Schrecengost, B.D. Lee, Y. Zhuang, S.N. Smith, J.L. 
Eberly, et al., Discovery and evaluation of inhibitors of human sphingosine 
kinase. Cancer Res, 2003. 63(18): p. 5962-9. 
 	  
	  
207	  
131. Kohno, M., M. Momoi, M.L. Oo, J.H. Paik, Y.M. Lee, K. Venkataraman, et 
al., Intracellular role for sphingosine kinase 1 in intestinal adenoma cell 
proliferation. Mol Cell Biol, 2006. 26(19): p. 7211-23. 
132. Pchejetski, D., N. Doumerc, M. Golzio, M. Naymark, J. Teissie, T. Kohama, 
et al., Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate 
cancer cell and animal models. Mol Cancer Ther, 2008. 7(7): p. 1836-45. 
133. Sauer, L., J. Nunes, V. Salunkhe, L. Skalska, T. Kohama, O. Cuvillier, et al., 
Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer 
to docetaxel. Int J Cancer, 2009. 125(11): p. 2728-36. 
134. Baran, Y., A. Salas, C.E. Senkal, U. Gunduz, J. Bielawski, L.M. Obeid, et al., 
Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the 
regulation of resistance to imatinib-induced apoptosis in K562 human chronic 
myeloid leukemia cells. J Biol Chem, 2007. 282(15): p. 10922-34. 
135. Bonhoure, E., A. Lauret, D.J. Barnes, C. Martin, B. Malavaud, T. Kohama, et 
al., Sphingosine kinase-1 is a downstream regulator of imatinib-induced 
apoptosis in chronic myeloid leukemia cells. Leukemia, 2008. 22(5): p. 971-9. 
136. Bonhoure, E., D. Pchejetski, N. Aouali, H. Morjani, T. Levade, T. Kohama, et 
al., Overcoming MDR-associated chemoresistance in HL-60 acute myeloid 
leukemia cells by targeting sphingosine kinase-1. Leukemia, 2006. 20(1): p. 
95-102. 
137. Guillermet-Guibert, J., L. Davenne, D. Pchejetski, N. Saint-Laurent, L. 
Brizuela, C. Guilbeau-Frugier, et al., Targeting the sphingolipid metabolism to 
defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine 
drug. Mol Cancer Ther, 2009. 8(4): p. 809-20. 
138. Hait, N.C., A. Bellamy, S. Milstien, T. Kordula, and S. Spiegel, Sphingosine 
kinase type 2 activation by ERK-mediated phosphorylation. J Biol Chem, 
2007. 282(16): p. 12058-65. 
139. Ding, G., H. Sonoda, H. Yu, T. Kajimoto, S.K. Goparaju, S. Jahangeer, et al., 
Protein kinase D-mediated phosphorylation and nuclear export of sphingosine 
kinase 2. J Biol Chem, 2007. 282(37): p. 27493-502. 
140. Liu, H., R.E. Toman, S.K. Goparaju, M. Maceyka, V.E. Nava, H. Sankala, et 
al., Sphingosine kinase type 2 is a putative BH3-only protein that induces 
apoptosis. J Biol Chem, 2003. 278(41): p. 40330-6. 
 	  
	  
208	  
141. Hofmann, L.P., S. Ren, S. Schwalm, J. Pfeilschifter, and A. Huwiler, 
Sphingosine kinase 1 and 2 regulate the capacity of mesangial cells to resist 
apoptotic stimuli in an opposing manner. Biol Chem, 2008. 389(11): p. 1399-
407. 
142. Oskeritzian, C.A., S.E. Alvarez, N.C. Hait, M.M. Price, S. Milstien, and S. 
Spiegel, Distinct roles of sphingosine kinases 1 and 2 in human mast-cell 
functions. Blood, 2008. 111(8): p. 4193-200. 
143. Lai, W.Q., A.W. Irwan, H.H. Goh, A.J. Melendez, I.B. McInnes, and B.P. 
Leung, Distinct roles of sphingosine kinase 1 and 2 in murine collagen-
induced arthritis. J Immunol, 2009. 183(3): p. 2097-103. 
144. Jo, S.K., A. Bajwa, H. Ye, A.L. Vergis, A.S. Awad, Y. Kharel, et al., 
Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. 
Kidney Int, 2009. 75(2): p. 167-75. 
145. Wadgaonkar, R., V. Patel, N. Grinkina, C. Romano, J. Liu, Y. Zhao, et al., 
Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am J 
Physiol Lung Cell Mol Physiol, 2009. 296(4): p. L603-13. 
146. Nemoto, S., M. Nakamura, Y. Osawa, S. Kono, Y. Itoh, Y. Okano, et al., 
Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon 
cancer cells through ceramide accumulation and Akt activation. J Biol Chem, 
2009. 284(16): p. 10422-32. 
147. Sankala, H.M., N.C. Hait, S.W. Paugh, D. Shida, S. Lepine, L.W. Elmore, et 
al., Involvement of sphingosine kinase 2 in p53-independent induction of p21 
by the chemotherapeutic drug doxorubicin. Cancer Res, 2007. 67(21): p. 
10466-74. 
148. Schnitzer, S.E., A. Weigert, J. Zhou, and B. Brune, Hypoxia enhances 
sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated 
chemoresistance in A549 lung cancer cells. Mol Cancer Res, 2009. 7(3): p. 
393-401. 
149. Weigert, A., S. Schiffmann, D. Sekar, S. Ley, H. Menrad, C. Werno, et al., 
Sphingosine kinase 2 deficient tumor xenografts show impaired growth and 
fail to polarize macrophages towards an anti-inflammatory phenotype. Int J 
Cancer, 2009. 125(9): p. 2114-21. 
 	  
	  
209	  
150. French, K.J., Y. Zhuang, L.W. Maines, P. Gao, W. Wang, V. Beljanski, et al., 
Pharmacology and antitumor activity of ABC294640, a selective inhibitor of 
sphingosine kinase-2. J Pharmacol Exp Ther, 2010. 333(1): p. 129-39. 
151. Beljanski, V., C. Knaak, and C.D. Smith, A novel sphingosine kinase inhibitor 
induces autophagy in tumor cells. J Pharmacol Exp Ther, 2010. 333(2): p. 
454-64. 
152. Beljanski, V., C.S. Lewis, and C.D. Smith, Antitumor activity of sphingosine 
kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma 
xenografts. Cancer Biol Ther, 2011. 11(5): p. 524-34. 
153. Antoon, J.W., M.D. White, E.M. Slaughter, J.L. Driver, H.S. Khalili, S. 
Elliott, et al., Targeting NFkB mediated breast cancer chemoresistance 
through selective inhibition of sphingosine kinase-2. Cancer Biol Ther, 2011. 
11(7): p. 678-89. 
154. Antoon, J.W., M.D. White, W.D. Meacham, E.M. Slaughter, S.E. Muir, S. 
Elliott, et al., Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor 
ABC294640. Endocrinology, 2010. 151(11): p. 5124-35. 
155. Antoon, J.W., W.D. Meacham, M.R. Bratton, E.M. Slaughter, L.V. Rhodes, 
H.B. Ashe, et al., Pharmacological inhibition of sphingosine kinase isoforms 
alters estrogen receptor signaling in human breast cancer. J Mol Endocrinol, 
2011. 46(3): p. 205-16. 
156. Schwab, S., J. Pereira, M. Matloubian, Y. Xu, Y. Huang, and J. Cyster, 
Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P 
gradients. Science, 2005. 309: p. 1735-1739. 
157. Pappu, R., S.R. Schwab, I. Cornelissen, J.P. Pereira, J.B. Regard, Y. Xu, et al., 
Promotion of lymphocyte egress into blood and lymph by distinct sources of 
sphingosine-1-phosphate. Science, 2007. 316(5822): p. 295-8. 
158. Hanel, P., P. Andreani, and M.H. Graler, Erythrocytes store and release 
sphingosine 1-phosphate in blood. FASEB J, 2007. 21(4): p. 1202-9. 
159. Yatomi, Y., Y. Ozaki, T. Ohmori, and Y. Igarashi, Sphingosine 1-phosphate: 
synthesis and release. Prostaglandins Other Lipid Mediat, 2001. 64: p. 107-
122. 
160. Spiegel, S. and S. Milstien, The outs and the ins of sphingosine-1-phosphate in 
immunity. Nat Rev Immunol, 2011. 11(6): p. 403-15. 
 	  
	  
210	  
161. Brinkmann, V., M.D. Davis, C.E. Heise, R. Albert, S. Cottens, R. Hof, et al., 
The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J 
Biol Chem, 2002. 277(24): p. 21453-7. 
162. Chiba, K., H. Matsuyuki, Y. Maeda, and K. Sugahara, Role of sphingosine 1-
phosphate receptor type 1 in lymphocyte egress from secondary lymphoid 
tissues and thymus. Cell Mol Immunol, 2006. 3(1): p. 11-9. 
163. Cohen, J.A., F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, X. Montalban, 
et al., Oral fingolimod or intramuscular interferon for relapsing multiple 
sclerosis. N Engl J Med, 2010. 362(5): p. 402-15. 
164. Lo, C.G., Y. Xu, R.L. Proia, and J.G. Cyster, Cyclical modulation of 
sphingosine-1-phosphate receptor 1 surface expression during lymphocyte 
recirculation and relationship to lymphoid organ transit. J Exp Med, 2005. 
201(2): p. 291-301. 
165. Pham, T.H., T. Okada, M. Matloubian, C.G. Lo, and J.G. Cyster, S1P1 
receptor signaling overrides retention mediated by G alpha i-coupled 
receptors to promote T cell egress. Immunity, 2008. 28(1): p. 122-33. 
166. Bankovich, A.J., L.R. Shiow, and J.G. Cyster, CD69 suppresses sphingosine 
1-phosophate receptor-1 (S1P1) function through interaction with membrane 
helix 4. J Biol Chem, 2010. 285(29): p. 22328-37. 
167. Massberg, S., P. Schaerli, I. Knezevic-Maramica, M. Köllnberger, N. Tubo, E. 
Moseman, et al., Immunosurveillance by hematopoietic progenitor cells 
trafficking through blood, lymph, and peripheral tissues. Cell, 2007. 131: p. 
994-1008. 
168. Kabashima, K., N.M. Haynes, Y. Xu, S.L. Nutt, M.L. Allende, R.L. Proia, et 
al., Plasma cell S1P1 expression determines secondary lymphoid organ 
retention versus bone marrow tropism. J Exp Med, 2006. 203(12): p. 2683-90. 
169. Ryser, M.F., F. Ugarte, R. Lehmann, M. Bornhauser, and S. Brenner, S1P(1) 
overexpression stimulates S1P-dependent chemotaxis of human CD34+ 
hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent 
migration and in vivo homing. Mol Immunol, 2008. 46(1): p. 166-71. 
170. Zhang, L., M. Orban, M. Lorenz, V. Barocke, D. Braun, N. Urtz, et al., A 
novel role of sphingosine 1-phosphate receptor S1pr1 in mouse 
thrombopoiesis. J Exp Med, 2012. 209(12): p. 2165-81. 
 	  
	  
211	  
171. Golfier, S., S. Kondo, T. Schulze, T. Takeuchi, G. Vassileva, A.H. Achtman, 
et al., Shaping of terminal megakaryocyte differentiation and proplatelet 
development by sphingosine-1-phosphate receptor S1P4. FASEB J, 2010. 
24(12): p. 4701-10. 
172. Donovan, E.E., R. Pelanda, and R.M. Torres, S1P3 confers differential S1P-
induced migration by autoreactive and non-autoreactive immature B cells and 
is required for normal B-cell development. Eur J Immunol, 2010. 40(3): p. 
688-98. 
173. Maeda, Y., N. Seki, N. Sato, K. Sugahara, and K. Chiba, Sphingosine 1-
phosphate receptor type 1 regulates egress of mature T cells from mouse bone 
marrow. Int Immunol, 2010. 22(6): p. 515-25. 
174. Mayol, K., V. Biajoux, J. Marvel, K. Balabanian, and T. Walzer, Sequential 
desensitization of CXCR4 and S1P5 controls natural killer cell trafficking. 
Blood, 2011. 118(18): p. 4863-71. 
175. Allende, M.L., G. Tuymetova, B.G. Lee, E. Bonifacino, Y.P. Wu, and R.L. 
Proia, S1P1 receptor directs the release of immature B cells from bone 
marrow into blood. J Exp Med, 2010. 207(5): p. 1113-24. 
176. Juarez, J.G., N. Harun, M. Thien, R. Welschinger, R. Baraz, A. Dela Pena, et 
al., Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells 
and their mobilization by CXCR4 antagonists in mice. Blood, 2012. 119(3): p. 
707-16. 
177. Tashiro, K., H. Tada, R. Heilker, M. Shirozu, T. Nakano, and T. Honjo, Signal 
sequence trap: a cloning strategy for secreted proteins and type I membrane 
proteins. Science, 1993. 261: p. 600-603. 
178. Golan, K., Y. Vagima, A. Ludin, T. Itkin, S. Cohen-Gur, A. Kalinkovich, et 
al., S1P promotes murine progenitor cell egress and mobilization via S1P1-
mediated ROS signaling and SDF-1 release. Blood, 2012. 119(11): p. 2478-
88. 
179. Ratajczak, M.Z., C. Kim, A. Janowska-Wieczorek, and J. Ratajczak, The 
expanding family of bone marrow homing factors for hematopoietic stem 
cells: stromal derived factor 1 is not the only player in the game. 
ScientificWorldJournal, 2012. 2012: p. 758512. 
180. Ratajczak, M.Z., C. Kim, W. Wu, D.M. Shin, E. Bryndza, M. Kucia, et al., 
The role of innate immunity in trafficking of hematopoietic stem cells-an 
 	  
	  
212	  
emerging link between activation of complement cascade and chemotactic 
gradients of bioactive sphingolipids. Adv Exp Med Biol, 2012. 946: p. 37-54. 
181. Keul, P., S. Lucke, K. von Wnuck Lipinski, C. Bode, M. Graler, G. Heusch, et 
al., Sphingosine-1-phosphate receptor 3 promotes recruitment of 
monocyte/macrophages in inflammation and atherosclerosis. Circ Res, 2011. 
108(3): p. 314-23. 
182. Cinamon, G., M.A. Zachariah, O.M. Lam, F.W. Foss, Jr., and J.G. Cyster, 
Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat 
Immunol, 2008. 9(1): p. 54-62. 
183. Nishimura, H., T. Akiyama, Y. Monobe, K. Matsubara, Y. Igarashi, M. Abe, 
et al., Expression of sphingosine-1-phosphate receptor 1 in mantle cell 
lymphoma. Mod Pathol, 2010. 23(3): p. 439-49. 
184. Liu, Y., J. Deng, L. Wang, H. Lee, B. Armstrong, A. Scuto, et al., S1PR1 is an 
effective target to block STAT3 signaling in activated B cell-like diffuse large 
B-cell lymphoma. Blood, 2012. 120(7): p. 1458-65. 
185. Cattoretti, G., J. Mandelbaum, N. Lee, A.H. Chaves, A.M. Mahler, A. 
Chadburn, et al., Targeted disruption of the S1P2 sphingosine 1-phosphate 
receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res, 
2009. 69(22): p. 8686-92. 
186. Stam, J.C., F. Michiels, R.A. van der Kammen, W.H. Moolenaar, and J.G. 
Collard, Invasion of T-lymphoma cells: cooperation between Rho family 
GTPases and lysophospholipid receptor signaling. EMBO J, 1998. 17(14): p. 
4066-74. 
187. Feng, H., D.L. Stachura, R.M. White, A. Gutierrez, L. Zhang, T. Sanda, et al., 
T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and 
ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell, 2010. 
18(4): p. 353-66. 
188. Li, Q.F., C.T. Wu, H.F. Duan, H.Y. Sun, H. Wang, Z.Z. Lu, et al., Activation 
of sphingosine kinase mediates suppressive effect of interleukin-6 on human 
multiple myeloma cell apoptosis. Br J Haematol, 2007. 138(5): p. 632-9. 
189. Zhang, R., M.V. Shah, J. Yang, S.B. Nyland, X. Liu, J.K. Yun, et al., Network 
model of survival signaling in large granular lymphocyte leukemia. Proc Natl 
Acad Sci U S A, 2008. 105(42): p. 16308-13. 
 	  
	  
213	  
190. Shatrov, V.A., V. Lehmann, and S. Chouaib, Sphingosine-1-phosphate 
mobilizes intracellular calcium and activates transcription factor NF-kappa B 
in U937 cells. Biochem Biophys Res Commun, 1997. 234(1): p. 121-4. 
191. Li, Q.F., W.R. Huang, H.F. Duan, H. Wang, C.T. Wu, and L.S. Wang, 
Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in 
chronic myeloid leukemia cells. Oncogene, 2007. 26(57): p. 7904-8. 
192. Salas, A., S. Ponnusamy, C.E. Senkal, M. Meyers-Needham, S.P. Selvam, 
S.A. Saddoughi, et al., Sphingosine kinase-1 and sphingosine 1-phosphate 
receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of 
protein phosphatase 2A. Blood, 2011. 117(22): p. 5941-52. 
193. Cuvillier, O. and T. Levade, Sphingosine 1-phosphate antagonizes apoptosis 
of human leukemia cells by inhibiting release of cytochrome c and 
Smac/DIABLO from mitochondria. Blood, 2001. 98(9): p. 2828-36. 
194. Le Scolan, E., D. Pchejetski, Y. Banno, N. Denis, P. Mayeux, W. 
Vainchenker, et al., Overexpression of sphingosine kinase 1 is an oncogenic 
event in erythroleukemic progression. Blood, 2005. 106(5): p. 1808-16. 
195. Paugh, S.W., B.S. Paugh, M. Rahmani, D. Kapitonov, J.A. Almenara, T. 
Kordula, et al., A selective sphingosine kinase 1 inhibitor integrates multiple 
molecular therapeutic targets in human leukemia. Blood, 2008. 112(4): p. 
1382-91. 
196. Wallington-Beddoe, C.T., J. Hewson, K.F. Bradstock, and L.J. Bendall, 
FTY720 produces caspase-independent cell death of acute lymphoblastic 
leukemia cells. Autophagy, 2011. 7(7): p. 707-15. 
197. Wallington-Beddoe, C., K. Bradstock, and L. Bendall, Identification of 
Sphingosine Kinases as Therapeutic Targets in B-lineage Acute 
Lymphoblastic Leukemia, in American Society of Hematology, 2012: Atlanta 
GA. p. 1499. 
198. Wallington-Beddoe, C., D. Ho, K. Bradstock, and L. Bendall, Sphingosine 
Kinase Inhibition has Pre-clinical Activity in Acute Lymphoblastic Leukemia, 
in American Society of Hematology, 2011: San Diego, CA. p. 3573. 
199. Li, Q.F., C.T. Wu, Q. Guo, H. Wang, and L.S. Wang, Sphingosine 1-
phosphate induces Mcl-1 upregulation and protects multiple myeloma cells 
against apoptosis. Biochem Biophys Res Commun, 2008. 371(1): p. 159-62. 
 	  
	  
214	  
200. Kilbey, A., A. Terry, A. Jenkins, G. Borland, Q. Zhang, M.J. Wakelam, et al., 
Runx regulation of sphingolipid metabolism and survival signaling. Cancer 
Res, 2010. 70(14): p. 5860-9. 
201. Lepine, S., J.C. Allegood, M. Park, P. Dent, S. Milstien, and S. Spiegel, 
Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced 
autophagy. Cell Death Differ, 2011. 18(2): p. 350-61. 
202. Levine, B. and G. Kroemer, Autophagy in the pathogenesis of disease. Cell, 
2008. 132(1): p. 27-42. 
203. Ricci, C., F. Onida, F. Servida, F. Radaelli, G. Saporiti, K. Todoerti, et al., In 
vitro anti-leukaemia activity of sphingosine kinase inhibitor. Br J Haematol, 
2009. 144(3): p. 350-7. 
204. Matsuoka, Y., Y. Nagahara, M. Ikekita, and T. Shinomiya, A novel 
immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia 
cells. Br J Pharmacol, 2003. 138(7): p. 1303-12. 
205. Yasui, H., T. Hideshima, N. Raje, A.M. Roccaro, N. Shiraishi, S. Kumar, et 
al., FTY720 induces apoptosis in multiple myeloma cells and overcomes drug 
resistance. Cancer Res, 2005. 65(16): p. 7478-84. 
206. Liu, Q., X. Zhao, F. Frissora, Y. Ma, R. Santhanam, D. Jarjoura, et al., 
FTY720 demonstrates promising preclinical activity for chronic lymphocytic 
leukemia and lymphoblastic leukemia/lymphoma. Blood, 2008. 111(1): p. 275-
84. 
207. Liu, Q., L. Alinari, C.S. Chen, F. Yan, J.T. Dalton, R. Lapalombella, et al., 
FTY720 shows promising in vitro and in vivo preclinical activity by 
downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin 
Cancer Res, 2010. 16(12): p. 3182-92. 
208. Roberts, K.G., A.M. Smith, F. McDougall, H. Carpenter, M. Horan, P. 
Neviani, et al., Essential requirement for PP2A inhibition by the oncogenic 
receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ 
cancers. Cancer Res, 2010. 70(13): p. 5438-47. 
209. Liao, A., K. Broeg, T. Fox, S.F. Tan, R. Watters, M.V. Shah, et al., 
Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood, 
2011. 118(10): p. 2793-800. 
210. Neviani, P., R. Santhanam, J.J. Oaks, A.M. Eiring, M. Notari, B.W. Blaser, et 
al., FTY720, a new alternative for treating blast crisis chronic myelogenous 
 	  
	  
215	  
leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. 
J Clin Invest, 2007. 117(9): p. 2408-21. 
211. Rodriguez-Lafrasse, C., G. Alphonse, M.T. Aloy, D. Ardail, J.P. Gerard, P. 
Louisot, et al., Increasing endogenous ceramide using inhibitors of 
sphingolipid metabolism maximizes ionizing radiation-induced mitochondrial 
injury and apoptotic cell killing. Int J Cancer, 2002. 101(6): p. 589-98. 
212. Li, Q.F., J. Yan, K. Zhang, Y.F. Yang, F.J. Xiao, C.T. Wu, et al., Bortezomib 
and sphingosine kinase inhibitor interact synergistically to induces apoptosis 
in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation 
Mcl-1. Biochem Biophys Res Commun, 2011. 405(1): p. 31-6. 
213. Alinari, L., R.A. Baiocchi, and M. Praetorius-Ibba, FTY720-induced blockage 
of autophagy enhances anticancer efficacy of milatuzumab in mantle cell 
lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma 
treatment? Autophagy, 2012. 8(3): p. 416-7. 
214. Schwamb, J., V. Feldhaus, M. Baumann, M. Patz, S. Brodesser, R. Brinker, et 
al., B-cell receptor triggers drug sensitivity of primary CLL cells by 
controlling glucosylation of ceramides. Blood, 2012. 120(19): p. 3978-85. 
215. Casson, L., L. Howell, L.A. Mathews, M. Ferrer, N. Southall, R. Guha, et al., 
Inhibition of Ceramide Metabolism Sensitizes Human Leukemia Cells to 
Inhibition of BCL2-Like Proteins. PLoS One, 2013. 8(1): p. e54525. 
216. Wallington-Beddoe, C.T., A.S. Don, J. Hewson, Q. Qiao, R.A. Papa, R.B. 
Lock, et al., Disparate in vivo efficacy of FTY720 in xenograft models of 
Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. 
PLoS One, 2012. 7(5): p. e36429. 
217. French, K.J., J.J. Upson, S.N. Keller, Y. Zhuang, J.K. Yun, and C.D. Smith, 
Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther, 
2006. 318(2): p. 596-603. 
218. Leroux, M.E., E. Auzenne, R. Evans, N. Hail, Jr., W. Spohn, S.C. Ghosh, et 
al., Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-
independent apoptosis in human prostatic adenocarcinoma cells. Prostate, 
2007. 67(15): p. 1699-717. 
219. Kapitonov, D., J.C. Allegood, C. Mitchell, N.C. Hait, J.A. Almenara, J.K. 
Adams, et al., Targeting sphingosine kinase 1 inhibits Akt signaling, induces 
 	  
	  
216	  
apoptosis, and suppresses growth of human glioblastoma cells and xenografts. 
Cancer Res, 2009. 69(17): p. 6915-23. 
220. Davis, M.D., J.J. Clemens, T.L. Macdonald, and K.R. Lynch, Sphingosine 1-
phosphate analogs as receptor antagonists. J Biol Chem, 2005. 280(11): p. 
9833-41. 
221. Sanna, M.G., S.K. Wang, P.J. Gonzalez-Cabrera, A. Don, D. Marsolais, M.P. 
Matheu, et al., Enhancement of capillary leakage and restoration of 
lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol, 2006. 
2(8): p. 434-41. 
222. Pyne, N.J. and S. Pyne, Sphingosine 1-phosphate and cancer. Nat Rev Cancer, 
2010. 10(7): p. 489-503. 
223. Gao, P., Y.K. Peterson, R.A. Smith, and C.D. Smith, Characterization of 
isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One, 
2012. 7(9): p. e44543. 
224. van Meeteren, L.A., V. Brinkmann, J.S. Saulnier-Blache, K.R. Lynch, and 
W.H. Moolenaar, Anticancer activity of FTY720: phosphorylated FTY720 
inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase 
D. Cancer Lett, 2008. 266(2): p. 203-8. 
225. Payne, S.G., C.A. Oskeritzian, R. Griffiths, P. Subramanian, S.E. Barbour, 
C.E. Chalfant, et al., The immunosuppressant drug FTY720 inhibits cytosolic 
phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood, 
2007. 109(3): p. 1077-85. 
226. Vessey, D.A., M. Kelley, J. Zhang, L. Li, R. Tao, and J.S. Karliner, 
Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 
form of sphingosine kinase from rat heart. J Biochem Mol Toxicol, 2007. 
21(5): p. 273-9. 
227. Bandhuvula, P., Y.Y. Tam, B. Oskouian, and J.D. Saba, The immune 
modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J Biol 
Chem, 2005. 280(40): p. 33697-700. 
228. Lahiri, S., H. Park, E.L. Laviad, X. Lu, R. Bittman, and A.H. Futerman, 
Ceramide synthesis is modulated by the sphingosine analog FTY720 via a 
mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain 
length-dependent manner. J Biol Chem, 2009. 284(24): p. 16090-8. 
 	  
	  
217	  
229. Nagaoka, Y., K. Otsuki, T. Fujita, and S. Uesato, Effects of phosphorylation of 
immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity 
against breast and colon cancer cells. Biol Pharm Bull, 2008. 31(6): p. 1177-
81. 
230. Wang, J.D., S. Takahara, N. Nonomura, N. Ichimaru, K. Toki, H. Azuma, et 
al., Early induction of apoptosis in androgen-independent prostate cancer cell 
line by FTY720 requires caspase-3 activation. Prostate, 1999. 40(1): p. 50-5. 
231. Hung, J.H., Y.S. Lu, Y.C. Wang, Y.H. Ma, D.S. Wang, S.K. Kulp, et al., 
FTY720 induces apoptosis in hepatocellular carcinoma cells through 
activation of protein kinase C delta signaling. Cancer Res, 2008. 68(4): p. 
1204-12. 
232. Lee, W.J., H.S. Yoo, P.G. Suh, S. Oh, J.S. Lim, and Y.M. Lee, Sphingosine 
mediates FTY720-induced apoptosis in LLC-PK1 cells. Exp Mol Med, 2004. 
36(5): p. 420-7. 
233. Azuma, H., S. Takahara, S. Horie, S. Muto, Y. Otsuki, and Y. Katsuoka, 
Induction of apoptosis in human bladder cancer cells in vitro and in vivo 
caused by FTY720 treatment. J Urol, 2003. 169(6): p. 2372-7. 
234. Ubai, T., H. Azuma, Y. Kotake, T. Inamoto, K. Takahara, Y. Ito, et al., 
FTY720 induced Bcl-associated and Fas-independent apoptosis in human 
renal cancer cells in vitro and significantly reduced in vivo tumor growth in 
mouse xenograft. Anticancer Res, 2007. 27(1A): p. 75-88. 
235. Azuma, H., S. Takahara, N. Ichimaru, J.D. Wang, Y. Itoh, Y. Otsuki, et al., 
Marked prevention of tumor growth and metastasis by a novel 
immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer 
Res, 2002. 62(5): p. 1410-9. 
236. Alinari, L., R.A. Baiocchi, and M. Praetorius-Ibba, FTY720-induced blockage 
of autophagy enhances anticancer efficacy of milatuzumab in mantle cell 
lymphoma: Is FTY720 the next autophagy-blocking agent in lymphoma 
treatment? Autophagy, 2012. 8(3). 
237. Chua, C.W., D.T. Lee, M.T. Ling, C. Zhou, K. Man, J. Ho, et al., FTY720, a 
fungus metabolite, inhibits in vivo growth of androgen-independent prostate 
cancer. Int J Cancer, 2005. 117(6): p. 1039-48. 
 	  
	  
218	  
238. Ho, J.W., K. Man, C.K. Sun, T.K. Lee, R.T. Poon, and S.T. Fan, Effects of a 
novel immunomodulating agent, FTY720, on tumor growth and angiogenesis 
in hepatocellular carcinoma. Mol Cancer Ther, 2005. 4(9): p. 1430-8. 
239. Lim, K.G., F. Tonelli, Z. Li, X. Lu, R. Bittman, S. Pyne, et al., FTY720 
analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, 
allosterism, proteasomal degradation, and actin rearrangement in MCF-7 
breast cancer cells. J Biol Chem, 2011. 286(21): p. 18633-40. 
240. Tonelli, F., K.G. Lim, C. Loveridge, J. Long, S.M. Pitson, G. Tigyi, et al., 
FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and 
promote its proteasomal degradation in human pulmonary artery smooth 
muscle, breast cancer and androgen-independent prostate cancer cells. Cell 
Signal, 2010. 22(10): p. 1536-42. 
241. Kennedy, A.J., T.P. Mathews, Y. Kharel, S.D. Field, M.L. Moyer, J.E. East, et 
al., Development of amidine-based sphingosine kinase 1 nanomolar inhibitors 
and reduction of sphingosine 1-phosphate in human leukemia cells. J Med 
Chem, 2011. 54(10): p. 3524-48. 
242. Schnute, M.E., M.D. McReynolds, T. Kasten, M. Yates, G. Jerome, J.W. 
Rains, et al., Modulation of cellular S1P levels with a novel, potent and 
specific inhibitor of sphingosine kinase-1. Biochem J, 2012. 444(1): p. 79-88. 
243. Kharel, Y., M. Raje, M. Gao, A.M. Gellett, J.L. Tomsig, K.R. Lynch, et al., 
Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-
phosphate. Biochem J, 2012. 447(1): p. 149-57. 
244. Xiang, Y., G. Asmussen, M. Booker, B. Hirth, J.L. Kane, Jr., J. Liao, et al., 
Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett, 
2009. 19(21): p. 6119-21. 
245. Raje, M.R., K. Knott, Y. Kharel, P. Bissel, K.R. Lynch, and W.L. Santos, 
Design, synthesis and biological activity of sphingosine kinase 2 selective 
inhibitors. Bioorg Med Chem, 2012. 20(1): p. 183-94. 
246. Knott, K., Y. Kharel, M.R. Raje, K.R. Lynch, and W.L. Santos, Effect of alkyl 
chain length on sphingosine kinase 2 selectivity. Bioorg Med Chem Lett, 
2012. 22(22): p. 6817-20. 
247. Gaundar, S.S., K.F. Bradstock, and L.J. Bendall, p38MAPK inhibitors 
attenuate cytokine production by bone marrow stromal cells and reduce 
 	  
	  
219	  
stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell 
Cycle, 2009. 8(18): p. 2975-83. 
248. Juarez, J., K. Bradstock, D. Gottlieb, and L. Bendall, Effects of inhibitors of 
the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. 
Leukemia, 2003. 17(7): p. 1294-1300. 
249. Crazzolara, R., A. Cisterne, M. Thien, J. Hewson, R. Baraz, K.F. Bradstock, et 
al., Potentiating effects of RAD001 (Everolimus) on vincristine therapy in 
childhood acute lymphoblastic leukemia. Blood, 2009. 113(14): p. 3297-306. 
250. Shaposhnikov, V.L., [Distribution of the bone marrow cells in the skeleton of 
mice]. Biull Eksp Biol Med, 1979. 87(5): p. 483-5. 
251. Jary, E., T. Bee, S.R. Walker, S.K. Chung, K.C. Seo, J.C. Morris, et al., 
Elimination of a hydroxyl group in FTY720 dramatically improves the 
phosphorylation rate. Mol Pharmacol, 2010. 78(4): p. 685-92. 
252. Webb, J., Effect of more than one inhibitor, in Enzymes and metabolic 
inhibitors, E. R. Hochster and J. Quastel, Editor 1963, Academic Press: New 
York. p. 487-512. 
253. Fielding, A.K., The treatment of adults with acute lymphoblastic leukemia. 
Hematology Am Soc Hematol Educ Program, 2008: p. 381-9. 
254. Brinkmann, V., J.G. Cyster, and T. Hla, FTY720: sphingosine 1-phosphate 
receptor-1 in the control of lymphocyte egress and endothelial barrier 
function. Am J Transplant, 2004. 4(7): p. 1019-25. 
255. Nagahara, Y., S. Enosawa, M. Ikekita, S. Suzuki, and T. Shinomiya, Evidence 
that FTY720 induces T cell apoptosis in vivo. Immunopharmacology, 2000. 
48(1): p. 75-85. 
256. Brinkmann, V., S. Chen, L. Feng, D. Pinschewer, Z. Nikolova, and R. Hof, 
FTY720 alters lymphocyte homing and protects allografts without inducing 
general immunosuppression. Transplant Proc, 2001. 33(1-2): p. 530-1. 
257. Kahan, B.D., J.L. Karlix, R.M. Ferguson, A.B. Leichtman, S. Mulgaonkar, 
T.A. Gonwa, et al., Pharmacodynamics, pharmacokinetics, and safety of 
multiple doses of FTY720 in stable renal transplant patients: a multicenter, 
randomized, placebo-controlled, phase I study. Transplantation, 2003. 76(7): 
p. 1079-84. 
258. Skerjanec, A., H. Tedesco, H.H. Neumayer, E. Cole, K. Budde, C.H. Hsu, et 
al., FTY720, a novel immunomodulator in de novo kidney transplant patients: 
 	  
	  
220	  
pharmacokinetics and exposure-response relationship. J Clin Pharmacol, 
2005. 45(11): p. 1268-78. 
259. Tedesco-Silva, H., G. Mourad, B.D. Kahan, J.G. Boira, W. Weimar, S. 
Mulgaonkar, et al., FTY720, A Novel Immunomodulator: Efficacy and Safety 
Results from the First Phase 2A Study in de novo Renal Transplantation. 
Transplantation, 2005. 79(11): p. 1553-1560. 
260. Braun, W.E., Renal transplantation: basic concepts and evolution of therapy. 
J Clin Apher, 2003. 18(3): p. 141-52. 
261. Brinkmann, V., FTY720: mechanism of action and potential benefit in organ 
transplantation. Yonsei Med J, 2004. 45(6): p. 991-7. 
262. Nagahara, Y., M. Ikekita, and T. Shinomiya, T cell selective apoptosis by a 
novel immunosuppressant, FTY720, is closely regulated with Bcl-2. Br J 
Pharmacol, 2002. 137(7): p. 953-62. 
263. Nagahara, Y., Y. Matsuoka, K. Saito, M. Ikekita, S. Higuchi, and T. 
Shinomiya, Coordinate involvement of cell cycle arrest and apoptosis 
strengthen the effect of FTY720. Jpn J Cancer Res, 2001. 92(6): p. 680-7. 
264. Eichhorn, P.J., M.P. Creyghton, and R. Bernards, Protein phosphatase 2A 
regulatory subunits and cancer. Biochim Biophys Acta, 2009. 1795(1): p. 1-
15. 
265. Suzuki, S., X.K. Li, S. Enosawa, and T. Shinomiya, A new 
immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in 
human lymphocytes. Immunology, 1996. 89(4): p. 518-23. 
266. Klionsky, D.J., H. Abeliovich, P. Agostinis, D.K. Agrawal, G. Aliev, D.S. 
Askew, et al., Guidelines for the use and interpretation of assays for 
monitoring autophagy in higher eukaryotes. Autophagy, 2008. 4(2): p. 151-75. 
267. Pattingre, S., A. Tassa, X. Qu, R. Garuti, X.H. Liang, N. Mizushima, et al., 
Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell, 2005. 
122(6): p. 927-39. 
268. Maiuri, M.C., G. Le Toumelin, A. Criollo, J.C. Rain, F. Gautier, P. Juin, et al., 
Functional and physical interaction between Bcl-X(L) and a BH3-like domain 
in Beclin-1. EMBO J, 2007. 26(10): p. 2527-39. 
269. Potteck, H., B. Nieuwenhuis, A. Luth, M. van der Giet, and B. Kleuser, 
Phosphorylation of the immunomodulator FTY720 inhibits programmed cell 
 	  
	  
221	  
death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation. Cell 
Physiol Biochem, 2010. 26(1): p. 67-78. 
270. Westermarck, J. and W.C. Hahn, Multiple pathways regulated by the tumor 
suppressor PP2A in transformation. Trends Mol Med, 2008. 14(4): p. 152-60. 
271. Van Hoof, C. and J. Goris, Phosphatases in apoptosis: to be or not to be, 
PP2A is in the heart of the question. Biochimica et Biophysica Acta (BBA) - 
Molecular Cell Research, 2003. 1640(2-3): p. 97-104. 
272. Levine, B. and J. Yuan, Autophagy in cell death: an innocent convict? J Clin 
Invest, 2005. 115(10): p. 2679-88. 
273. Tsujimoto, Y. and S. Shimizu, Another way to die: autophagic programmed 
cell death. Cell Death Differ, 2005. 12 Suppl 2: p. 1528-34. 
274. Yu, L., A. Alva, H. Su, P. Dutt, E. Freundt, S. Welsh, et al., Regulation of an 
ATG7-beclin 1 program of autophagic cell death by caspase-8. Science, 2004. 
304(5676): p. 1500-2. 
275. Wu, Y.T., H.L. Tan, Q. Huang, Y.S. Kim, N. Pan, W.Y. Ong, et al., 
Autophagy plays a protective role during zVAD-induced necrotic cell death. 
Autophagy, 2008. 4(4): p. 457-66. 
276. Bonapace, L., B.C. Bornhauser, M. Schmitz, G. Cario, U. Ziegler, F.K. Niggli, 
et al., Induction of autophagy-dependent necroptosis is required for childhood 
acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J 
Clin Invest, 2010. 120(4): p. 1310-23. 
277. Zhang, N., Y. Qi, C. Wadham, L. Wang, A. Warren, W. Di, et al., FTY720 
induces necrotic cell death and autophagy in ovarian cancer cells: a 
protective role of autophagy. Autophagy, 2010. 6(8): p. 1157-67. 
278. Shin, D.Y., G.Y. Kim, W. Li, B.T. Choi, N.D. Kim, H.S. Kang, et al., 
Implication of intracellular ROS formation, caspase-3 activation and Egr-1 
induction in platycodon D-induced apoptosis of U937 human leukemia cells. 
Biomed Pharmacother, 2009. 63(2): p. 86-94. 
279. Kizaki, M., M. Xian, M. Sagawa, and Y. Ikeda, Induction of apoptosis via the 
modulation of reactive oxygen species (ROS) production in the treatment of 
myeloid leukemia. Curr Pharm Biotechnol, 2006. 7(5): p. 323-9. 
280. McGowan, A.J., A.G. Bowie, L.A. O'Neill, and T.G. Cotter, The production of 
a reactive oxygen intermediate during the induction of apoptosis by cytotoxic 
insult. Exp Cell Res, 1998. 238(1): p. 248-56. 
 	  
	  
222	  
281. Zhang, D.W., J. Shao, J. Lin, N. Zhang, B.J. Lu, S.C. Lin, et al., RIP3, an 
energy metabolism regulator that switches TNF-induced cell death from 
apoptosis to necrosis. Science, 2009. 325(5938): p. 332-6. 
282. Gaynon, P.S., A.L. Angiolillo, W.L. Carroll, J.B. Nachman, M.E. Trigg, H.N. 
Sather, et al., Long-term results of the children's cancer group studies for 
childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology 
Group Report. Leukemia, 2010. 24(2): p. 285-97. 
283. Fielding, A., S. Richards, R. Chopra, H. Lazarus, M. Litzow, G. Buck, et al., 
Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (ALL); 
an MRC UKALL12/ECOG 2993 study. Blood, 2007. 109(3): p. 944-950. 
284. Mandala, S., R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie, J. Milligan, et 
al., Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor 
agonists. Science, 2002. 296(5566): p. 346-9. 
285. Matloubian, M., C.G. Lo, G. Cinamon, M.J. Lesneski, Y. Xu, V. Brinkmann, 
et al., Lymphocyte egress from thymus and peripheral lymphoid organs is 
dependent on S1P receptor 1. Nature, 2004. 427(6972): p. 355-60. 
286. Mudry, R.E., J.E. Fortney, T. York, B.M. Hall, and L.F. Gibson, Stromal cells 
regulate survival of B-lineage leukemic cells during chemotherapy. Blood, 
2000. 96(5): p. 1926-32. 
287. Juarez, J., K.F. Bradstock, D.J. Gottlieb, and L.J. Bendall, Effects of inhibitors 
of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in 
vitro. Leukemia, 2003. 17(7): p. 1294-300. 
288. Juarez, J., R. Baraz, S. Gaundar, K. Bradstock, and L. Bendall, Interaction of 
interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-
cell progenitor acute lymphoblastic leukemia. Haematologica, 2007. 92(4): p. 
450-9. 
289. Nikolova, Z., A. Hof, Y. Baumlin, and R.P. Hof, Combined 
FTY720/cyclosporine A treatment promotes graft survival and lowers the 
peripheral lymphocyte count in DA to lewis heart and skin transplantation 
models. Transpl Immunol, 2001. 8(4): p. 267-77. 
290. Meno-Tetang, G.M. and P.J. Lowe, On the prediction of the human response: 
a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic 
Clin Pharmacol Toxicol, 2005. 96(3): p. 182-92. 
 	  
	  
223	  
291. Sensken, S.C., C. Bode, and M.H. Graler, Accumulation of fingolimod 
(FTY720) in lymphoid tissues contributes to prolonged efficacy. J Pharmacol 
Exp Ther, 2009. 328(3): p. 963-9. 
292. Kappos, L., E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, 
et al., A placebo-controlled trial of oral fingolimod in relapsing multiple 
sclerosis. N Engl J Med, 2010. 362(5): p. 387-401. 
293. Shea, B.S., S.F. Brooks, B.A. Fontaine, J. Chun, A.D. Luster, and A.M. Tager, 
Prolonged S1P1 Agonist Exposure Exacerbates Vascular Leak, Fibrosis, and 
Mortality after Lung Injury. Am J Respir Cell Mol Biol, 2010. 43(6): p. 662-
73. 
294. Murakami, A., H. Takasugi, S. Ohnuma, Y. Koide, A. Sakurai, S. Takeda, et 
al., Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 
receptor: investigation based on a new S1P3 receptor antagonist. Mol 
Pharmacol, 2010. 77(4): p. 704-13. 
295. Shimizu, S., T. Kanaseki, N. Mizushima, T. Mizuta, S. Arakawa-Kobayashi, 
C.B. Thompson, et al., Role of Bcl-2 family proteins in a non-apoptotic 
programmed cell death dependent on autophagy genes. Nat Cell Biol, 2004. 
6(12): p. 1221-8. 
296. Germain, M., A.P. Nguyen, J.N. Le Grand, N. Arbour, J.L. Vanderluit, D.S. 
Park, et al., MCL-1 is a stress sensor that regulates autophagy in a 
developmentally regulated manner. EMBO J, 2011. 30(2): p. 395-407. 
297. Baines, A.T., D. Xu, and C.J. Der, Inhibition of Ras for cancer treatment: the 
search continues. Future Med Chem, 2011. 3(14): p. 1787-808. 
298. Kim, D.H. and T. Sim, Novel small molecule Raf kinase inhibitors for targeted 
cancer therapeutics. Arch Pharm Res, 2012. 35(4): p. 605-15. 
299. Zhang, J., C.G. Mullighan, R.C. Harvey, G. Wu, X. Chen, M. Edmonson, et 
al., Key pathways are frequently mutated in high-risk childhood acute 
lymphoblastic leukemia: a report from the Children's Oncology Group. Blood, 
2011. 118(11): p. 3080-7. 
300. Steelman, L.S., S.C. Pohnert, J.G. Shelton, R.A. Franklin, F.E. Bertrand, and 
J.A. McCubrey, JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell 
cycle progression and leukemogenesis. Leukemia, 2004. 18(2): p. 189-218. 
301. Dang, C.V., MYC on the path to cancer. Cell, 2012. 149(1): p. 22-35. 
 	  
	  
224	  
302. Arvanitis, C. and D.W. Felsher, Conditional transgenic models define how 
MYC initiates and maintains tumorigenesis. Semin Cancer Biol, 2006. 16(4): 
p. 313-7. 
303. Seo, J.Y., S.H. Lee, H.J. Kim, K.H. Yoo, H.H. Koo, Y.G. Cho, et al., MYC 
rearrangement involving a novel non-immunoglobulin chromosomal locus in 
precursor B-cell acute lymphoblastic leukemia. Ann Lab Med, 2012. 32(4): p. 
289-93. 
304. Meeker, N.D., A.M. Cherry, C.D. Bangs, and J.K. Frazer, A pediatric B 
lineage leukemia with coincident MYC and MLL translocations. J Pediatr 
Hematol Oncol, 2011. 33(2): p. 158-60. 
305. Levens, D., You Don't Muck with MYC. Genes Cancer, 2010. 1(6): p. 547-554. 
306. Ott, C.J., N. Kopp, L. Bird, R.M. Paranal, J. Qi, T. Bowman, et al., BET 
bromodomain inhibition targets both c-MYC and IL7R in high-risk acute 
lymphoblastic leukemia. Blood, 2012. 
307. Coustan-Smith, E., G. Song, C. Clark, L. Key, P. Liu, M. Mehrpooya, et al., 
New markers for minimal residual disease detection in acute lymphoblastic 
leukemia. Blood, 2011. 117(23): p. 6267-76. 
308. Liang, J., M. Nagahashi, E.Y. Kim, K.B. Harikumar, A. Yamada, W.C. 
Huang, et al., Sphingosine-1-phosphate links persistent STAT3 activation, 
chronic intestinal inflammation, and development of colitis-associated cancer. 
Cancer Cell, 2013. 23(1): p. 107-20. 
309. Bild, A.H., G. Yao, J.T. Chang, Q. Wang, A. Potti, D. Chasse, et al., 
Oncogenic pathway signatures in human cancers as a guide to targeted 
therapies. Nature, 2006. 439(7074): p. 353-7. 
310. Schuhmacher, M., F. Kohlhuber, M. Holzel, C. Kaiser, H. Burtscher, M. 
Jarsch, et al., The transcriptional program of a human B cell line in response 
to Myc. Nucleic Acids Res, 2001. 29(2): p. 397-406. 
311. Consortium., E.P., A user's guide to the encyclopedia of DNA elements 
(ENCODE). PLoS Biol, 2011. 9(4): p. e1001046. 
312. Chipuk, J.E., G.P. McStay, A. Bharti, T. Kuwana, C.J. Clarke, L.J. Siskind, et 
al., Sphingolipid metabolism cooperates with BAK and BAX to promote the 
mitochondrial pathway of apoptosis. Cell, 2012. 148(5): p. 988-1000. 
313. Gao, P. and C.D. Smith, Ablation of sphingosine kinase-2 inhibits tumor cell 
proliferation and migration. Mol Cancer Res, 2011. 9(11): p. 1509-19. 
 	  
	  
225	  
314. Xiao, M., Y. Liu, and F. Zou, Sensitization of human colon cancer cells to 
sodium butyrate-induced apoptosis by modulation of sphingosine kinase 2 and 
protein kinase D. Exp Cell Res, 2012. 318(1): p. 43-52. 
315. Gomez, L., M. Paillard, M. Price, Q. Chen, G. Teixeira, S. Spiegel, et al., A 
novel role for mitochondrial sphingosine-1-phosphate produced by 
sphingosine kinase-2 in PTP-mediated cell survival during cardioprotection. 
Basic Res Cardiol, 2011. 106(6): p. 1341-53. 
316. Dai, Y., S. Chen, L. Wang, X.Y. Pei, L.B. Kramer, P. Dent, et al., Bortezomib 
interacts synergistically with belinostat in human acute myeloid leukaemia 
and acute lymphoblastic leukaemia cells in association with perturbation in 
NF-kappaB and Bim. Br J Haematol, 2011. 
317. Lucas, D.M., L. Alinari, D.A. West, M.E. Davis, R.B. Edwards, A.J. Johnson, 
et al., The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity 
in B-cell malignancies in vitro and in vivo. PLoS One, 2010. 5(6): p. e10941. 
318. Parent, R., D. Kolippakkam, G. Booth, and L. Beretta, Mammalian target of 
rapamycin activation impairs hepatocytic differentiation and targets genes 
moderating lipid homeostasis and hepatocellular growth. Cancer Res, 2007. 
67(9): p. 4337-45. 
319. Oram, J.F., ATP-binding cassette transporter A1 and cholesterol trafficking. 
Curr Opin Lipidol, 2002. 13(4): p. 373-81. 
320. Kellner-Weibel, G., Cytotoxic cellular cholesterol is selectively removed by 
apoA-I via ABCA1. Atherosclerosis, 2003. 171(2): p. 235-243. 
321. Liu, Y. and C. Tang, Regulation of ABCA1 functions by signaling pathways. 
Biochim Biophys Acta, 2012. 1821(3): p. 522-9. 
322. Puntoni, M., F. Sbrana, F. Bigazzi, and T. Sampietro, Tangier disease: 
epidemiology, pathophysiology, and management. Am J Cardiovasc Drugs, 
2012. 12(5): p. 303-11. 
323. Favari, E., I. Zanotti, F. Zimetti, N. Ronda, F. Bernini, and G.H. Rothblat, 
Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb 
Vasc Biol, 2004. 24(12): p. 2345-50. 
324. Wu, C.A., M. Tsujita, M. Hayashi, and S. Yokoyama, Probucol inactivates 
ABCA1 in the plasma membrane with respect to its mediation of 
apolipoprotein binding and high density lipoprotein assembly and to its 
proteolytic degradation. J Biol Chem, 2004. 279(29): p. 30168-74. 
 	  
	  
226	  
325. Witting, S.R., J.N. Maiorano, and W.S. Davidson, Ceramide enhances 
cholesterol efflux to apolipoprotein A-I by increasing the cell surface presence 
of ATP-binding cassette transporter A1. J Biol Chem, 2003. 278(41): p. 
40121-7. 
326. Lee, B.H., M.G. Taylor, P. Robinet, J.D. Smith, J. Schweitzer, E. Sehayek, et 
al., Dysregulation of cholesterol homeostasis in human prostate cancer 
through loss of ABCA1. Cancer Res, 2013. 73(3): p. 1211-8. 
327. Dean, M., Y. Hamon, and G. Chimini, The human ATP-binding cassette 
(ABC) transporter superfamily. J Lipid Res, 2001. 42(7): p. 1007-17. 
328. Prochazka, L., S. Koudelka, L.F. Dong, J. Stursa, J. Goodwin, J. Neca, et al., 
Mitochondrial targeting overcomes ABCA1-dependent resistance of lung 
carcinoma to alpha-tocopheryl succinate. Apoptosis, 2013. 18(3): p. 286-99. 
329. Shirai, K., T. Kaneshiro, M. Wada, H. Furuya, J. Bielawski, Y.A. Hannun, et 
al., A role of sphingosine kinase 1 in head and neck carcinogenesis. Cancer 
Prev Res (Phila), 2011. 4(3): p. 454-62. 
330. Bellodi, C., M.R. Lidonnici, A. Hamilton, G.V. Helgason, A.R. Soliera, M. 
Ronchetti, et al., Targeting autophagy potentiates tyrosine kinase inhibitor-
induced cell death in Philadelphia chromosome-positive cells, including 
primary CML stem cells. J Clin Invest, 2009. 119(5): p. 1109-23. 
331. Kimura, T., Y. Takabatake, A. Takahashi, and Y. Isaka, Chloroquine in 
cancer therapy: a double-edged sword of autophagy. Cancer Res, 2013. 73(1): 
p. 3-7. 
332. Verschooten, L., K. Barrette, S. Van Kelst, N. Rubio Romero, C. Proby, R. De 
Vos, et al., Autophagy inhibitor chloroquine enhanced the cell death inducing 
effect of the flavonoid luteolin in metastatic squamous cell carcinoma cells. 
PLoS One, 2012. 7(10): p. e48264. 
333. Neviani, P., R. Santhanam, R. Trotta, M. Notari, B.W. Blaser, S. Liu, et al., 
The tumor suppressor PP2A is functionally inactivated in blast crisis CML 
through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer 
Cell, 2005. 8(5): p. 355-68. 
334. Perrotti, D. and P. Neviani, ReSETting PP2A tumour suppressor activity in 
blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J 
Cancer, 2006. 95(7): p. 775-81. 
 	  
	  
227	  
335. Saddoughi, S.A., S. Gencer, Y.K. Peterson, K.E. Ward, A. Mukhopadhyay, J. 
Oaks, et al., Sphingosine analogue drug FTY720 targets I2PP2A/SET and 
mediates lung tumour suppression via activation of PP2A-RIPK1-dependent 
necroptosis. EMBO Mol Med, 2013. 5(1): p. 105-21. 
336. Jiang, P., A.D. Smith, R. Li, R. Jaladanki, J.M. Donahue, J.Y. Wang, et al., 
Sphingosine Kinase 1 overexpression stimulates intestinal epithelial cell 
proliferation through increased c-Myc translation. Am J Physiol Cell Physiol, 
2013. 
337. Knapp, M., Cardioprotective role of sphingosine-1-phosphate. J Physiol 
Pharmacol, 2011. 62(6): p. 601-7. 
338. Cascon, A. and M. Robledo, MAX and MYC: a heritable breakup. Cancer Res, 
2012. 72(13): p. 3119-24. 
339. He, T.C., A.B. Sparks, C. Rago, H. Hermeking, L. Zawel, L.T. da Costa, et al., 
Identification of c-MYC as a target of the APC pathway. Science, 1998. 
281(5382): p. 1509-12. 
340. Lynch, K.R., Building a better sphingosine kinase-1 inhibitor. Biochem J, 
2012. 444(1): p. e1-2. 
341. Johnson, G.R., D. Metcalf, and J.W. Wilson, Development of B-lymphocyte 
colony-forming cells in foetal mouse tissues. Immunology, 1976. 30(6): p. 
907-14. 
342. Hauer, J., C. Mullighan, E. Morillon, G. Wang, J. Bruneau, N. Brousse, et al., 
Loss of p19Arf in a Rag1(-/-) B-cell precursor population initiates acute B-
lymphoblastic leukemia. Blood, 2011. 118(3): p. 544-53. 
343. Ensor, H.M., C. Schwab, L.J. Russell, S.M. Richards, H. Morrison, D. Masic, 
et al., Demographic, clinical, and outcome features of children with acute 
lymphoblastic leukemia and CRLF2 deregulation: results from the MRC 
ALL97 clinical trial. Blood, 2011. 117(7): p. 2129-36. 
344. Shieh, A., A.F. Ward, K.L. Donlan, E.R. Harding-Theobald, J. Xu, C.G. 
Mullighan, et al., Defective K-Ras oncoproteins overcome impaired effector 
activation to initiate leukemia in vivo. Blood, 2013. 
345. Pan, J., Y.F. Tao, Z. Zhou, B.R. Cao, S.Y. Wu, Y.L. Zhang, et al., An novel 
role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of 
esophageal carcinoma. J Transl Med, 2011. 9: p. 157. 
